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ABSTRACT 
 
 
In cancer, aberrant activation of developmental signaling pathways such as the 
Hippo Pathway has been shown to drive proliferation and invasion of cancer cells. 
Therefore, understanding the normal function of the Hippo Pathway during embryonic 
development can provide critical insight into how aberrant activity contributes to 
tumorigenesis. This dissertation explores the role of the Hippo Pathway members YAP 
and TAZ in gastrointestinal (GI) development and tumorigenesis. I use mouse genetics to 
systematically dissect the roles of YAP/TAZ in the endoderm-derived gastrointestinal 
epithelia and mesoderm-derived gastrointestinal mesenchyme during mammalian 
development. In the GI epithelium, I demonstrate that YAP/TAZ are dispensable for 
development and homeostasis. However, YAP/TAZ are required for Wnt pathway-driven 
tumorigenesis. I find that YAP/TAZ are direct transcriptional targets of Wnt/TCF4 
signaling. In the GI mesenchyme, I describe a previously unknown requirement for 
YAP/TAZ activity during mammalian GI development. YAP/TAZ are involved in 
normal GI mesenchymal differentiation and function as transcriptional co-repressors in a 
progenitor cell population. In this way, YAP/TAZ act as molecular gatekeepers prior to 
Hedgehog-mediated differentiation into smooth muscle cells. This work unveils a 
previously unknown requirement for Hippo pathway signaling in the mammalian GI tract 
and a novel mechanism wherein YAP/TAZ  function as transcriptional co-repressors to 
maintain a mesenchymal progenitor cell population.  
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PREFACE 
 
 The majority of the work presented in this dissertation, including all mouse model 
generation and dissection, represents my own work at the University of Massachusetts in 
the lab of Dr. Junhao Mao, with the following exceptions listed below. 
 
 The data presented in Chapters II and III represent a single publication which is 
under revision. The following authors contributed to this manuscript: 
Jennifer L. Cotton, Qi Li, Lifang Ma, Joo-Seop Park, Jiayi Wang, Jianhong Ou, Lihua J. 
Zhu, Y. Tony Ip, Randy L. Johnson, and Junhao Mao 
 
CHAPTER II:  
Fig. 2.3.A-F, Fig. 2.4.A-D: I generated the VillinCreYapflox/floxTazflox/flox animals. Dr. Qi Li 
and I dissected the mice together and performed IHC. Dr. Qi Li imaged the slides. Dr. Qi 
Li isolated epithelia from animals, purified RNA, and performed qPCR analysis.  
Fig. 2.5.A,B: Dr. Jianhong Ou performed bioinformatics analysis to compare ChIPseq 
data sets and contributed these panels. 
Fig. 2.5.C: Dr. Jiayi Wang performed ChIP and contributed this panel. 
Fig. 2.6.A, Fig. 2.7A: Lifang Ma performed DN-TCF4 transfection and qPCR. Lifang 
Ma also performed shRNA knockdown and soft agar colony assay. 
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Fig. 2.6.B-D: I generated the UbcCreERYapflox/floxTazflox/flox animals. Dr. Qi Li dissected the 
animals, and then isolated and cultured intestinal organoids. Dr. Qi Li performed the 
Wnt3a, 4OH-TM, and DA-β-catenin experiments and contributed these panels. 
Fig. 2.7.B-C: I generated the AhCreApcflox/+ and AhCreApcflox/+Yapflox/floxTazflox/flox animals 
and induced Cre expression with β-napthoflavone injection. Dr. Qi Li and I dissected the 
animals together. Dr Qi Li performed the qPCR analysis. Dr. Qi Li and I both performed 
IHC and imaged the slides.  
 
CHAPTER III:  
Fig. 3.1.B-C: I generated the mice in this experiment. Dr. Qi Li and I dissected the 
animals together. Dr. Qi Li performed western blotting analysis. 
Fig. 3.22: I generated and dissected mutant embryos, and performed crosslinking. Dr. 
Joo-Seop Park performed immunoprecipitation. I performed qPCR and analyzed the data. 
Fig. 3.23.A: Dr. Jianhong Ou performed sequence alignment and contributed this panel. 
 
APPENDIX A:  
Fig. A.7.A: Dr. He Huang isolated RNA from VillinCreR26Smad7/+ polyps. Dr. Jianhong 
Ou performed data set comparison and analysis. 
 
APPENDIX B: 
No contributing authors for these figures.  
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CHAPTER I 
Introduction 
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Overview 
 
 In embryogenesis, a finely tuned molecular symphony directs a single totipotent 
stem cell to develop into a complex multicellular organism. Stem cells differentiate into 
dedicated cell lineages with specialized functions. Proliferation and growth expands cell 
populations into new tissues. Cell polarity determines the patterning which gives rise to 
the caudal-rostral axis, dorsal-ventral, and left-right axis. Cells migrate in a tightly 
regulated movement during gastrulation to establish the germ layers. Cells undergo 
epithelial to mesenchymal transition (EMT) to eventually form individual organs. Blood 
vessel networks are generated through angiogenesis to disseminate nutrients throughout 
the organism. This tightly orchestrated sequence of cellular events in embryogenesis is 
controlled in part by developmental signaling pathways.  
 Developmental signaling pathways are transduction cascades that transmit cellular 
messages both intrinsically and extrinsically. Activation of developmental signaling 
pathways at specific time-points in embryogenesis tightly coordinates growth and 
differentiation. Conversely, termination of these signals is also critical for appropriate 
organismal development. For example, the Hippo Pathway is directly responsible for 
sensing overall liver size and halts growth once the appropriate organ size has been 
reached (Lee et al., 2010; Lu et al., 2010; Song et al., 2010). Other developmental 
signaling pathways, such as the Wnt and Hedgehog pathway, are frequently aberrantly 
activated in cancer. In some cases, mutations in a developmental signaling pathway may 
be the initial oncogenic mutation in the genetic path to tumorigenesis. For example, 
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mutations in the Wnt pathway member APC are common in colorectal cancer and 
mutations in the Hedgehog pathway member GLI are common to both basal cell 
carcinomas and medulloblastomas (Fearon and Vogelstein, 1990; Goodrich and Scott, 
1998).  
In cancer, aberrant activation of developmental signaling pathways drives 
proliferation and invasion of cancer cells. The hallmarks of cancer overlap with 
developmental processes, including angiogenesis, cell migration, EMT, and 
dedifferentiation (Hanahan and Weinberg, 2000). This observation has led to the 
hypothesis that cancer can be explained simply as development gone awry. Therefore, a 
detailed understanding of developmental signaling pathways during normal 
embryogenesis should reveal the microevolutionary advantages gained when these 
pathways are aberrantly activated in cancer cells. Ultimately, expanding our 
understanding of development will help us understand the biology of cancer as well as 
identify novel targets for drug therapies in patients. 
 In this chapter, I explore what is currently known about the etiology of colorectal 
cancer, including both sporadic and inherited oncogenic mutations in developmental 
signaling pathways, as well as genetic tools available for investigating in vivo 
tumorigenesis. Following that is a detailed discussion of the known functions of the 
Hippo Pathway in cancer as well as development, with a specific focus on the 
gastrointestinal tract. I conclude by delving into the importance of the mesenchyme in 
both gastrointestinal development and tumorigenesis. 
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Colorectal Cancer 
 
Colorectal cancer (CRC) is currently the third leading cause of cancer-related 
death in the United States for both men and women. It is estimated that in 2016 alone, 
there will be 134,490 new colorectal cancer diagnoses and 49,190 deaths (Siegel et al., 
2016). Statistically, 1 in 21 men and 1 in 23 women will develop invasive colorectal 
cancer in their lifetime.  
Common symptoms of colorectal cancer specific to the colon include abdominal 
pain, bleeding, or a change in bowel habits, but can also include more vague systemic 
symptoms such as weight loss and fatigue (Hamilton et al., 2005). Routine screening by 
colonoscopy every 10 years for average patients beginning at age 50 is integral for early 
detection screening and better overall survival, yet colonoscopy screening is dependent 
on patient compliance with the screening process (Edwards et al., 2010). Just 19% of 
patients aged 50-75 had undergone a routine colonoscopy screening in 2000, but by 2013, 
this number had increased to 53% of all patients (Siegel et al., 2016). As can be 
predicted, as the numbers of patients participating in early-detection colonoscopy 
screening increased, the number of colorectal cancer cases and related deaths has 
decreased from 2003 to 2012.  
During a routine colonoscopy, if early polyp lesions are detected, they are 
immediately removed and biopsied. Patients who are diagnosed with CRC in the 
localized disease phase have a 90% overall survival rate after 5 years (Siegel et al., 2016). 
This high overall survival percentage is due to the slow progression of early polyp lesion 
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to distant metastasis in the average patient; removal of early polyps is usually sufficient 
to prevent that particular lesion from progressing to metastatic disease. However, 56% of 
patients will be diagnosed with more advanced stage disease and face a far poorer 
prognosis for overall survival, with a dismal 13% overall 5 year survival rate for patients 
diagnosed with metastatic colorectal cancer (Siegel et al., 2016). Patients with late stage 
metastasis are also at higher risk for developing resistance to the current chemotherapy 
treatment regimes, further jeopardizing their overall survival (Edwards et al., 2010). 
As such, the future of colorectal cancer research and treatment requires a two-part 
approach. First and foremost, early detection screening by colonoscopy is necessary for 
CRC prevention. However, many CRC patients with metastasis have developed 
resistance to chemotherapies. These patients desperately need a greater understanding of 
acquired resistance in the CRC cell as well as the pro-survival niche created by the tumor 
cell microenvironment. These breakthroughs will pave the way for more effective 
therapeutics that will ultimately improve patient prognosis and overall survival.  
 
Etiology of Colorectal Cancer 
 
 Environmental Risk Factors 
 
 Colorectal cancer arises in the epithelial cells lining the gastrointestinal tract in 
the colon and rectum. GI epithelial cells are highly proliferative to continually replace 
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cells that are sloughed off as food passes through the GI tract. Due to the process of 
digestion, GI epithelial cells are constantly exposed to the external environment.  
 This constant environmental exposure explains why certain lifestyle factors 
significantly increase the risk for developing colorectal cancer over time. High fat diets, 
especially animal fats and red meat, have been shown to increase the risk of developing 
colorectal cancer (Haggar and Boushey, 2009). High consumption of meats cooked at 
high temperature, such as on a grill, increases the risk for colorectal cancer due to the 
generation of polycyclic hydrocarbons and heterocyclic amines during the cooking 
process (Santarelli et al., 2008; Sinha, 2002). Being overweight or obese also increases 
the risk of developing colorectal cancer, whereas regular exercise and weight loss can 
reduce this risk (de Jong et al., 2005). Additionally, diets lacking in fresh fruits and 
vegetables have been shown to increase the risk for CRC, likely due to a lack of 
necessary dietary fiber (Haggar and Boushey, 2009).  
 In addition to consumption of certain foods, cigarette smoking and alcohol use 
also dramatically increases the chance for developing colorectal cancer (Haggar and 
Boushey, 2009). The carcinogens in cigarettes can increase the risk for tumor initiation 
due to mutations and can also increase the rate of growth of existing cancer. Is is 
therefore unsurprising that approximately 12% of all deaths due to colorectal cancer are 
linked to cigarette smoking (Zisman et al., 2006). Alcohol consumption is also strongly 
correlated with elevated colorectal cancer risk, partially due to the generation of 
carcinogenic metabolites, such as acetaldehyde (Haggar and Boushey, 2009; Zisman et 
al., 2006).  
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 As well as the consumption of carcinogens, certain pathological conditions can 
generate a pro-tumorigenic environment. Chronic inflammation has been positively 
correlated with increased cancer risk in many solid tumors; the liver inflammation in 
cirrhosis has been linked to hepatocellular carcinoma (HCC) and pancreatitis leads to 
pancreatic ductal adenocarcinoma (PDAC). Similarly, inflammatory bowel disease 
(IBD), including ulcerative colitis (UC) and Crohn’s Disease (CD), is a strong risk factor 
for developing CRC (Rubin et al., 2012; Terzic et al., 2010). This chronic inflammation 
in the gastrointestinal tract results in approximately 20% of patients with (IBD) 
developing CRC over their lifetime, and more than 50% will die due to metastatic disease 
(Terzic et al., 2010).   
 Overall, due to the constant exposure to the external environment, the GI epithelia 
is constantly coming into contact with potential carcinogens. However, with lifestyle and 
diet adjustment, patients can reduce their exposure to environmental CRC risk factors. 
 
 Inherited Colon Cancer Syndromes 
 
 Some patients also have an elevated risk for developing colorectal cancer due to 
inheriting certain genetic mutations. Patients born with familial hereditary colon cancer 
syndromes comprise approximately 5% of all colorectal cancer cases, but individuals 
born with a familial colon cancer syndrome have 50-100% risk of developing CRC in 
their lifetime (Jasperson et al., 2010). Genetic testing is now available for the most 
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common inherited mutations and allows patients the opportunity to begin preventative 
screening measures once their genetic mutation is confirmed. 
Familial adenomatous polyposis syndrome (FAP) is inherited in an autosomal 
dominant manner and is characterized by 100-1000 adenomatous polyps in the colon. 
FAP is caused by an inherited mutation in the APC gene that causes FAP patients to have 
elevated Wnt pathway signaling in all somatic cells (Lynch and de la Chapelle, 2003). 
Aberrant Wnt pathway activation in the gastrointestinal tract is sufficient to drive 
tumorigenesis, and FAP patients have a 100% chance of developing CRC in their lifetime 
due to the constitutive Wnt pathway activation. These patients therefore need to begin 
routine colonoscopy screening every 2 years when they reach early adolescence 
(Jasperson et al., 2010). Early detection screening is critical for preventing disease 
progression. 
Lynch syndrome is another inherited familial cancer syndrome and has been 
linked to mutations in DNA mismatch repair enzymes such as MLH1, MLH2, MSH6, and 
PSM2 (Hampel et al., 2008; Jasperson et al., 2010). Polyps arising in Lynch syndrome 
patients are characteristic of microsatellite instability due to defects in DNA repair. 
Patients with Lynch syndrome have a 50-80% chance of developing CRC in their 
lifetime, but they also have elevated risk of developing other solid tumor cancers as well, 
such as endometrial, stomach, ovarian, liver, and pancreatic cancer (Jasperson et al., 
2010).  
Patients with gastrointestinal hamartomatous polyposis syndromes such as Peutz-
Jeghers Syndrome (PJS), Juvenile Polyposis Syndrome (JPS), and PTEN Hamartoma 
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Syndromes (such as Cowden’s Syndrome (CS)) also have a 40-80% chance to develop 
CRC. Clinically, these patients develop hamartomatous polyps as juveniles and require 
regular colonoscopies to prevent obstruction and remove precancerous lesions (Chen and 
Fang, 2009; Jasperson et al., 2010; Jelsig et al., 2014; Shaco-Levy et al., 2016). GI 
hamartoma syndromes are caused by inherited mutations in tumor suppressor genes, such 
as LKB1, SMAD4, BMPR1A, and PTEN; patients are statistically more likely to develop 
other solid tumor as well (Brosens et al., 2007; Gammon et al., 2009).  
For patients with inherited genetic mutations, the risk of developing CRC is so 
high that regular screening is an absolute necessity to extend lifespan. However, the 
overall percentage of CRC patients that develop CRC due to an inherited disorder is 
relatively low compared to the number of CRC cases caused by sporadic mutations. 
 
Aberrant Wnt Pathway Signaling in CRC 
 
 The majority of colorectal cancers arise due to sporadic mutations in the somatic 
cells rather than inherited genetic mutations. Many of these sporadic mutations can be 
caused by exposure to carcinogens; therefore it is important to minimize exposure to 
environmental risk factors. As in all cancers, mutations to either inactivate a tumor 
suppressor or to constitutively activate an oncogene are tumorigenic—in the case of 
CRC, this generally happens in the gastrointestinal epithelia. The most commonly 
mutated gene in colorectal cancer is an inactivating mutation in the tumor suppressor 
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APC. Approximately 80% of all colorectal tumors have an inactivating mutation in APC 
(Kwong and Dove, 2009).  
 APC (adenomatous polyposis coli) protein is a main component of the Wnt 
pathway (Aoki and Taketo, 2007; Clevers and Nusse, 2012; Fodde, 2002; Komiya and 
Habas, 2008; Kwong and Dove, 2009; Novellasdemunt et al., 2015; Rowan et al., 2000). 
The Wnt developmental signaling pathway was first identified by a mutation in the 
wingless gene in Drosophila melanogaster, and is involved in regulating cell growth, 
migration, polarity, and differentiation during development. When Wnt pathway 
signaling is inactive, β-catenin is associated with the Apc-Axin-GSK3β destruction 
complex in the cytosol. When bound to the Apc-Axin-GSK3β destruction complex, β-
catenin is phosphorylated by both CK1 and GSK3-β, and then degraded via β-TrCP and 
the proteasome.  
Wnt pathway signaling is activated when Wnt ligand binds to the Frizzled 
receptor and the LRP5/6 co-receptor. Once Wnt signaling is activated, the Apc-Axin-
GSK3β destruction complex is disrupted by Axin translocating to the plasma membrane 
to associate with Dishevelled, Frizzled, and the LRP5/6 receptors. With the disruption of 
the Apc-Axin-GSK3β destruction complex, β-catenin degradation is halted; this allows β-
catenin protein to translocate to the nucleus. Once in the nucleus, β-catenin binds to 
TCF/Lef proteins to drive Wnt target gene transcription (Clevers and Nusse, 2012; 
Komiya and Habas, 2008; Novellasdemunt et al., 2015; Stamos and Weis, 2013).  
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Figure 1.1. The Mammalian Wnt Pathway.  
Canonical Wnt Pathway is dependent on secreted Wnt ligand for activation. When Wnt 
Pathway is inactive, β-catenin associates with the Destruction Complex: GSK3β, Axin, 
and APC in the cytoplasm. β-catenin phosphorylation is mediated by β-TrCP, and 
phosphorylated β-catenin is degraded via the proteasome. Wnt pathway is activated when 
Wnt ligand binds to Frizzled and LRP5/6. The Destruction Complex is disrupted and 
Axin is recruited to the plasma membrane, where it associates with LRP5/6. GSK3β is 
inhibited by Dishevelled (Dsh), and then β-catenin accumulates. Accumulated β-catenin 
translocates to the nucleus, where it associates with Tcf to drive Wnt target gene 
transcription.  
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Activated Wnt signaling is critical for intestinal stem cell maintenance. The stem 
cells in the intestinal crypt display elevated levels of nuclear β-catenin and Wnt target 
gene expression, whereas differentiated epithelial cells exhibit cytoplasmic β-catenin 
localization and lower expression of Wnt target genes (Radtke and Clevers, 2005). With 
certain mutations in the APC gene, the resulting mutant APC protein is unable to 
associate with the Apc-Axin-GSK3β destruction complex to inhibit and degrade β-
catenin. The accumulation of nuclear β-catenin results in constitutive expression of Wnt 
pathway target genes (Radtke and Clevers, 2005). Constitutively active Wnt signaling 
drives proliferation of undifferentiated cells, eventually giving rise to tumors. Elevated 
Wnt target gene expression and accumulation of nuclear β-catenin is a hallmark of the 
majority of colorectal cancers (Fodde, 2002; Novellasdemunt et al., 2015; Rowan et al., 
2000).  
 APC mutations are also the initiating step in the Vogelstein model of 
carcinogenesis (Fearon and Vogelstein, 1990; Powell et al., 1992; Su et al., 1992). Fearon 
and Vogelstein first proposed that colorectal cancer occurs through the sequential 
accumulations of mutations, with mutations in APC acting as initiating event in the 
sequence. In traditional adenomas, the Vogelstein model hypothesis generally holds true; 
loss of APC generates constitutively activated Wnt signaling which leads to dysplastic 
aberrant crypt foci (Siu et al., 1997; Yuan et al., 2001). Over time, additional mutations in 
other genes such as KRAS, BRAF, SMAD4, and TP53 accumulate as the histology of the 
lesions progress from dysplasia to adenoma and eventually to adenocarcinoma (Fearon 
and Vogelstein, 1990; Yuan et al., 2001). Constitutively activated Wnt signaling through 
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sporadic Apc mutation contributes to tumorigenesis by generating a pro-growth 
environment that is more susceptible to tumorigenesis if subsequent sporadic mutations 
occur. 
 
 Apc-Mutant Mouse Models of Colorectal Cancer 
 
In order to understand the contribution by different tissue compartments in vivo 
during both normal homeostasis and tumorigenesis, genetically engineered mouse models 
(GEMMs) represent a powerful tool available for researchers (Oshima and Oshima, 2012; 
Roper and Hung, 2012; Taketo and Edelmann, 2009). Mouse models allow for spatial 
and temporal control of gene expression in an in vivo system, ultimately providing a 
robust system to understand both normal and tumorigenic environments at the organismal 
level. GEMMs also allow for the investigation of the ramifications of specific genetic 
events in vivo on a time scale and cost scale that is far more amenable than human 
clinical trials (Roper and Hung, 2012).  
 The first mouse model for colorectal cancer, which is now known as the ApcMin 
mouse, was discovered in 1990 by William Dove’s group following a mutagen screen 
with the carcinogen ethylnitrosourea (Moser et al., 1990) and later determined to be 
caused by a nonsense mutation in the Apc gene (Su et al., 1992). The ApcMin allele is 
transmitted via the germline in an autosomal dominant manner and yields a phenotype 
strikingly similar to the human FAP syndrome in both dominant inheritance pattern as 
well as the histological morphology of gastrointestinal polyps (Su et al., 1992). ApcMin 
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mice allowed for in depth characterization of CRC progression in a mammalian model 
for the first time (Moser et al., 1990) 
Because ApcMin heterozygous animals die due to anemia within a few months of 
birth, breeding the animals is easiest when the male is carrying the mutation. 
Interestingly, somatic homozygous loss of Apc in ApcMin/Min animals was found to be 
embryonic lethal; homozygous embryos have a severe defect in the primitive ectoderm, 
thereby indicating the critical requirement for functional APC/Wnt signaling during early 
development (Moser et al., 1995).  
 Since the identification of the ApcMin mutant, other transgenic mouse lines 
carrying somatic mutations in the Apc gene have been generated and characterized: 
Apc1638N/+ (Fodde et al., 1994; Smits et al., 1997) , ApcΔ716/+ (Oshima et al., 1995), 
ApcΔ14/+ (Colnot et al., 2004), ApcΔ15/+ (Robanus-Maandag et al., 2010), ApcΔ1309/+ 
(Quesada et al., 1998), ApcΔ508/+ (Kuraguchi et al., 2006), Apc+/Min-FCCC  (Cooper et al., 
2005), and Apc+/Δe1-15 (Cheung et al., 2010). Additionally, an Apc floxed allele was 
generated and recapitulates the ApcMin phenotype when Cre-recombination is induced in 
the intestinal epithelia (Shibata et al., 1997). All Apc mutant transgenic mice develop 
gastrointestinal polyps histologically similar to those in human FAP patients and patients 
with APC mutations. 
 Introducing a secondary mutation into an Apc mutant background is sufficient to 
accelerate tumor onset and severity in Apc-mouse models. Mouse models carrying 
mutations in either Kras or Smad4 accelerate tumorigenicity when crossed into a mutant 
Apc background, although interestingly loss of the tumor suppressor p53 does not 
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(Calcagno et al., 2008; Fazeli et al., 1997; Feng et al., 2011; Luo et al., 2009; Takuku et 
al., 1998; Trobridge et al., 2009). Overall, these experiments provide evidence that Apc-
mutant mouse models recapitulate the canonical Vogelstein model of colorectal 
carcinogenesis. Therefore, these mouse models are a robust genetic tool for investigating 
tumor initiation and progression in vivo.  
  
Hippo Signaling Pathway 
 
 While constitutively activated Wnt pathway signaling is the most common 
developmental pathway associated with colorectal cancer, other developmental signaling 
pathways have been implicated in tumorigenesis. One such developmental signaling 
pathway that plays a critical role in embryogenesis and is also commonly inactivated in a 
multitude of cancers is the Hippo Signaling Pathway. The Hippo Signaling Pathway was 
first characterized in Drosophila melanogaster, after members of the pathway were 
identified in a series of genetic screens for tissue growth regulation (Reddy and Irvine, 
2008). Now known to be a critical regulator of organ size and growth control (Halder and 
Camargo, 2013; Halder and Johnson, 2011; Pan, 2010; Varelas, 2014; Zhao et al., 
2010a), the Hippo Pathway takes its name from the fly hpo mutant; animals with mutant 
hpo in their imaginal eye discs develop oversized eyes and wrinkled head phenotype, 
reminiscent of the wrinkled skin of a hippopotamus (Udan et al., 2003). Mutations in 
Warts (Wts), another protein kinase in the Hippo Pathway, result in a similar phenotype 
to Hippo (Hpo) mutants. Genetic loss of either hpo or wts in developing imaginal discs 
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results in flies with enlarged organs as adults due to increased cellular proliferation and 
decreased apoptosis (Harvey et al., 2003; Jia et al., 2003; Justice et al., 1995; Pantalacci 
et al., 2003; Udan et al., 2003; Wu et al., 2003; Xu et al., 1995). The Hippo Pathway in 
Drosophila has since been shown to be a core protein kinase cascade pathway that 
restricts cellular proliferation and promotes apoptosis, thereby regulating organ and tissue 
size during development (Jia et al., 2003; Pantalacci et al., 2003; Wu et al., 2003).  
Hpo and Wts are the core components of the Hippo Pathway along with Sav 
(Salvador) and Mats (Mob As a Tumor Suppressor) (Kango-Singh et al., 2002; Tapon et 
al., 2002). These proteins converge on the transcriptional co-activator Yorkie (Yki) to 
regulate gene expression of growth and proliferation targets. Yorkie does not bind to 
DNA directly, but rather associates with Scalloped, a TEAD family transcription factor, 
to drive downstream gene expression (Goulev et al., 2008; Huang et al., 2005; Wu et al., 
2008).  
Mechanistically, when the Hippo Pathway is active, Hpo complexes with Sav and 
then phosphorylates to activate Wts. Phosphorylated Wts associates with Mats and then 
phosphorylates Yki on three canonical Wts phosphorylation sites- serine 111, (S111), 
serine 168 (S168), and serine 250 (S250) (Dong et al., 2007; Huang et al., 2005). 
Canonical Hippo Pathway regulation of Yki is inhibitory; phosphorylation of Yki by Wts 
kinase inhibits Yki activity. Phosphorylated Yki is excluded from the cell nucleus and 
then can be sequestered by 14-3-3 proteins or sent to the proteasome for degradation (Oh 
and Irvine, 2008, 2009). The eye overgrowth phenotype observed in hpo mutant flies 
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hinted at the critical role that the Hippo Pathway plays in mammalian organ size and 
regulation.  
 
 Mammalian Hippo Signaling Pathway 
 
The Hippo Pathway is not restricted to Drosophila melanogaster; in 2007 it was 
shown that the Hippo Pathway is also present in mammals, suggesting that it is an 
evolutionarily conserved pathway across species (Dong et al., 2007). The mammalian 
Hippo Pathway is also a kinase cascade pathway with a core set of pathway components 
homologous to the Drosophila melanogaster Hippo Pathway proteins. In the human 
pathway, the Hpo homologs are MST1/MST2 (Mammalian sterile-20-like kinase 1 and 
2). MST1/MST2 associate with SAV1 to phosphorylate and activate the Wts homologs, 
LATS1/LATS2 (Large tumor suppressor 1 and 2) (Creasy and Chernoff, 1995a, b; Tao et 
al., 1999; Tapon et al., 2002; Yabuta et al., 2000).  
Once phosphorylated, activated LATS1/LATS2 then phosphorylate the Yki 
homologs, YAP (Yes-associated protein) and its paralog TAZ (transcriptional co-
activator with PDZ-binding motif). As in Drosophila melanogaster, phosphorylation of 
YAP/TAZ by LATS1/LATS2 drives YAP/TAZ out of the nucleus into the cytoplasm 
(Chan et al., 2005; Hao et al., 2008; Lei et al., 2008; Oka et al., 2008; Zhang et al., 2008; 
Zhao et al., 2010b; Zhao et al., 2007). Like Yorkie, YAP/TAZ cannot bind DNA directly 
but must instead bind to transcriptional co-activator proteins, predominantly TEAD1-4, to  
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Figure 1.2. The Mammalian Hippo Signaling Pathway.  
When Hippo Pathway is activated, MST1/2 phosphorylates and activates LATS1/2, 
which phosphorylate and inhibit YAP/TAZ. Phosphorylated YAP/TAZ are sequestered in 
the cytoplasm by 14-3-3 proteins and can also be degraded via the proteasome. When 
upstream Hippo Signaling is inactivated, LATS1/2-mediated inhibitory phosphorylation 
is released and YAP/TAZ translocate to the nucleus, where they associate with TEAD 
proteins to drive transcription of downstream target genes.  
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regulate transcription of downstream gene targets (Chan et al., 2009; Vassilev et al., 
2001; Zhang et al., 2009). However, our lab and others have implicated AP1 as an 
additional YAP transcriptional co-activator in certain contexts (Liu et al., 2016; 
Zanconato et al., 2015). 
YAP and its paralog TAZ share 45% amino acid sequence homology and are both 
WW-domain containing proteins; YAP contains two WW domains and TAZ contains one 
WW domain. WW domains recognize the proline-rich PPxY motif sequence on many 
transcription factors and are believed to be important for transcriptional activation. 
YAP/TAZ both contain N-terminal TEAD transcription factor binding domains and 
associate with TEAD1-4 at this binding site (Varelas, 2014). Additionally, both YAP and 
TAZ contain binding sites for 14-3-3 proteins. When their 14-3-3 binding sites are 
phosphorylated, YAP/TAZ bind to 14-3-3 proteins and are sequestered in the cytoplasm 
(Kanai et al., 2000; Yagi et al., 1999). 
YAP is phosphorylated by LATS1/LATS2 kinase on 5 critical serine sites: S61, 
S109, S127, S164, and S381, all located within conserved HXRXXS recognition 
sequences. A sixth serine, S94, has been identified as a LATS1/LATS2 phosphorylation 
site, but the S94 site is more involved with YAP binding to TEAD proteins, rather than 
cytoplasmic sequestration (Zhao et al., 2008). A mutant YAP5SA construct, with the 5 
canonical LATS1/LATS2 phosphorylation sites mutated from serine to alanine, has been 
shown to render YAP impervious to LATS-mediated inhibitory phosphorylation. This 
results in the YAP5SA protein accumulating in the cell nucleus and driving target gene 
transcription, resulting in upregulation of growth and invasion in cell lines (Zhao et al., 
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2008). TAZ also has four canonical LATS1/LATS2 kinase recognition sequence motifs 
and is phosphorylated at S66, S89, S117, and S311. Mutating these four serines to alanine 
in TAZ4SA renders TAZ resistant to LATS-mediated inhibitory phosphorylation. Like 
the YAP5SA mutants, TAZ4SA results in a similar accumulation of nuclear TAZ and 
increase in growth (Lei et al., 2008) 
When Hippo Pathway members MST1/MST2 are genetically ablated from the 
liver in vivo using Cre-Lox alleles, a liver overgrowth phenotype is observed (Lee et al., 
2010; Lu et al., 2010; Song et al., 2010). Additionally, two groups showed in 2007 that 
doxycycline-induced liver specific overexpression of either YAP or YAP-S127A quickly 
induced hepatomegaly due to increase in cellular proliferation (Camargo et al., 2007; 
Dong et al., 2007). Importantly, this overgrowth was completely reversible; once mice 
were taken off doxycyline to stop expression of the YAP transgene, the mutant livers 
quickly returned to the same size as wildtype liver (Camargo et al., 2007; Dong et al., 
2007). 
These significant findings revealed that in mammals, organs sense the size they 
are supposed to attain during growth and development, and conclusively identified the 
Hippo Pathway as a master regulator of this important developmental size control 
mechanism.  
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 Upstream Regulation of Hippo Pathway 
 
 The core components of the Hippo Pathway include the kinase cascade from 
MST1/MST2 to LATS1/LATS2 to YAP/TAZ. Beyond the core kinase cascade, a number 
of cellular mechanisms have been shown to interact with the core Hippo Pathway 
components under a myriad of conditions to ultimately converge on YAP/TAZ regulation 
(Meng et al., 2016).  
In addition to evidence that MST1/MST2 proteins undergo autophosphorylation 
(Praskova et al., 2004), MST1/MST2 have also been shown to be activated through direct 
phosphorylation by TAO kinases 1/2/3 (Boggiano et al., 2011; Poon et al., 2011). 
Independently of canonical Hippo Pathway regulation by MST1/MST2, LATS1/LATS2 
can be phosphorylated by other protein kinases. MAP4K proteins have been shown to 
directly phosphorylate and activate LATS1/LATS2 under certain conditions, thereby 
inhibiting downstream YAP/TAZ activity (Meng et al., 2015; Zheng et al., 2015). 
Additionally, our lab helped collaborators show that in Drosophila, MAP4K4 homolog 
Msn can directly phosphorylate Wts to negatively regulate Yki in enteroblasts in the fly 
gut (Li et al., 2014a). Therefore, there is evidence that MAP4K protein kinases can 
impact Hippo Pathway members through direct phosphorylation of both LATS1/2 as well 
as YAP/TAZ.  
 Cell-cell contact and cell density have also been shown to regulate Hippo 
Pathway signaling (Nishioka et al., 2009; Ota and Sasaki, 2008; Zhao et al., 2007). When 
cells are seeded at very high density, the Hippo Pathway is activated to phosphorylate 
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YAP/TAZ through LATS1/LATS2. At conditions of low cell density, the Hippo Pathway 
is inactivated and the inhibitory phosphorylation on YAP/TAZ is released to allow 
YAP/TAZ to translocate to the nucleus and upregulate target genes for proliferation and 
growth. Contact-mediated YAP inhibition has been shown to be required for different 
developmental processes, including the specification of the trophectoderm during early 
mouse development (Nishioka et al., 2009). 
 Related to cell-cell contact, YAP/TAZ have also been shown to be responsive to 
mechanical forces generated by the extracellular matrix. When cells are plated on ECM 
with varying stiffness, YAP/TAZ subcellular localization changes as a result of the 
tension forces placed on the actin cytoskeleton by the ECM (Dupont et al., 2011). 
Recently, it has been shown that stretch forces transferred to the nuclear envelope via the 
cytoskeleton is critical for YAP/TAZ activation in mesenchymal stem cells (Driscoll et 
al., 2015). Regulation of nuclear YAP after cell attachment to ECM is through activation 
of Rho-GTPases (Yu et al., 2012). Additionally, LATS1/LATS2 have been shown to be 
activated through cell detachment, resulting in inhibition of YAP/TAZ (Zhao et al., 
2012). These data suggest the possibility that the mechanical forces that exist within 
growing tissues may be a mechanism through which the Hippo Pathway senses overall 
organ size. 
The Hippo Pathway could also be sensing external stimuli through direct 
interactions with the actin cytoskeleton. This interaction has been shown to be mediated 
in part by interactions with the angiomotin protein family. Angiomotin family proteins 
localize to tight junctions, are known to be important for cell-cell contact, and also 
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interact with the F-actin cytoskeleton. Angiomotin family proteins have been shown to 
inhibit YAP/TAZ. The angiomotin family protein AMOTL2 is a scaffolding protein that 
binds both LATS2 and YAP/TAZ, which promotes LATS-mediated YAP/TAZ 
phosphorylation (Paramasivam et al., 2011; Zhao et al., 2011). Angiomotins are also 
direct phosphorylation targets of LATS1/LATS2 (Dai et al., 2013). Once phosphorylated 
by LATS1/LATS2, the interaction between AMOT and actin fibers is disrupted, resulting 
in reduction of focal adhesions and the inhibition of cell migration. These data provide 
further evidence that cell-cell contact and organization of the actin cytoskeleton, in this 
case through the angiomotions, represents a critical upstream regulation of Hippo 
Pathway signaling. 
In addition to cell-cell contact, the Hippo Pathway can be regulated by G-protein 
coupled receptors (GPCRs) and Rho-GTPases. Secreted factors, such as hormones, have 
been shown to regulate YAP/TAZ activity through GPCRs. GPCRs can both inhibit and 
activate YAP/TAZ, dependent on context and GPCR receptor type. For example, 
LATS1/LATS2 are inhibited, and YAP/TAZ subsequently activated, by G12/13-coupled 
receptors when HEK293A and MCF10A cells are stimulated with either lysophosphatidic 
acid (LPA) or sphingosine 1-phosphophate (S1P) (Yu et al., 2012). In contrast, when Gs-
coupled receptors are stimulated with the hormones glucagon or epinephrine, 
LATS1/LATS2 are activated, and YAP/TAZ subsequently inhibited (Yu et al., 2012). 
Since this critical finding, other groups have confirmed GPCR regulation of YAP/TAZ to 
be universally conserved mechanisms to both positively and negatively regulate Hippo 
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Pathway signaling (Miller et al., 2012; Mo et al., 2012; Yu et al., 2013; Zhou et al., 
2015b).  
Finally, the Hippo Pathway has recently been shown to regulate itself through a 
YAP/TAZ feedback regulation mechanism (Dai et al., 2015; Meng et al., 2015; Moroishi 
et al., 2015b). Knockout of YAP in either liver or intestinal epithelia results in the 
accumulation of TAZ. YAP directly activates its own upstream inhibitors LATS2 and 
AMOTL2 through transcriptional upregulation (Dai et al., 2015). Additionally, both YAP 
and TAZ directly activate LATS1/LATS2 in MCF10A and HEK293A cells (Moroishi et 
al., 2015b). YAP/TAZ feedback regulation also explains the phenotype observed in 
YapS112A transgenic mice. In these mice, animals appear normal and healthy unless 
stressed with the carcinogen diethylnitrosoamine (DEN), and animals then develop 
hepatocellular carcinoma (Chen et al., 2015). This overall phenotypic normality in 
YapS112A transgenic mice may be due to phosphorylation at other LATS1/LATS2 
phosphorylation sites other than S112. However, this phenotype could also be caused in 
part by feedback regulation; TAZ is downregulated in response to the increase in YAP 
protein.  
Upstream regulation of YAP/TAZ by canonical Hippo Pathway as well as non-
canonical regulation is both multi-faceted and context-specific. Continued exploration 
into how this complex regulation functions during development and homeostasis will 
shed insight into how aberrant Hippo Pathway activation contributes to tumorigenesis. 
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 Hippo Pathway in Cancer 
 
 The Hippo Pathway plays a critical role in organ size control during development 
and regeneration. Through strict regulation of YAP/TAZ, upstream kinases maintain 
homeostasis and prevent uncontrolled cell growth. However, nuclear YAP/TAZ is 
associated with many human cancers. Thus, similar to the aberrant activation of the Wnt 
and Hedgehog developmental signaling pathways, constitutive YAP/TAZ activity is also 
considered to be tumorigenic.  
 Many human cancers display elevated levels of nuclear YAP/TAZ protein (Chan 
et al., 2008; Fernandez et al., 2009; Harvey et al., 2013; Johnson and Halder, 2014; Mo et 
al., 2014; Moroishi et al., 2015a; Overholtzer et al., 2006; Steinhardt et al., 2008; Xu et 
al., 2009; Zender et al., 2006). In MCF10A cells, YAP overexpression is sufficient to 
induce epithelial-to-mesenchymal transition (EMT) and increase proliferation 
(Overholtzer et al., 2006). In hepatocellular carcinoma cells, YAP overexpression 
increases tumor growth after xenograft (Zender et al., 2006). TAZ protein has also been 
shown to be overexpressed in highly invasive breast cancer cell lines and knockdown of 
TAZ is sufficient to reduce invasion (Chan et al., 2008). Overall, these studies indicate 
that YAP/TAZ activity is oncogenic in solid tumors.  
Recent studies have continued to investigate whether nuclear YAP/TAZ can be 
considered a bona fide prognostic marker for overall survival in human patients. In 
human hepatocellular carcinoma (HCC) tumor samples, one group reported 62% of HCC 
cases examined displayed nuclear YAP staining patterns and found a positive correlation 
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between nuclear YAP and more undifferentiated tumor cells (Xu et al., 2009). Another 
group investigated non-small cell lung cancer (NSCLC) and found nuclear YAP 
expressed in 66.3% (61/92) patient cases, and identified a correlation between nuclear 
YAP expression and shorter overall patient survival (Wang et al., 2010). A similar study 
in NSCLC patients showed a similar correlation between upregulation of TAZ protein in 
66.8% (121/181) patients and shorter overall survival (Xie et al., 2012b). Finally, in 
breast cancer cell lines, higher levels of TAZ protein expression indicated greater 
resistance to the chemotherapeutic agent taxol through activation of downstream target 
genes CTGF and CYR61, and knockdown of TAZ was sufficient to sensitize cells to taxol 
treatment (Lai et al., 2011). These studies provide support that nuclear YAP/TAZ 
indicates a poor overall prognosis in a number of solid tumor cancers. 
YAP/TAZ nuclear localization has also been shown to be a prognostic marker in 
gastrointestinal cancers. In esophageal and gastric adenocarcinomas, YAP protein levels 
were significantly increased in both cytoplasm and nucleus (Lam-Himlin et al., 2006). In 
gastric cancer, another group investigated gastric cancer patient samples and found high 
TAZ protein expression in 77.4% (113/146) of samples investigated, and when stratified 
by subtype of cancer, saw that signet cell carcinoma patient samples exhibited high TAZ 
protein expression in 85.7% of samples (Yue et al., 2014). Finally, in colorectal cancer 
patients, a survey of data from 522 patients revealed that patients with high levels of Taz 
or the YAP/TAZ target genes expression had significantly shorter overall survival (Yuen 
et al., 2013). 
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 Overall, solid tumor samples from human patients showed a strong correlation 
between invasive cancer and nuclear YAP/TAZ levels in breast, lung, and colorectal 
cancer (Steinhardt et al., 2008). These data also provide evidence that inhibiting 
YAP/TAZ activity with targeted therapies may be a beneficial strategy to inhibit cancer 
cell growth. 
When YAP/TAZ translocate to the nucleus, they bind to the TEAD family of 
transcription factors. YAP/TAZ are unable to bind DNA directly, and must instead 
interact with DNA-binding proteins in order to induce target gene expression (Vassilev et 
al., 2001). Therefore, nuclear accumulation of YAP/TAZ can be oncogenic due to 
YAP/TAZ functioning as transcriptional co-activators to upregulate genes involved with 
growth and proliferation. Additionally, in certain contexts YAP/TAZ/TEAD can 
associate with additional transcription factors to drive target gene expression and promote 
oncogenesis. For example, we and others have shown that AP-1 and TEAD cooperate to 
increase YAP/TAZ target gene expression in cancer cell lines, which results in increased 
migration and invasion (Liu et al., 2016; Zanconato et al., 2015).  
While a correlation between accumulation of nuclear YAP/TAZ and poor 
prognosis for overall patient survival has been observed in many different types of solid 
tumors, it is surprising how few somatic or germline mutations have been identified in 
the Hippo Pathway in patients (Johnson and Halder, 2014; Moroishi et al., 2015a; 
Zanconato et al., 2016).  One explanation for this observation could be an increase in 
gene copy number; genomic amplification of the Yap gene has been observed in mouse 
mammary tumors (Overholtzer et al., 2006). This could explain why YAP/TAZ proteins 
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are often observed to be overexpressed in human tumors despite the lack of genetic 
mutations. Another confounding observation is that despite playing a critical role in 
growth and differentiation, the list of canonical YAP/TAZ target genes is relatively short. 
This conundrum was recently addressed in the discovery by Zanconato et al. that 
YAP/TAZ can act as super enhancers to increase gene transcription of general growth 
and proliferation genes through chromatin looping (Zanconato et al., 2015). The finding 
that YAP/TAZ play a critical role in gene expression by acting at super enhancer regions 
was also confirmed by Galli et al., with an additional finding that YAP/TAZ directly 
recruit the Mediator complex to super enhancer sites (Galli et al., 2015). These data 
suggest that the YAP/TAZ can contribute to tumorigenesis through many mechanisms. 
Conversely, it also been recently discovered that YAP/TAZ can act as tumor 
suppressors instead of oncogenes. Therefore, loss of YAP/TAZ might actually be tumor 
promoting in certain contexts. One study showed that a number of breast cancer patients 
had lost YAP protein expression in their tumors, as assayed by immunohistochemistry 
staining of biopsy sections, as well as through sequencing (Yuan et al., 2008). Another 
study showed that shRNA knockdown of YAP in MDA-MB-231 cells was sufficient to 
protect from anoikis and to increase anchorage-independent cell growth (Yuan et al., 
2008). Finally, in contrast to earlier work showing that YAP acts as an oncogene in the 
intestinal epithelia, Barry et al. showed that intestinal epithelial knockout of Yap was 
sufficient to drive elevated Wnt signaling and expansion of the stem cell population after 
radiation-induced injury (Barry et al., 2013; Cai et al., 2010; Camargo et al., 2007). 
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Overall, these findings highlight the complexity of YAP/TAZ activity in tumorigenesis 
and the importance for further exploration into their context-specific roles. 
Finally, while the general canon in the Hippo Pathway field has been that 
YAP/TAZ act as transcriptional co-activators to drive transcription of gene targets for 
growth and proliferation, it has recently been shown that under certain circumstances, 
YAP/TAZ can act as transcriptional co-repressors. Kim et al. showed that in MCF10A 
cells, YAP/TAZ-TEAD directly recruit and interact with the NURD complex to repress 
expression of the tumor suppression genes DDIT4 and TRAIL (Kim et al., 2015b). When 
YAP/TAZ are removed from the system via siRNA knockdown, YAP/TAZ/NURD-
repression of DDIT4 and TRAIL is relieved, the promoters are acetylated, and the tumor 
suppressor genes are actively expressed. YAP/TAZ are still functioning as oncogenes; 
however, they are acting as transcriptional co-repressors of known tumor suppressor 
genes, rather than transcriptional co-activators of oncogenes. 
Recent studies have elucidated the complex relationship between YAP/TAZ 
activity and tumorigenesis; it is no longer sufficient to assume that accumulation of 
nuclear YAP/TAZ is an oncogenic event in every situation. Further exploration into the 
context-specific function of nuclear YAP/TAZ and how it relates to tumorigenesis is 
desperately needed to help tease apart the intricacies of this complex pathway. 
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 Molecular Compounds to Target the Hippo Pathway 
 
 While recent work has suggested that YAP/TAZ activity can be both tumor 
suppressive as well as oncogenic, there remains clinical interest in developing 
pharmacological agents to target Hippo Pathway members. Directly inhibiting YAP/TAZ 
activity or activating upstream Hippo Pathway members in human cancers with nuclear 
accumulation of YAP/TAZ is an attractive therapeutic strategy (Steinhardt et al., 2008). 
Many groups have shown that knockdown of either YAP/TAZ or TEAD proteins is 
sufficient to reduce growth and proliferation in cancer cell lines or mouse models of 
tumorigenesis (Ota and Sasaki, 2008; Wu et al., 2008; Zhang et al., 2009; Zhao et al., 
2008). Therefore, an ideal candidate for YAP/TAZ inhibition could act through a number 
of mechanisms (e.g. inhibit YAP/TAZ protein, activate LATS1/LATS2, or inhibit TEAD 
proteins) to achieve the desired outcome: inhibition of YAP/TAZ-directed transcription 
of growth and survival genes in cancer cells.  
 Initial efforts to generate drugs to inhibit YAP/TAZ in patients focused on 
identifying small molecule compounds that inhibit YAP activity. A small molecule 
screen identified verteporfin, a member of the porphyrin molecule family, as a direct 
YAP protein inhibitor. Verteporfin binds to YAP directly and disrupts the YAP-TEAD 
interaction (Liu-Chittenden et al., 2012). Treatment of HEK293 cells with verteporfin 
increases trypsin-mediated degradation of YAP protein, and inhibited YAP-driven liver 
enlargement in mouse models with YAP overexpression (Liu-Chittenden et al., 2012). 
This identification of verteporfin as a YAP-inhibitor was particularly promising because 
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verteporfin had already been shown to be well-tolerated in human patients, and had been 
used in the clinic as a photodynamic therapy for macular degeneration (Michels and 
Schmidt-Erfurth, 2001). Verteporfin has since been shown to be effective in inhibiting 
retinoblastoma (Rb) cell growth in vitro through inhibition of YAP-TEAD (Brodowska et 
al., 2014). It has also been shown to inhibit growth of uveal melanoma cells carrying 
mutated copies of either GNAQ or GNA11, mutations that have been shown to activate 
YAP protein, both in vitro and in vivo in xenograft models (Yu et al., 2014). Overall, 
these in vitro studies suggested that verteporfin was a robust YAP inhibitor and could be 
a groundbreaking new drug for patients with cancer. 
However, despite the excitement surrounding verteporfin as a promising cancer 
drug, clinical trials have proved to be less exciting. Verteporfin is a robust YAP inhibitor 
in vitro, but this inhibitory effect is not nearly as robust when the drug is administered 
systemically (Gibault et al., 2016). Indeed, while it has been shown that verteporfin is 
able to inhibit growth of colorectal cancer cells in vitro, this anti-tumorigenic effect was 
found to be due to a YAP-independent mechanism; verteporfin was found to inhibit p62 
and STAT3 to inhibit colorectal cancer cell growth (Zhang et al., 2015). Additionally, 
verteporfin has been shown to significantly inhibit growth of cancer cell lines derived 
from other solid tumors that have been depleted of YAP protein through shRNA 
knockdown (Zhang et al., 2015). Based on these findings, verteporfin remains an 
important tool for in vitro experiments studying YAP inhibition, but is not an ideal drug 
for systemic treatment in vivo in mice or humans (Gibault et al., 2016).  
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 More recent efforts to generate YAP/TAZ inhibitors have been focused on 
developing a drug capable of interfering with the YAP-TEAD binding interaction (Liu-
Chittenden et al., 2012; Pobbati and Hong, 2013). When TEAD1 protein is mutated at 
just a single site, Y406H, in BEL-7404 hepatocellular carcinoma cells, the YAP-TEAD 
interaction is disrupted and growth of xenograft tumors is inhibited (Zhou et al., 2015c). 
Additionally, one group developed 17-mer peptides that bind directly to TEAD proteins 
at the YAP-TEAD binding interface to inhibit YAP activity (Zhou et al., 2015c). These 
studies suggest that small molecule inhibition of YAP-TEAD binding could provide 
therapeutic benefit for patients with constitutive YAP activation. 
 Endogenous proteins that inhibit the YAP-TEAD interaction in vivo are also ideal 
candidates for targeted therapies. It may be therapeutically challenging to develop a drug 
that inhibits YAP activity directly at a concentration that has minimal side effects in 
humans. However, it may be easier to activate an endogenous protein with YAP-
inhibitory function. One such protein, Vestigial-like protein 4 (VGLL4), was recently 
shown to disrupt the YAP-TEAD interaction through competitive TEAD binding (Zhang 
et al., 2014). In both lung and gastric cancer, VGLL4 is downregulated in a significant 
number of patient cases, and when VGLL4 protein is added back to the system, tumor 
growth is inhibited (Chen et al., 2004; Jiao et al., 2014; Jin et al., 2011; Zhang et al., 
2014). Additionally, a peptide that mimics the structure of VGLL4 binding site to the 
TEAD proteins also inhibits the YAP-TEAD interaction and results in growth inhibition 
of cancer cells both in vitro and in vivo (Jiao et al., 2014). Therefore, activation of an 
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endogenous YAP inhibitor such as VGLL4 represents a potential therapeutic strategy for 
cancer patients. 
 Overall, developing YAP/TAZ inhibitors is important for future research as well 
as eventual treatment strategies for patients. However, recent work has shown that 
YAP/TAZ activity and function is context-specific. Therefore, it is imperative that we 
understand YAP/TAZ activity during development and homeostasis in a range of tissues. 
This knowledge will ultimately improve our insight into how this pathway contributes to 
tumorigenesis.  
   
 Hippo Pathway in Mammalian Development 
 
 The Hippo Pathway is a major contributor to mammalian development, even as 
early as the pre-implantation stages of embryogenesis. YAP/TAZ nuclear localization is 
required in the patterning of the mouse embryonic trophectoderm. Cells in the outer layer 
of the developing mouse embryonic blastocyst, which eventually gives rise to the 
trophectoderm, display nuclear YAP/TAZ subcellular localization. By contrast, cells in 
the inner cell mass (ICM) display cytoplasmic YAP/TAZ localization (Nishioka et al., 
2009). Similarly, siRNA knockdown of both LATS1/LATS2 early in development also 
results in severe developmental defects; mutant tissue is unable to differentiate into either 
epiblast or primitive endoderm tissues (Lorthongpanich et al., 2013). Finally, it was 
shown that the Hippo-regulated determination of cell polarity, which is critical for 
differentiation at pre-implantation development stages, is acting through the Angiomotin 
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proteins. This Amot-LATS interaction is critical for regulation of YAP/TAZ (Hirate et 
al., 2013). These findings illustrate that Hippo Pathway signaling is involved with a 
number of complex developmental processes during early embryogenesis. 
Further evidence that Hippo Pathway activity is critical in early stages of 
embryogenesis comes from in vivo mouse model experiments. Simultaneous homozygous 
knockout of both Yap and Taz is embryonic lethal; mouse embryos lacking both YAP and 
TAZ die early in development at the morula stage due to cell fate defects (Nishioka et al., 
2009). However, animals lacking just Yap or Taz survive past this early developmental 
stage. This indicates that YAP/TAZ can compensate for each other in this developmental 
instance through functional redundancy. 
While YAP/TAZ exhibit functional redundancy at very early developmental 
stages, this relationship does not continue through embryogenesis. Whole body knockout 
of Taz is tolerated by animals and embryos survive through to birth, but adult Taz-/- 
animals develop renal cysts as they age (Hossain et al., 2007). This indicates that TAZ is 
dispensable for mammalian development and YAP is able to functionally compensate for 
loss of TAZ throughout the entirety of embryogenesis as well as most of adulthood. 
However, the reverse relationship is not true. Whole body knockout of Yap is embryonic 
lethal by E8.5 and Yap-/- embryos exhibited severe defects in yolk sac vasculogenesis 
(Morin-Kensicki et al., 2006). This indicates that TAZ is only able to compensate for 
YAP loss until E8.5, when YAP activity is critical for vasculogenesis.  
YAP activity is required for embryonic development. However, too much YAP 
activity is similarly incompatible with development; YAP/TAZ function is tightly 
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regulated by upstream Hippo Pathway kinases. Whole body Lats1 knockout animals 
survive through to adulthood, although Lats1-/- animals are prone to developing ovarian 
tumors and sarcomas (St et al., 1999). By contrast, Lats2-/-- is embryonic lethal due to a 
cardiac development defect phenotype (McPherson et al., 2004). The important balance 
between YAP activity and upstream kinases during development is highlighted by an 
experiment that investigated MST1/MST2 activity during embryogenesis. Knockout of 
MST1/MST2 causes embryos to die around E8.5, and interestingly, mutant embryos 
exhibit similar phenotype to Yap-/- mutants. Specifically, Mst1-/-Mst2-/- embryos display 
impaired vasculogenesis in both the yolk sac and embryo (Oh et al., 2009). Therefore, 
there exists a critical balance between YAP/TAZ activation and inhibition at this 
developmental timepoint, which is tightly controlled by canonical Hippo Pathway 
signaling. 
Hippo Pathway signaling is also required in the lung epithelia during 
development. Genetic knockout of both Mst1 and Mst2 in the developing lung endoderm 
results in a lung differentiation defect phenotype. ShhCreMst1flox/floxMst2flox/flox lung tissue 
exhibits elevated proliferation as well as accumulation of nuclear YAP protein (Lin et al., 
2015). This phenotype is ameliorated when Yap is also knocked out in the MST1/MST2 
null background. Additionally, knockout of YAP alone in the developing lung endoderm 
also results in a lethal phenotype; mutant embryos die at birth and exhibit a profound 
lung branching defect (Mahoney et al., 2014). Together, this suggests that canonical 
Hippo Pathway kinase activity is regulating YAP activity in the developing lung 
endoderm. 
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In addition to the previously discussed developmental requirements, Hippo 
Pathway signaling is also essential in the mammalian heart during embryonic 
development. When the conditional Cre driver Nkx2.5Cre is used to knock out Sav1 in the 
developing cardiac crescent in the heart, mutant animals develop cardiomegaly and 
eventually die after birth (Moses et al., 2001). Both genetic knockouts of Lats1/Lats2 and 
Mst1/Mst2 using the same Nkx2.5Cre allele yield similar enlarged heart phenotypes due to 
increased cardiomyocyte proliferation (Heallen et al., 2011a). Additionally, 
overexpression of YAP using a Tet-On system for expression of a mutant Yap-S127A 
allele starting from E8.5 resulted in embryonic lethality by E15.5 due to heart failure 
caused by cardiomegaly (von Gisea et al., 2012). Together, these genetic experiments 
suggest that too much YAP activity is detrimental to proper heart development. 
Conversely, too little YAP activity is also incompatible to successful cardiac 
development. Genetic YAP knockout using Tnnt2Cre to delete Yapflox alleles at E12.5 in 
cardiomyocytes is sufficient to cause lethality in all mutant embryos by E16.5 due to 
heart failure (von Gisea et al., 2012).  
Similar to what was observed with tightly regulated Hippo Pathway signaling 
contributing to differentiation during pre-implantation stages in the mouse embryo, YAP 
levels must also be balanced for successful cardiac development. Overall, tightly 
regulated control of YAP/TAZ by Hippo Pathway signaling is essential to maintain the 
optimal balance of nuclear YAP/TAZ in multiple key developmental processes.  
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 Hippo Pathway in GI Homeostasis and Regeneration 
 
The Hippo Pathway has also been shown to have critical functions in the 
mammalian intestine during both development and regeneration. The intestinal epithelia 
is highly proliferative in the crypt, where intestinal stem cells constantly divide and 
differentiate into different classes of epithelial cells to continually repopulate the 
epithelial compartment. These diverse classes include the paneth cells and endocrine 
cells, which reside in the crypt, as well as the enterocyte and goblet cells that leave the 
crypt to populate the surface of the villi. The cells on the surface of the villi are important 
for nutrient absorption (Barker et al., 2007; Paxton et al., 2003; Radtke and Clevers, 
2005; Shaker and Rubin, 2010). The subcellular localization of YAP/TAZ protein has 
been well characterized in normal intestinal epithelial tissues; YAP/TAZ protein is 
predominantly cytoplasmic in the epithelial cells lining the villi and is predominantly 
nuclear in the crypt cells, where the ISCs reside (Barry et al., 2013).  
Several groups have shown that constitutive YAP overexpression and/or 
accumulation of nuclear YAP in the mouse intestinal epithelia is sufficient to drive 
proliferation of undifferentiated ISCs (Azzolin et al., 2014; Cai et al., 2010; Camargo et 
al., 2007; Zhou et al., 2011). In 2007, Camargo et al. generated a Tet-On YAPS127A 
gain of function mouse allele which has the critical phosphorylation site for 14-3-3 
binding mutated from serine to alanine. They showed that upregulated expression of the 
YAPS127A allele induces rapid proliferation of undifferentiated cells and tissue 
dysplasia in the intestinal epithelia, which is quickly reversed once expression of the 
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YAP transgene is turned off (Camargo et al., 2007). In 2010, Cai et al. reported that when 
the upstream Hippo Pathway component Salvador is knocked out in the intestinal 
epithelia, VillinCreSav1flox/flox animals exhibited elevated epithelial cell proliferation, crypt 
hyperplasia, and eventually develop sessile serrated colonic polyps by 13 months of age. 
Polyp onset was greatly accelerated if animals are treated with dextran sodium sulfate 
(DSS) to induce chemical colitis (Cai et al., 2010). Additionally, when MST1/MST2 are 
knocked out in the intestinal epithelia, VillinCreMst1flox/floxMst2flox/flox mutants exhibit 
reduced survival with a median survival of 13 weeks, in addition to highly proliferative, 
dysplastic crypts and polyps in the cecum (Zhou et al., 2011). These genetic experiments 
highlighted the link between YAP/TAZ activation and tumorigenesis in the intestinal 
epithelia. 
While the observation that accumulation of nuclear YAP is sufficient to drive 
proliferation of undifferentiated ISCs and eventually lead to tumorigenesis is relatively 
straightforward, the opposite experiment, genetic ablation of YAP protein, has revealed a 
far more complex relationship between YAP protein and intestinal 
homeostasis/regeneration. Surprisingly, genetic knockout of YAP in VillinCreYapflox/flox 
mutants yielded no observable phenotype. Mutant animals appear healthy and 
phenotypically normal with no differentiation defects (Barry et al., 2013; Cai et al., 
2010). As the VillinCre transgene expression induces Cre-mediated recombination of 
floxed alleles in all intestinal epithelial cells starting from E12.5 (Madison et al., 2002), 
this indicates that YAP protein is completely dispensable for normal intestinal 
homeostasis starting at E12.5 and through postnatal stages. One hypothesis to explain 
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why YAP knockout yields no phenotype in the developing intestinal epithelia is that 
endogenous TAZ protein could be functionally compensating for YAP. However it has 
recently been shown by a number of groups that knockout of both YAP and TAZ in the 
intestinal epithelia does not cause any phenotype in double knockout animals under 
normal intestinal homeostasis conditions (Azzolin et al., 2014; Cai et al., 2015; 
Zanconato et al., 2015). These data show that YAP/TAZ are completely dispensable in 
the intestinal epithelia during development, which is in contrast to many other tissues 
such as the lung and heart. Further research is needed to fully understand why YAP/TAZ 
are not required in the intestinal epithelia during development and homeostasis. 
While not required under normal conditions, a severe regeneration phenotype has 
been observed when the YAP-deficient intestinal epithelium is injured. As briefly 
discussed in an earlier section (see Hippo Pathway in Cancer), Cai et al. first showed that 
an intestinal epithelial knockout of Yap was phenotypically normal under conditions of 
homeostasis but generated a severe regeneration phenotype following injury (Cai et al., 
2010). When VillinCreYapflox/flox animals were treated with DSS, mutant animals 
experienced increased mortality and complete loss of intestinal crypts, in addition to a 
significant reduction in epithelial cell proliferation and an increase in apoptotic cells. Cai 
et al. concluded that this severe phenotype indicated that YAP protein was dispensable 
for intestinal epithelial development but becomes essential during tissue regeneration 
(Cai et al., 2010).  
In 2013, Barry et al. published work that directly contradicted Cai et al.’s 
findings. Barry et al. claimed that YAP is acting as a tumor suppressor, rather than an 
42 
 
oncogene, in the intestinal epithelia to inhibit growth and regeneration (Barry et al., 
2013). Using the same genetic knockout strategy, VillinCreYapflox/flox, Barry et al. induced 
intestinal tissue damage using whole-body irradiation instead of treatment with DSS. 
Instead of observing the complete loss of intestinal crypt cells due to apoptosis, they 
observed expansion of undifferentiated Lgr5+ stem cells in the intestinal stem cell niche 
(Barry et al., 2013). From these data, they concluded that epithelial YAP restricts ISC 
growth during regeneration. 
However, it must be noted that the two methods of injury-induction could be the 
cause for the contrasting observations. DSS treatment acts directly on the intestinal 
epithelia by increasing epithelial cell permeability and inducing acute colitis (Tamaru et 
al., 1993). Whole-body irradiation damages rapidly dividing cells, such as intestinal 
epithelial cells. Unlike DSS, irradiation also affects non-epithelial cells in the 
gastrointestinal tract such as adjacent mesenchymal cells (Potten, 1990). One hypothesis 
to explain the differing phenotypes is that the irradiation affects the signaling crosstalk 
between tissue compartments in the intestinal epithelia. Regardless, these two findings 
highlight the complexity that exists in Hippo Pathway regulation in the intestinal epithelia 
as well as the importance of context-specificity.  
 
 Intersection between Hippo Pathway and Wnt Pathway 
 
 One complexity is the intersection between Hippo and Wnt Pathway signaling in 
the intestinal epithelia. In certain contexts, nuclear YAP/TAZ activates Wnt pathway in 
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the intestinal epithelia. Imajo et al. reported that the phosphorylated YAP/TAZ directly 
binds to phosphorylated β-catenin (Imajo et al., 2012). The authors concluded that Hippo 
Pathway kinases inhibit Wnt target gene expression through this protein-protein 
interaction. Therefore, when upstream Hippo Pathway kinase activity is lost and 
YAP/TAZ translocate to the nucleus to drive gene expression, the phosphoYAP/TAZ-
mediated inhibition of β-catenin is also relieved. 
 YAP/TAZ have also been shown to inhibit Wnt pathway signaling in the 
intestinal epithelia. One group found that YAP acts to inhibit Wnt pathway signaling 
independently of the APC-Axin-GSK3β destruction complex through inhibition of the 
Wnt effector, DVL (Barry et al., 2013). They observed that Wnt pathway signaling was 
upregulated, and undifferentiated stem cells were expanded in YAP-deficient tissue 
following injury caused by either irradiation or treatment with the Wnt agonist R-
spondin. These observations supported a similar previous finding, when Varelas et al. 
reported that TAZ acts to inhibit Wnt/β-catenin pathway signaling through direct binding 
to, and inhibition of Dishevelled in the mouse kidney (Varelas et al., 2010). More 
recently, another group also showed that during intestinal regeneration, YAP inhibits Wnt 
pathway signaling to prevent differentiation while allowing for Lgr5+ stem cells to be 
reprogrammed (Gregorieff et al., 2015). Collectively, these data suggest that YAP 
inhibits Wnt pathway in the intestinal epithelia during regeneration. 
 Reciprocal regulation, with Wnt signaling regulating YAP/TAZ independently of 
canonical Hippo Pathway kinases, has also been proposed. Azzolin et al. showed that 
YAP/TAZ were critical components of the β-catenin destruction complex during Wnt 
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signal transduction (Azzolin et al., 2014; Azzolin et al., 2012). The authors reported that 
TAZ acts in a non-canonical, Hippo Pathway-independent manner as part of activated 
Wnt pathway signaling. In that study, they observed that when Wnt signaling is inactive, 
phosphoryled β-catenin and phosphorylated TAZ both interact via the destruction 
complex. This interaction aids in ubiquitin-mediated degradation of phosphorylated TAZ 
(Azzolin et al., 2012). When Wnt signaling is activated, APC-Axin-GSK3β-mediated 
degradation of both β-catenin and TAZ is inhibited, and both proteins are able to 
accumulate, translocate to the nucleus, and drive transcription of downstream target 
genes (Azzolin et al., 2012). A few years later, the same group also reported that YAP 
functions in a similar manner as TAZ. Cytoplasmic YAP/TAZ bind to Axin when Wnt 
signaling is inactive. Through the interaction with Axin in the destruction complex, 
YAP/TAZ act to help inhibit β-catenin (Azzolin et al., 2014). When Wnt signaling is 
activated, YAP/TAZ and β-catenin dissociate from the destruction complex and are able 
to translocate to the nucleus, where they associate with the TEAD and TCF4 proteins, 
respectively, to drive gene target transcription (Azzolin et al., 2014). According to this 
model, Wnt pathway directly regulates YAP/TAZ independently of canonical Hippo 
Pathway signaling. 
 The relationship between YAP/TAZ and Wnt pathway signaling is complex in the 
intestinal epithelia. Conflicting molecular models have been proposed to explain the 
mechanistic interactions between the two pathways. However, one pair of observations 
has been observed by multiple groups: APC-mutant polyps exhibit elevated YAP/TAZ 
nuclear protein levels, and a genetic knockout of both Yap and Taz in the intestinal 
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epithelia is sufficient to inhibit APC-driven tumorigenesis in Apc knockout animals 
(Azzolin et al., 2014; Cai et al., 2015; Gregorieff et al., 2015). However, there is a lack of 
consensus in the field about the exact molecular interactions between YAP/TAZ and Wnt 
signaling, and more insight is needed to provide clarification for this important 
mechanism.  
 
 Hippo Pathway interactions with Hedgehog Pathway 
 
 In addition to the significant overlap with the Wnt pathway, the Hippo Pathway 
also crosstalks with other developmental signaling pathways in a myriad of contexts. One 
group reported that YAP/TAZ interacts with the mTOR growth pathway through 
regulation of the PTEN tumor suppressor via miR-29 (Tumaneng et al., 2012). Another 
group recently showed that YAP/TAZ regulates TGFβ signaling to control liver cell 
differentiation and proliferation (Lee et al., 2016). YAP/TAZ has been linked to the 
Hedgehog signaling pathway as well, although the exact interaction between the two 
pathways appears to be highly context-specific.  
 A number of groups have reported that Hedgehog signaling acts upstream of YAP 
and regulates activity in differentiation. One such study showed that in Drosophila 
melanogaster ovarian follicle stem cells, Hedgehog signaling activated Yki by 
upregulating yki transcription (Huang and Kalderon, 2014). Another group showed that 
Hedgehog activates YAP in hepatic stem cells (HSCs) to drive proliferation and 
differentiation into myofibroblast cells during liver regeneration (Swiderska-Syn et al., 
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2014; Swiderska-Syn et al., 2016). In cerebellar granuale neuron precursor cells 
(CGNPs), the Hedgehog ligand Sonic Hedgehog (Shh) upregulates YAP. This suggests 
that YAP is a downstream effector of Hedgehog Pathway signaling in medulloblastoma, 
a type of brain cancer commonly associated with mutations in the Hedgehog Pathway 
(Fernandez et al., 2009).  
 The reciprocal relationship has also been observed, wherein YAP acts upstream of 
Hedgehog Pathway signaling in stem cell maintenance and differentiation. One recent 
publication showed that in both mouse embryonic fibroblasts (MEFs) and in NIH-3T3 
cells, YAP acts upstream of the Hedgehog pathway by activating Shh pathway signaling 
to prevent differentiation of neuronal progenitor cells (Lin et al., 2012). Interestingly, yet 
another group also showed that YAP acts upstream of Hedgehog signaling, but 
conversely showed that YAP inhibits Shh signaling in MEFs and pancreatic stellate cells. 
They reconciled these contrary views by suggesting that Hedgehog activates YAP in a 
negative feedback loop (Tariki et al., 2014).  
To reconcile the numerous examples of signaling crosstalk observed, it stands to 
reason that the Hippo Pathway interacts with a multitude of other developmental 
signaling pathways in both a temporal and spatial-dependent manner. Context specificity 
is integral to understanding how the Hippo Pathway interacts with other developmental 
signaling pathways, like Wnt and Hedgehog, in the gastrointestinal tract. To fully clarify 
this crosstalk, it is important to assess individual pathway function in a tissue-
compartment specific manner during gastrointestinal development. 
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Mesenchyme in Development and Cancer 
 
 Mammalian Gastrointestinal Development 
 
 The mammalian gastrointestinal tract is comprised of two distinct tissue layers: 
the endoderm-derived epithelia and mesoderm-derived mesenchyme (Kedinger et al., 
1998). During embryonic development, gastrointestinal development occurs as a finely 
timed sequence of events. First, the visceral endoderm recruits adjacent splanchnic 
mesoderm to form a primitive gut tube. This will eventually give rise to the organs in the 
gastrointestinal tract such as lung, stomach, pancreas, and small and large intestine. 
Following gastrulation, the E7.25 mouse embryo is shaped like a cup and has the 
endoderm lining the outside of the embryo structure, with the mesoderm located 
immediately underneath the endoderm. By E8.0, the endodermal tissue begins to 
invaginate at the anterior and posterior ends, forming the anterior intestinal portal (AIP) 
and caudal intestine portal (CIP). Both the AIP and CIP invaginate and eventually meet 
to create the fused gut tube. This process is occurring during the mouse turning process; 
therefore by E9.0 the embryo has completed turning and the gut tube is fused (Lawson et 
al., 1986; Spence et al., 2011).  
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 Mesodermal-Endodermal Signaling in GI Development 
 
While the gut tube is forming, signaling from the gut mesoderm to the endoderm 
is critical for establishing the GI anterior-posterior axis by E8.0 (Kiefer, 2003; Lewis and 
Tam, 2006; Wells and Melton, 1999, 2000; Zorn and Wells, 2007; Zorn and Wells, 
2009). To pattern the A-P axis, the gut mesoderm expresses secretion factors such as 
FGF, Wnt, and BMP, as well as Wnt and BMP inhibitors, along expression gradients 
(Dessimoz et al., 2006; Kiefer, 2003; Kim et al., 2005; Kumar et al., 2003; McLin et al., 
2007; Tiso et al., 2002). Mesodermally secreted ligands and inhibitors form an 
overlapping signal gradient that relays positional information to the adjacent epithelia, 
thereby establishing the GI axis.  
In addition to the its role in A-P patterning, mesenchymal-epithelial signaling also 
plays a critical role in organogenesis. The lateral plate mesoderm has been shown to 
induce differentiation of pancreatic endoderm by inducing pancreatic-specific 
transcription factors such as p48 and Pdx1 (Kumar et al., 2003). One pathway important 
for mesenchymal-epithelial signaling is the Wnt pathway. Mesodermally-secreted Wnt 
antagonists inhibit Wnt pathway activity in the foregut endoderm, allowing for 
differentiation into pancreas tissue. Conversely, activation of Wnt pathway in the hindgut 
endoderm by mesodermally-secreted Wnt ligands allows for differentiation into intestinal 
tissue (McLin et al., 2007).  
 Mesenchymal-epithelial signaling is also involved with patterning and 
differentiation of adjacent intestinal epithelial cells. The forkhead transcription factor 
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Fkh6 is expressed specifically in the mesenchyme of the gastrointestinal tract to regulate 
intestinal cell proliferation. When Fkh6 is genetically ablated in Fkh6-/- animals, the GI 
epithelia displays an increase in proliferation in addition to abnormal architecture and 
elongated villi (Kaestner et al., 1997). Additionally, Hedgehog-responsive mesenchymal 
cells in the gastrointestinal mesenchyme are involved with intestinal villi patterning 
(Walton et al., 2012). 
 Another mesenchymal-specific transcription factor, Barx1, has been well 
characterized for its role in stomach differentiation and patterning. Mesenchymal Barx1 
protein induces differentiation of endoderm into stomach epithelia, while also inhibiting 
differentiation into intestinal epithelia through regulation of epithelial Wnt signaling. 
Genetic ablation of Barx1 in a whole body Barx1 knockout is embryonic lethal by E13.0, 
and Barx1-/- embryos exhibit a significantly smaller and deformed stomach (Kim et al., 
2005).  
Mechanistically, Barx1 has been shown to inhibit Wnt signaling in the stomach 
epithelia through upregulation of the Wnt antagonist proteins, sFRPs. These antagonists, 
when secreted by the mesenchyme to the overlying endoderm, inhibit Wnt/β-catenin 
activity and thus allow differentiation into stomach epithelia instead of intestinal epithelia 
(Kim et al., 2005). Gastric epithelial differentiation, driven by mesodermal signals to the 
endoderm, begins by E15.5 in the mouse; the forestomach endoderm differentiates into 
stratified squamous epithelia and the hindstomach endoderm differentiates into glandular 
epithelia. The glandular stomach contains the gastric glands, which are somewhat 
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analogous to the crypt structures in the intestine and colon (Karam et al., 1997; van den 
Brink, 2007).  
Like mesodermal-endodermal signaling, reciprocal signaling from the endoderm 
to the mesoderm is also critical during gastrointestinal differentiation (Buller et al., 2012; 
Huang & Cotton et al., 2013; Li et al., 2007; Mao et al., 2010; Zacharias et al., 2011). 
Secreted factors from the mouse stomach epithelium are involved with induction of 
smooth muscle differentiation in the underlying mesenchyme. This is detected by the 
upregulation of α-smooth muscle actin in mesenchymal progenitor cells starting from 
E12.0 (McHugh, 1995; Takahashi et al., 1998). This was first shown in vitro when it was 
observed that a mixture of epithelia and mesenchymal cells isolated from E11.0 embryos 
induced upregulation of the differentiation marker α-smooth muscle actin after a few 
days in culture. However, when E11.0 mesenchyme is cultured independently of the 
overlying epithelia, the mesenchyme is unable to differentiate (Takahashi et al., 1998). It 
was later discovered that the Hedgehog ligands Shh and Ihh are secreted by the stomach  
epithelium during development, with the Shh expression gradient highest in forestomach 
and Ihh expression gradient highest in the hindstomach. In this way, the stomach 
epithelia regulates differentiation of the underlying mesenchyme through the secretion of 
Ihh/Shh ligands (Ramalho-Santos et al., 2000).  
 
 
51 
 
 
 
 
Figure 1.3. Differentiation in the gastrointestinal mesenchyme.  
(A, C) In the gastrointestinal mesenchyme, the first marker for differentiation that can be 
easily detected by IHC/IF is the upregulation of  ⍺-smooth muscle actin  
(⍺ -SMA), which is first detected at E12.0. (B, D) By E13.5, ⍺-SMA staining is robustly 
detected in a tight band of differentiated smooth muscle progenitor cells in the 
gastrointestinal mesenchyme. 
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 Hedgehog Pathway Signaling in GI Mesenchymal Differentiation 
 
 Paracrine Hedgehog pathway signaling is tightly linked to mesenchymal 
differentiation in the mammalian gastrointestinal tract (Huang & Cotton et al., 2013; 
Kolterud et al., 2009; Madison et al., 2005; Mao et al., 2010; van den Brink, 2007; 
Walton et al., 2012; Zacharias et al., 2011). In mammals, when the Hedgehog pathway is 
inactive, the transmembrane receptor Patched (Ptch) inhibits the transmembrane protein 
Smoothened (Smo). Hedgehog pathway signaling is activated when Hedgehog ligand 
binds to Ptch, thereby relieving the Ptch-mediated Smo-inhibition. Activated Smo 
relieves the Suppressor of Fused (Sufu)-mediated inhibition of Gli proteins, resulting in 
nuclear Gli translocation. Once in the nucleus, Gli directly binds to the DNA to drive 
transcription of downstream target gene expression (Varjosalo and Taipale, 2008). 
Paracrine Hedgehog pathway signaling provides a signaling bridge through which 
adjacent but dissimilar cells can communicate.  
 Hedgehog ligands can be secreted by both epithelial and mesenchymal cells. 
However, in the mammalian gastrointestinal tract only the GI epithelium secretes 
Hedgehog ligands, which bind to Ptch receptors expressed by mesenchymal cells 
(Kolterud et al., 2009). Both Shh and Ihh expression can be detected in the developing 
gastrointestinal endoderm as early as E8.5, and their expression is critical for both 
gastrointestinal development and proper development of the muscularis externa (Bitgood 
and McMahon, 1995; Mao et al., 2010). 
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Figure 1.4. The Mammalian Hedgehog Pathway.  
Canonical Hedgehog Pathway is dependent on secreted Hedgehog ligand for activation. 
When Hedgehog Pathway is inactive, the transmembrane receptor Patched (Ptch1) 
inhibits the transmembrane protein Smoothened (Smo). When Hedgehog ligand (Hh) 
binds to Ptch1, inhibition of Smo is released. Activated Smo activates Gli proteins, which 
then translocate to the nucleus, where they bind Gli-binding sites to activate transcription 
of Hedgehog target genes.  
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In a previous study, our lab knocked out both Shh and Ihh specifically in the 
developing gastrointestinal endoderm using ShhCre. We observed a severely diminished 
mesenchymal compartment by E18.5, due to a drastic reduction in overall proliferation 
(Mao et al., 2010). Additionally, the gastrointestinal mesenchyme failed to induce the 
smooth muscle progenitor differentiation, as noted by a lack of α-smooth muscle actin+ 
mesenchymal cells in ShhCre/floxIhhflox/flox mutant embryos (Mao et al., 2010). Overall, this 
indicated that the gastrointestinal epithelium has a critical role in mesenchymal 
development through activation of Hedgehog signaling in the mesenchyme by epithelial 
secretion of Shh and Ihh ligand. 
Recently, we further investigated the role of Hedgehog signaling in the 
developing mesenchyme of the gastrointestinal tract. We first knocked out the 
transmembrane protein Smoothened in the developing mesoderm using the Nkx3.2Cre 
allele. In these mutant Nkx3.2CreSmoflox/flox embryos, we observed diminished 
mesenchymal compartments as well as complete inhibition of epithelial villi development 
(Huang & Cotton et al., 2013). Conversely, when we activated Hedgehog pathway 
signaling by expressing a Smoothened gain of function allele in the developing 
mesoderm, Nkx3.2CreR26SmoM2/+ mutant embryos exhibited a profound expansion of the 
gastrointestinal mesenchymal compartment. Hedgehog gain-of-function mutant 
mesenchymal cells were strongly positive for α-smooth muscle actin, indicating the 
expansion of a differentiated mesenchymal cell population (Huang & Cotton et al., 2013; 
Mao et al., 2010). Additionally, we showed that activated Hedgehog pathway signaling in 
the developing gastrointestinal mesenchyme is converging on Gli2, not Gli3, to drive 
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downstream gene transcription for mesenchymal differentiation (Huang & Cotton et al., 
2013). Together, these data reveal that Hedgehog Pathway signaling between the 
epithelia and mesenchyme in the GI tract is a carefully controlled system to drive 
differentiation during development. 
  Mechanistically, it is believed that tight regulation of Hedgehog signaling during 
mesenchymal development is what initiates the Myocardin master-regulatory complex 
for smooth muscle differentiation in the gastrointestinal tract (Zacharias et al., 2011). In 
smooth muscle progenitor cells, Myocardin associates with serum response factor (SRF) 
form the Myocardin-SRF master regulatory complex. This complex induces 
differentiation through transcription of genes such as α-smooth muscle actin (α-SMA), 
Smooth Muscle Protein 22-Alpha (SM22α), and smooth muscle myosin heavy chain 
(SMMHC) (Du et al., 2003).  Hedgehog signaling promotes differentiation of 
mesenchymal progenitor cells through direct regulation of Myocd. When Hedgehog 
pathway is activated during mesenchymal development, Gli proteins may bind to several 
conserved Gli-binding sites within the Myocd gene, thereby driving Myocd transcription 
and allowing for the formation of the Myocardin-SRF master regulatory complex 
(Zacharias et al., 2011).  
 How Hedgehog Pathway signaling activates Myocardin-SRF to induce 
mesenchymal differentiation has been well characterized. However, what remains unclear 
is what happens before Hedgehog initiates differentiation. Further investigation into the 
biology of the gastrointestinal mesenchymal stem cell is needed to understand this 
process. 
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 Stromal Contribution to Colorectal Cancer 
 
 Expanding our understanding of gastrointestinal mesenchymal progenitor cell 
differentiation is also critical to advancing our understanding of colorectal cancer. 
Colorectal cancer arises from aberrant proliferation of gastrointestinal epithelial cells 
with stem cell characteristics and expression patterns (Barker, 2014). Consequently, CRC 
research has focused on the biology of epithelial cell transformation for many years. 
However, the underlying intestinal mesenchyme maintains the intestinal stem cell niche 
as well as contributes to the tumor cell microenvironment (Gerling et al., 2016; Kabiri et 
al., 2014; Kosinski et al., 2010; Li et al., 2014b; Shaker and Rubin, 2010). Mesenchymal 
cells regulate intestinal stem cell quiescence, proliferation, and renewal through the 
secretion of factors such as Wnt, BMP, Notch, and EGFR ligands (Clevers, 2013; Kabiri 
et al., 2014; Sailaja et al., 2016). This critical role of the mesenchyme helps to maintain 
the dedifferentiated state of the intestinal stem cells and support growth within the 
intestinal stem cell niche (Barker, 2014).  
However, the mesenchymally-secreted pro-growth signals that are so integral to 
stem cell maintenance during normal intestinal epithelial homeostasis can also confer a 
survival advantage to epithelial cancer cells during tumorigenesis by maintaining a 
supportive, pro-growth microenvironment (Barker, 2014). Myofibroblasts are α-smooth 
muscle actin+ mesenchymal cells involved in both structural support as part of the 
extracellular matrix (ECM) as well as secretion of growth factors. However, when 
present in solid tumors such as colorectal cancer, invasive ductal breast cancer, and oral 
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squamous cell carcinoma, myofibroblasts are correlated with an overall poor prognosis 
(Kellermann et al., 2007; Surowiak et al., 2007; Tsujino et al., 2007). Additionally, 
tumors with greater numbers of cancer associated fibroblasts (CAFs) are generally more 
invasive and yield a poorer prognosis for overall survival (Calon et al., 2015). Stromal-
specific gene signatures in tumors have also been linked to a worse prognosis in 
colorectal cancer survival (Calon et al., 2015; Isella et al., 2015). Together, these data 
illustrate that mesenchymal tissue is integrally involved with tumorigenesis. 
It is clear that the tumor-promoting environment created by the stromal secretion 
of pro-growth factors, primarily by CAFs, is critical to overall tumor prognosis and 
patient survival. Therefore, myofibroblasts in the tumor stroma represent an attractive 
therapeutic target for cancer treatment. However, a better understanding of how the 
gastrointestinal mesenchyme regulates normal homeostasis as well as its involvement in 
tumorigenesis is required.  
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Scope of Dissertation 
 
 Colorectal cancer is the third leading cause of cancer-related death in the United 
States and has a dismal 13% overall 5 year survival rate for patients diagnosed with 
metastatic disease. A deeper understanding of colorectal cancer initiation and 
progression, in addition to further elucidating the supportive role that the underlying 
mesenchyme provides to the tumor microenvironment, is desperately needed to 
understand disease etiology and develop novel drugs for targeted therapies.  
The Hippo Pathway has emerged as a key regulator in organ size control and 
progenitor cell maintenance, and has also been shown to be aberrantly regulated in a wide 
spectrum of solid tumors. In particular, YAP/TAZ have been linked to intestinal 
epithelial regeneration, in addition to Wnt-driven colorectal tumorigenesis. However, 
many questions remain about the specifics of the interactions between the Hippo Pathway 
and the Wnt Pathway in intestinal homeostasis and tumorigenesis. Additionally, nothing 
is known about the role of the Hippo Pathway in the intestinal mesenchyme in either 
development or postnatal stages.  
My dissertation broadly explores the role of developmental signaling pathways in 
gastrointestinal development and tumorigenesis. In this dissertation, I systematically 
dissect the roles of YAP/TAZ in both gastrointestinal development and homeostasis by 
genetically removing both proteins from the endoderm-derived gastrointestinal epithelia 
and mesoderm-derived gastrointestinal mesenchyme.  
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In Chapter II, I demonstrate an anterior endodermal requirement of YAP/TAZ 
during embryonic development. I find that YAP/TAZ are dispensable for gastrointestinal 
epithelial differentiation, as well as dispensable for Wnt signal transduction during 
normal development and homeostasis. I find that YAP/TAZ act as direct transcriptional 
targets of Wnt pathway signaling during epithelial cell transformation.  
In Chapter III, I uncover a previously unknown requirement of YAP/TAZ 
function in gastrointestinal mesenchymal growth and differentiation. I describe a novel 
transgenic YAP gain of function mouse allele engineered to be spatially and temporally 
controlled via Cre recombinase to investigate Hippo Pathway signaling in vivo. Next, I 
identify a functional interaction between YAP/TAZ and Hedgehog signaling in the 
specification of the smooth muscle lineage, wherein YAP/TAZ act as a molecular 
gatekeeper to differentiation. Finally, I demonstrate for the first time in vivo that 
YAP/TAZ can act as transcriptional co-repressors; YAP/TAZ function as co-repressors to 
maintain a mesenchymal progenitor cell population in the developing gastrointestinal 
mesoderm. 
In  Appendix A, I explore the role of SMAD7 in the intestinal epithelia. I describe 
a unique role for SMAD7 in polyp initiation and progression, independent of either an 
Apc mutation or Wnt pathway activation, in a novel mouse model for serrated polyposis. 
I characterize the molecular signature in the SMAD7-mutant serrated polyps and find that 
significant gene expression overlap with human serrated polyps, indicating that my 
mouse model represents the first bona fide model for serrated polyp initiation and 
progression.  
60 
 
In Appendix B, I explore the role of developmental signaling pathways in the 
postnatal mesenchyme. I first identify a mesenchymal shared cell of origin for 
gastrointestinal hamartomatous polypsis syndromes. I generate three novel mouse models 
for gastrointestinal hamartomatous polyposis syndromes: (1) Peutz Jegher’s Syndrome, 
(2) Juvenile Polyposis Syndrome, and (3) PTEN Hamartoma Syndrome/Cowden’s 
Syndrome. Furthermore, I investigate whether the three gastrointestinal hamartomatous 
syndromes converge on a shared downstream signaling pathway to drive polyposis. I find 
that although the three syndromes share a common cell of origin, they diverge onto 
independent downstream signaling mechanisms to drive polyposis. 
Overall, this dissertation both uncovers novel roles for the Hippo Pathway in the 
mammalian gastrointestinal tract as well as highlights the critical importance of spatial 
and temporal regulation of developmental signaling pathways in both gastrointestinal 
development and tumorigenesis. 
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CHAPTER II 
The role of YAP and TAZ in the GI epithelium 
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Abstract 
 
 YAP and TAZ are the major intracellular mediators of Hippo Pathway signaling 
in mammals. However the precise function of YAP/TAZ in gastrointestinal development 
and homeostasis remains poorly understood. Here I use mouse genetics to systematically 
knock out both YAP and TAZ from the developing endodermal epithelia as well as 
intestinal epithelia during mammalian development. I find that YAP/TAZ are dispensable 
for Wnt pathway signaling and GI epithelial cell differentiation during development and 
homeostasis. However, I report that YAP/TAZ are required for Wnt-driven tumorigenesis 
in colorectal cancer cell lines as well as in APC-mutant mouse models. Finally, I show 
that YAP/TAZ are direct Wnt/TCF4 targets during epithelial cell transformation. Overall 
these findings highlight the complexity that exists between Hippo Pathway and Wnt 
Pathway signaling in the intestinal epithelia and uncovers an additional layer of 
YAP/TAZ regulation in tumorigenesis. 
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Results 
 
Differential requirement of YAP/TAZ in endoderm-derived epithelia 
We first decided to investigate the role of YAP/TAZ in the intestinal epithelia 
using mouse genetics to target the developing endoderm. We crossed Yap (Xin et al., 
2011a) and Taz conditional alleles (Xin et al., 2013) to the ShhCre allele (Harfe et al., 
2004), to restrict Cre recombination starting at embryonic day 8.5 (E8.5) to the 
embryonic endoderm, which eventually gives rise to epithelia of the lung, esophagus, 
stomach, and intestine. Genetic ablation of both YAP and TAZ from the early developing 
endoderm in ShhCreYapflox/floxTazflox/flox mutants caused embryonic lethality at E18.5. 
Mutant embryos exhibited severe lung epithelial branching (Fig. 2.1.A and insets) and 
differentiation defects, assayed by Sox2 expression (Fig. 2.1.D), and resemble the YAP 
knockout phenotype recently reported in the developing lung (Mahoney et al., 2014).  
However, in contrast to the severe lung defect, genetic ablation of YAP/TAZ had 
no effect in the gastrointestinal epithelia; both the stomach and intestine appeared normal 
at E18.5 (Fig.2.1.B). Despite having lost YAP protein (Fig.2.1.C), proliferation (assayed 
by Ki67 immunohistochemical staining) (Fig.2.1.E) and parietal cell differentiation 
(assayed by H/K-ATPase immunohistochemical staining) (Fig.2.1.F) in 
ShhCreYapflox/floxTazflox/flox mutants appears indistinguishable from control staining. We 
observed no obvious defect in mesenchymal differentiation (Fig.2.2.A,B) or enteric 
neuron innervation (Fig.2.2.C) in ShhCreYapflox/floxTazflox/flox mutants as compared to 
control. Finally, we examined whether Wnt signaling was affected in intestinal crypts  
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Figure 2.1. Compartmental requirement of YAP/TAZ in the endodermal epithelia. 
Histology of (A) lung (inset at 40x magnification, scale at 10 µm) and (B) stomach in 
control and YAP/TAZ deficient endoderm (ShhCreYapflox/floxTazflox/flox) animals at E18.5. 
(C) Immunohistochemical YAP staining in control and YAP/TAZ deficient intestinal 
epithelia. (D) Sox2 (lung epithelial marker), (E) Ki67 (proliferation marker), and (F) 
H/K-ATPase (gastric parietal cell marker) immunohistochemical staining in lung and 
stomach in control and ShhCreYapflox/floxTazflox/flox animals at E18.5. Scale bar = 20 µm. 
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Figure 2.2. Loss of YAP/TAZ in the developing endoderm does not affect 
mesenchymal differentiation or Wnt/β-signaling in intestinal crypts.  
(A-C) Immunohistochemical staining for mesenchymal, smooth muscle, and neuronal 
cells, (A) smooth muscle actin, (B) desmin, (C) β-tubulin III. Immunohistochemical 
staining for Wnt/β-signaling (D-E) in intestinal crypt cells (F), (D) β-catenin, (E) CD44, 
(F) Sox9. Scale bar = 5 µm.  
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null for YAP/TAZ in ShhCreYapflox/floxTazflox/flox animals and observed no difference in β-
catenin, CD44, or Sox9 staining patterns in mutants as compared to control at E18.5 
(Fig.2.2.D-F). 
We next decided to restrict the epithelial knockout of YAP/TAZ specifically to 
the gastrointestinal epithelia using VillinCre (Madison et al., 2002), which drives Cre-
mediated recombination in the intestinal epithelia starting from E12.5. Consistent with 
the results observed in ShhCreYapflox/floxTazflox/flox mutant embryos at E18.5, we observed 
that removal of both Yap and Taz (Fig.2.3.B,C) in the intestinal epithelia in 
VillinCreYapflox/floxTazflox/flox animals generated normal crypt-villi architecture (Fig.2.3.A). 
Additionally, we observed no discernible patterning defects in either proliferation or 
differentiation, including the goblet cell and Paneth cell lineage, in 
VillinCreYapflox/floxTazflox/flox animals (Fig.2.3.D-F).  
We again decided to investigate Wnt signaling in YAP/TAZ null intestinal crypts 
in VillinCreYapflox/floxTazflox/flox animals. We observed that nuclear localization of β-catenin 
(Fig.2.4.A) in YAP/TAZ null intestinal crypts maintained wild-type patterning. 
Additionally, expression of Wnt target genes CD44 and Sox9 (Fig.2.4.B,C), as well as 
Axin2 and Lgr5 (Fig.2.4.D) was unaffected in mutants as compared to control. 
Together, our analyses revealed that YAP/TAZ are required for lung development 
in developing embryonic endoderm. However, YAP/TAZ are dispensable for epithelial 
proliferation and differentiation in the gastrointestinal tract, as well as for Wnt pathway 
signal transduction during normal intestinal crypt development and homeostasis.  
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Figure 2.3. YAP and TAZ are dispensable for intestinal epithelial homeostasis.  
(A) Histology of intestine and (B) immunohistochemical YAP staining in control and 
YAP/TAZ deficient intestinal epithelia (VillinCreYapflox/floxTazflox/flox) animals at 12 months 
old. (C) Real-time qPCR analysis of mRNA levels of TAZ and Hippo targets, Ctgf and 
Cyr61, in intestinal epithelia of control and VillinCreYapflox/floxTazflox/flox animals at 12 
months old. (D) Ki67 immunohistochemical, (E) Alcian Blue (Goblet cell), and (F) 
lysozyme (Paneth cells) immunofluorescence staining in control and 
VillinCreYapflox/floxTazflox/flox animals at 12 months old. Scale bar = 20 µM. Data are mean ± 
S.D., * = p value ≤ 0.05; ** = p value ≤ 0.01.  
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Figure 2.4. YAP/TAZ deletion does not affect Wnt/β-catenin signal transduction in 
the intestinal epithelium during normal homeostasis. 
Immunohistochemical staining of (A) β-catenin, (B) CD44, and (C) Sox9 in intestinal 
epithelia of control and VillinCreYapflox/floxTazflox/flox animals at 12 months old. (D) Real-
time qPCR analysis of mRNA levels of canonical YAP/TAZ target, Ankrd1, and 
canonical Wnt targets, Axin2 and Lgr5 in intestinal epithelia of control and 
VillinCreYapflox/floxTazflox/flox animals. Scale bar = 20 µm. Data are mean ± S.D., ns = p 
value > 0.05, * = p value ≤ 0.05; ** = p value ≤ 0.01. 
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YAP/TAZ are critical Wnt/TCF4 transcriptional targets during transformation.  
 Our lab has previously published a study showing that YAP can be regulated by 
Wnt signaling at both transcriptional and posttranscriptional levels in liver cancer cells 
(Wang et al., 2013).  Therefore, although we and others have shown that YAP/TAZ are 
likely not the primary Wnt signaling transducers in gastrointestinal epithelial cells during 
normal development and homeostasis (Azzolin et al., 2014; Barry et al., 2013; Cai et al., 
2010; Gregorieff et al., 2015), we wondered whether YAP/TAZ could be downstream 
targets of Wnt signaling during pathway hyperaction in colon cancer cells. 
To address this possibility, we first performed genome-wide analysis of publically 
available TCF4 ChIPseq datasets (http://genome.ucsc.edu/ENCODE/downloads.html) in 
HCT116 cells, a cell line carrying a β-catenin mutation which leads to constitutive Wnt 
pathway hyperactivation. Interestingly, our analysis revealed TCF4 occupancy at both the 
YAP and TAZ loci (Fig.2.5.A,B). We intersected the TCF4 ChipSeq data with HCT116 
genome ChIPseq datasets of histone modification, including H3K4me1 (markers of 
active enhancers) and H3K4me3 (markers of active promoters). We found that TCF4 was 
able to bind to the active promoter region of the YAP gene and occupied an active 
enhancer site 5’ upstream of the transcriptional start site of the TAZ gene. We next 
performed chromatin immunoprecipitation (ChIP) using TCF4 antibody in HCT116 cells 
and further confirmed via ChIP-qPCR that TCF4 binds to cis-regulatory elements at both 
the YAP and TAZ loci in vitro (Fig.2.5.C).  
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Figure 2.5. TCF4 binds directly to cis regulatory elements of both Yap and Taz loci 
in cancer cells with Wnt/β-catenin hyperactivation.  
Track views of H3K4me1 (markers of active enhancers), H3K4me3 (markers of active 
promoters), and TCF4 peaks in the  (A) Yap and (B) Taz loci from the HCT116 genome. 
(C) ChIP-qPCR in HCT116 was performed with control IgG or TCF4 antibody (Ab), and 
enrichment of the TCF4 enhancer regions from the YAP and TAZ loci was measured by 
qPCR. Data are mean ± S.D., * = p value ≤ 0.05; ** = p value ≤ 0.01. 
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Moreover, we found that blocking Wnt pathway activation with DN-TCF4, a 
TCF4 repressor lacking the β-catenin interacting domain (van de Wetering et al., 2002), 
significantly inhibited YAP and TAZ transcription in both HCT116 (β-catenin gain-of-
function mutation, loss of S45 phosphorylation site) and DLD1 (APC loss-of-function 
mutation, truncated protein) colon cancer cells (Fig.2.6.A). In agreement with our 
hypothesis that Yap and Taz are Wnt transcriptional targets during pathway 
hyperactivation, Yap mRNA levels were also elevated ex vivo in wild-type mouse 
intestinal organoids treated with the Wnt3A ligand for 6 hours (Fig.2.6.B).  
To test whether the increased YAP/TAZ levels are critical for Wnt/β-catenin 
oncogenic activity during pathway hyperactivation, we first generated organoid cultures 
from isolated intestinal crypts of UbcCreERYapflox/floxTazflox/flox mice. We then introduced 
DA-β-catenin, a dominantly active form of β-catenin that lacks the GSK3β 
phosphorylation sites (Barth et al., 1997), into the cultured organoids via lentiviral 
infection. UbcCreER (Ruzankina et al., 2007) is a general inducible Cre allele allowing 
Tamoxifen-induced Cre recombination and subsequent Yap/Taz knock-out in 
UbcCreERYapflox/floxTazflox/flox intestinal organoids.  We found that removal of Yap/Taz 
resulted in the collapse of both Yap/Taz-null organoids as well as Yap/Taz-null + 
constitutive expression of DA-β-catenin as compared to control organoids (Fig.2.6.C,D). 
Next we expressed lentiviral-based shRNA constructs against YAP and TAZ in HCT116 
and DLD1 colon cancer cells and found that YAP/TAZ knockdown inhibited the  
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Figure 2.6. YAP/TAZ are TCF4 transcriptional targets during Wnt/β-catenin 
pathway hyperactivation.  
(A) Real-time qPCR analysis of Yap and Taz mRNA levels in HCT116 (β-catenin 
mutant) and DLD1 (Apc mutant) colon cancer cells with or without DN-TCF4 
expression. (B) Real-time qPCR analysis of Yap and Taz mRNA levels in mouse 
intestinal organoids with or without Wnt3a treatment for 6 hours. (C) Images of control 
and Ubc-CreERYapflox/floxTazflox/flox organoids following 4-hydroxytamoxifen treatment for 
48 hours. (D) Images of Ubc-CreERYapflox/floxTazflox/flox intestinal organoids expression DA-
β-catenin with or without 4-hydroxytamoxifen treatment. Data are mean ± S.D., ns = p 
value > 0.05, * = p value ≤ 0.05; ** = p value ≤ 0.01. 
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Figure 2.7. Double homozygous knockout of YAP/TAZ is sufficient to inhibit Wnt-
driven polyposis.  
(A) Relative soft agar colony formation in HCT116 and DLD1 cells with or without 
lentiviral expression of shRNAs against YAP and TAZ. (B) Real-time qPCR analysis of 
mRNA levels of Yap and Taz in mouse control intestine and APC-deficient intestinal 
polyps. (C) Immunohistochemical YAP staining in control, Apc mutant (AhCreApcflox/+), 
and Apc mutant-Yap/Taz deficient AhCreApcflox/+Yapflox/floxTazflox/flox) animals. Scale bar = 
10 µm. Data are mean ± S.D., * = p value ≤ 0.05; ** = p value ≤ 0.01. 
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tumorigenicity of both colon cancer cell lines, as measured by anchorage-independent 
soft agar colony formation (Fig.2.7.A).  
Finally, we examined the requirement of YAP and TAZ in Wnt-induced intestinal 
tumorigenesis in vivo. We first observed that in vivo, polyps driven by Apc deficiency in 
mouse intestinal epithelial cells exhibit elevated levels of both Yap and Taz mRNA as 
compared to control intestine (Fig.2.7.B). Lastly, we used the β-napthoflavone-inducible 
AhCre allele (Ireland et al., 2004) to target the intestinal epithelia in 
AhCreApcflox/+Yapflox/floxTazflox/flox animals, and specifically investigate the postnatal 
requirement for YAP/TAZ in a Wnt pathway hyperactivated background. In conjunction 
with heterozygous loss of APC, postnatal removal of both YAP and TAZ from the 
intestinal epithelia effectively blocked Apc mutation-induced polyposis in 
AhCreApcflox/+Yapflox/floxTazflox/flox mice (Fig.2.7.C). Taken together, our data provide 
further evidence that Yap and Taz are dispensable for normal intestinal epithelial 
development and homeostasis, but are direct TCF4 transcriptional targets only during 
conditions when Wnt signaling is hyperactivated, thereby mediating, at least in part, Wnt 
pathway driven transformation in gastrointestinal epithelia. 
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Materials and Methods 
 
Mouse Genetics 
ShhCre (Harfe et al., 2004), VillinCre (Madison et al., 2002), UbcCreER (Ruzankina et 
al., 2007), Apcflox (Cheung et al., 2010) and R26mT/mG (Muzumdar et al., 2007) mice were 
obtained from the Jackson laboratory. AhCre (Ireland et al., 2004), Yapflox (Xin et al., 
2011d) and Tazflox (Xin et al., 2013) mice were kindly provided by Drs. WE Zimmer, OJ 
Sansom, DJ Winton, and EN Olson. The University of Massachusetts Medical School 
Transgenic Animal Core performed ES cell targeting and blastocyst injection to generate 
chimeric animals. To target the endodermal and gastrointestinal epithelia, ShhCre, 
VillinCre, AhCre animals were bred with Yapflox, Tazflox, Apcflox mice. Postnatal AhCre 
activation was achieved by intraperitoneal injection of 80 mg/kg β-napthoflavone at 
postnatal day 30, and intestinal tissue were collected 5 months later. All mouse 
experiments were conducted according to the University of Massachusetts Medical 
School IACUC guidelines. 
 
Tissue Collection and Histology 
Following dissection, mouse tissue was fixed in 10% Neutral Buffered Formalin 
(NBF) at 4°C overnight.  Tissues for paraffin sectioning were dehydrated, embedded in 
paraffin wax, and sectioned at 6 µm. Tissues for frozen sectioning were dehydrated in 
30% sucrose overnight at 4°C, embedded in OCT, and sectioned at 12 µm. Paraffin 
sections were stained using standard hematoxylin & eosin reagents.  
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Immunohistochemistry and Immunofluorescence  
For immunohistochemistry(IHC), 6 µm tissue sections were deparaffinized, 
rehydrated, and then subjected to heat-induced antigen retrieval in 10 mM sodium citrate 
buffer (pH 6.0) for 30 minutes. Sections were first blocked for endogenous peroxidase for 
20 minutes at room temperature then blocked in blocking buffer (5% BSA, 1% goat 
serum, 0.1% Tween-20 buffer) in PBS for 1 hour at room temperature. Sections were 
incubated overnight in primary antibody diluted in blocking buffer or SignalStain® 
Antibody Diluent (Cell Signaling) at 4°C. Sections were incubated for 1 hour at room 
temperature in biotinylated secondary antibody and Vectastain Elite ABC kit (Vector 
Laboratories) was used to detect signal.  
 For immunofluorescence (IF), 12 µm tissue sections were blocked for 1 hour at 
room temperature in blocking buffer and then incubated in primary antibody diluted in 
blocking buffer overnight at 4°C. Sections were incubated in Alexa Fluor-conjugated 
secondary antibodies (Invitrogen) at 1:500 dilution in blocking buffer for 1 hour at room 
temperature then mounted with mounting media with DAPI (EMS). Primary antibodies 
used for IHC/IF are listed in Table 2.1.   
 
Mouse intestinal crypt organoid culture. 
The intestinal crypt organoid culture was established according to the 
Sato/Clevers protocol(Sato and Clevers, 2013). Briefly, the intestinal crypts from the 
UbcCreERYapflox/floxTazflox/flox mice were isolated following EDTA treatment and 
centrifugation, and then maintained in a matrigel mixture containing recombinant 
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Noggin, EGF and R-spondin (R&D systems). For RNA isolation, organoids were treated 
with 1ug/ml recombinant Wnt3a (R&D systems) for 6 hours. For YAP/TAZ functional 
assay, UbcCreERYapflox/flox Tazflox/flox organoids were infected with a lentiviral construct 
expressing DA-β-catenin (pLV-beta-catenin deltaN90 was a gift from Bob Weinberg 
(Addgene # 36985)) for 7 days, and Cre-mediated recombination was induced with 
addition of 2ug/ml 4-OH-Tamoxifen (Sigma).  
 
Cell culture, lentiviral infection and soft agar colony formation  
HCT116, DLD1 and HEK293T cells were obtained from ATCC and cultured in 
DMEM supplemented with 10% FBS. For lentiviral infection, pGIPZ or pLKO based 
constructs expressing DN-TCF4 or shRNAs against human YAP and TAZ were 
transfected along with the packaging plasmids into growing HEK293T cells. shRNA 
primer sequences are listed in Table 2.3. Viral supernatants were collected 48 hours after 
transfection, and target cells were infected and underwent selection with puromycin for 
3-4 days, prior to RNA isolation or subsequent anchorage-independent soft-agar colony 
formation assay, which was described previously (Rajurkar et al., 2012). 
 
TCF4, H3K4me1 and H3K4me3 ChIP-seq analysis 
TCF4, H3K4me1, and H3K4me3 ChIP-seq data in HCT116 cells were 
downloaded from the ENCODE (http://genome.ucsc.edu/ENCODE/downloads.html) 
project website. The following antibodies were used for chromatin immunoprecipitation: 
TCF4 (Cell Signaling, 2569), H3K4me1 (Abcam, ab8895) and H3K4me3 (Abcam, 
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ab8580). The TCF4, H3K4me1, and H3K4me3 ChIP peaks were annotated using 
R/Bioconductor package ChIPpeakAnno (Zhu et al., 2010). BigWig tracks were plotted 
with TrackViewer (https://bioconductor.org/packages/devel/bioc/html/trackViewer.html).   
 
Chromatin immunoprecipitation-qPCR analysis 
ChIP assays were performed according to the manufacturer’s instructions (Active 
Motif, CA). Briefly, 2×107 cells were fixed with 1% formaldehyde, washed with cold 
PBS and lysed in lysis buffer. After sonication, protein-DNA complexes were incubated 
with TCF4 antibody (Cell Signaling, 2569)-coupled protein G beads at 4℃ overnight. 
After elution and reverse cross-link, DNA was purified for subsequent PCR analysis. The 
primers used for real-time PCR of TCF4 cis-regulatory elements are listed in Table 2.4. 
 
Quantitative Real-Time PCR 
Trizol reagent (Invitrogen) was used to isolated RNA from both animal tissues 
and cultures cells, and SuperscriptII Reverse Transcriptase (Invitrogen) was used for 
reverse-transcription. Sybr Mastermix (Kapa Bioscience) was used for quantitative real-
time PCR. Primer sequences used for real-time PCR are listed in Table 2.2. All qPCR 
experiments were conducted in biological triplicates, error bars represent mean ± 
standard deviation, and Student’s t-test was used to generate p-values (* = p value ≤0.05; 
** = p value ≤0.01; *** = p value ≤0.001). 
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Table 2.1: Antibodies for IHC/IF 
 
Antibody Dilution Company 
YAP 1:200 Cell Signaling 
Sox2 1:2000 Seven Hills Bioreagents 
Ki67 1:10000 Abcam 
H/K-ATPase 1:500 MBL 
Lysozyme 1:1000 Novus Biologicals 
β-catenin  1:500 BD Biosciences 
CD44 1:400 eBioscience 
Sox9 1:200 Abcam 
Desmin 1:400 ThermoFisher 
α-SMA 1:5000 Abcam 
β-tubulin III  1:800 Covance 
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Table 2.2: qPCR Primers 
 
qPCR Primers Sequence 
mouse YAP forward ACCCTCGTTTTGCCATGAAC 
mouse YAP reverse TGTGCTGGGATTGATATTCCGTA 
mouse TAZ forward GAAAATCACCACATGGCAAGACCC 
mouse TAZ reverse TTACAGCCAGGTTAGAAAGGGCTC 
mouse CTGF forward TGTGCACTGCCAAAGATGGTGCAC 
mouse CTGF reverse TGGGCAGGCGCACGTCCATG 
mouse Cyr61 forward GAGGCTTCCTGTCTTTGGCAC 
mouse Cyr61 reverse ACTCTGGGTTGTCATTGGTAAC 
mouse ANKRD1 forward GGAACAACGGAAAAGCGAGAA 
mouse ANKRD1 reverse GAAACCTCGGCACATCCACA 
mouse Axin2 forward AAGCCTGGCTCCAGAAGATCACAA 
mouse Axin2 reverse TTTGAGCCTTCAGCATCCTCCTGT 
mouse LRG5 forward TGCAGAATGAGCGCCAACCT 
mouse LGR5 reverse CACCCTGAGCAGCATCCTG 
mouse GAPDH forward GTGAAGGTCGGTGTGAACG 
mouse GAPDH reverse ATTTGATGTTAGTGGGGTCTCG 
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Table 2.3: shRNA Primers 
 
shRNA Primers Sequence 
human YAP shRNA AAGCTTTGAGTTCTGACATCC 
human TAZ shRNA AGAGGTACTTCCTCAATCA 
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Table 2.4: ChIP-qPCR Primers 
 
 
ChIP-qPCR Primers Sequence 
human YAP forward CATCAATGCCGGCTCACGGTATCTA 
human YAP reverse CTTTGGTCTCCGACAGGAGACTATA 
human TAZ forward AATTACTGTGCAGCTAGAGTGGATG 
human TAZ reverse CAGGACCTTGGAAAGTTCCCATGAA 
human intergenic region forward CTCATGTACTCTATTGGCTTC 
human intergenic region reverse GCATCTTCACCTGCCCAAGAA 
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CHAPTER III 
The role of YAP/TAZ in the developing GI mesenchyme 
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Abstract 
 
 We and others showed that the Hippo Pathway members YAP and TAZ are 
dispensable in the gastrointestinal epithelia during development and homeostasis. 
However, the role of YAP and TAZ in the gastrointestinal mesenchyme is unknown. 
Here I use mouse genetics to systematically explore the YAP/TAZ requirement in the 
developing gastrointestinal mesenchyme during mammalian embryogenesis. 
Surprisingly, I find that both YAP/TAZ loss of function as well as gain of function in the 
GI mesenchyme is embryonic lethal, indicating a Goldilocks Effect for YAP/TAZ 
activity in this tissue during development. I find that YAP/TAZ functions as a molecular 
gatekeeper in a mesenchymal progenitor cell population prior to Hedgehog-mediated 
differentiation. Finally, I demonstrate that YAP/TAZ function as transcriptional co-
repressors in the developing GI mesenchyme. Overall these findings uncover a novel 
mechanism for Hippo Pathway activity in the developing GI tract. 
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Results 
 
YAP and TAZ are highly expressed in the gastrointestinal mesenchyme  
The increased levels of YAP/TAZ and the correlated functional requirement 
during epithelial transformation prompted us to more closely examine YAP/TAZ protein 
expression in the developing endoderm and gastrointestinal tract. Immunohistochemical 
YAP staining showed that, in the embryonic lung, YAP is highly expressed in the nuclei 
of both epithelial and mesenchymal cells (Fig. 3.1.A).  Interestingly, we found that YAP 
expression was much higher in the mesenchyme than the epithelia in the stomach and 
intestine (Fig. 3.1.A). This dichotomy in expression levels of YAP/TAZ continued at 
perinatal and adult stages, with significantly higher mesenchymal expression (Fig. 3.1.B, 
C). The higher expression and nuclear localization of YAP/TAZ in lung epithelia as 
compared to gastrointestinal epithelia may explain the disparate requirement of 
YAP/TAZ in the developing endoderm while the differential expression levels of 
YAP/TAZ in gastrointestinal epithelia and mesenchyme raises an intriguing possibility 
that YAP/TAZ may have a role in the gastrointestinal mesenchyme. 
 
YAP and TAZ are essential for gastrointestinal mesenchymal development  
To investigate the role of YAP/TAZ in the gastrointestinal mesenchyme, we used 
Nkx3.2Cre (Verzi et al., 2009) mice to specifically target the gastrointestinal mesoderm 
during development. Nkx3.2Cre is expressed from E8.5 in the lateral plate mesoderm 
which gives rise to the gastrointestinal mesenchyme (Verzi et al., 2009). Mesenchymal  
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Figure 3.1. Expression of YAP/TAZ in endodermal epithelia and mesenchyme of 
embryonic lung and stomach.  
(A) Immunohistochemical YAP staining in wild-type lung, stomach, and small intestine 
tissue at E13.5. (B-C) Western blot analysis. Protein lysates from intestinal epithelia and 
intestinal mesenchyme of wild-type postnatal day 5 (P5) mice (B) and 12 month old mice 
(C) were probed with YAP and TAZ antibodies. Scale Bar = 10µM. 
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homozygous knockout of both YAP and TAZ resulted in perinatal embryonic lethality 
(Fig. 3.2.A) and a dramatic mesenchymal growth defect (Fig. 3.2.B). Consistent with a 
caudal-rostral time-dependent expression gradient for Nkx3.2, gastrointestinal 
mesenchymal reduction in the Nkx3.2CreYapflox/floxTazflox/flox animals was most pronounced 
in the stomach and less so in the intestine (Fig. 3.2.B, C). As such, we focused our 
analysis on the stomach of mutant animals. Although YAP/TAZ double mutant animals 
(Fig 3.3.A) exhibited a significant loss of overall gastrointestinal mesenchyme (Fig. 
3.2.C), the different mesenchymal cell populations such as smooth muscle cells, 
myofibroblasts, and enteric neurons were still present, albeit greatly reduced (Fig. 3.3. E-
G). Gastric epithelia adjacent to YAP/TAZ deficient mesenchyme exhibited apparently 
normal Wnt signaling activity as assayed by β-catenin and CD44 expression (Fig. 3.3. 
B,C) and normal epithelial differentiation, including H/K-ATPase+ parietal cells (Fig. 3.3 
D).  
Further analysis of YAP/TAZ mutant animals at an earlier embryonic time point, 
E14.5, revealed similar phenotypic characteristics (Fig 3.4). YAP/TAZ mutant embryos 
exhibited a smaller mesenchymal compartment as compared to controls yet the induction 
of the mesenchymal lineages, including smooth muscle cells, enteric neurons, and 
endothelial cells, still occurred (Fig 3.4. A-C). Moreover, the mutant mesenchyme did not 
exhibit increased apoptosis (Fig 3.4. D), but did display a proliferation defect, as 
measured by Ki67 staining (Fig 3.4. E, F). Together, our genetic analyses reveal an 
essential requirement of YAP/TAZ in gastrointestinal mesenchymal development, and 
suggest an interesting hypothesis that YAP/TAZ might be involved in the expansion of  
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Figure 3.2. YAP and TAZ are required for gastrointestinal mesenchymal 
development.  
(A) Mesodermal loss of Yap and Taz is perinatal lethal. (B) Histology of forestomach, 
corpus, and intestine of control and YAP/TAZ deficient mesenchyme 
(Nkx3.2CreYapflox/floxTazflox/flox) animals at E18.5. (C) Relative mesenchyme width 
quantification. Scale bar = 20µM. Data are mean ± S.D., n = 3, * = p value ≤0.05; ** = p 
value ≤0.01; *** = p value ≤0.001, Student’s t-test. 
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Figure 3.3.  YAP/TAZ knockout in GI mesenchyme does not affect intestinal 
epithelia Wnt target expression or intestinal cell differentiation at E18.5.  
YAP/TAZ deficient mesenchyme differentiates into muscle with innervation by enteric 
neurons. Immunohistochemical (A) YAP, (B) β-catenin, (C) CD44, (D) H/K-ATPase, (E) 
α-smooth muscle actin (α-SMA), (F) desmin, and (G) β-TubulinIII staining in stomach 
mesenchyme of control and Nkx3.2CreYapflox/floxTazflox/flox animals at E18.5. Scale bar = 
20µM. 
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Figure 3.4. YAP/TAZ knockout in GI mesenchyme at E14.5 exhibits significantly 
reduced mesenchymal proliferation.  
(A) a-SMA, (B) β-TubulinIII, (C) CD31, (D) cleaved caspase 3, and (E) Ki67 
immunofluorescence staining and (F) Ki67 quantification in stomach mesenchyme of 
control and Nkx3.2CreYapflox/floxTazflox/flox animals at E14.5. Data are mean ± S.D., n = 3, * 
= p value ≤0.05. Student’s t-test. Scale bar = 20µM. 
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early mesenchymal progenitor populations, and the overall mesenchymal reduction in 
YAP/TAZ mutant animals is due to the failure of early progenitors to adequately 
proliferate before subsequent differentiation. 
 
YAP activation promotes mesenchymal growth 
To further examine the role of YAP in early gastrointestinal mesenchyme, we 
generated a conditional Rosa26 allele, R26YAP5SA, which enables the in vivo expression of 
YAP5SA, a constitutively active form of YAP (Fig. 3.5.A). YAP5SA has five canonical 
LATS phosphorylation sites mutated from serine to alanine to prevent Hippo/Lats 
mediated inhibition and degradation (Zhao et al., 2007). The R26YAP5SA allele also carries 
a 1X-Flag tag, an N-terminal nuclear localization signal (NLS), and a C-terminal IRES-
nuclear LacZ tag, under the control of a CMV enhancer/β-actin hybrid CAGGS promoter 
targeted into the Rosa26 locus. Subcellular localization of R26YAP5SA protein product is 
strictly nuclear following Cre-mediated recombination (Fig. 3.5.B). 
To investigate the function of this active YAP in the gastrointestinal mesenchyme, 
the R26YAP5SA allele was crossed to the Nkx3.2Cre mice. Nkx3.2Cre R26YAP5SA animals were 
embryonic lethal by E14.5 (Fig. 3.6.A) with an enlarged abdomen (Fig. 3.6.B) and 
expanded somites (Fig. 3.6.C). Upon dissection, we observed a striking enlargement of 
the gastrointestinal tract in mutant animals (Fig. 3.7.A). Expression of the R26YAP5SA 
transgene in the mesenchyme was detected by nuclear lacZ expression (Fig. 3.8.A) and 
nuclear YAP staining (Fig. 3.8.B). As expected, transcription of the YAP target genes, 
such as Ctgf and Ankrd1, were significantly up-regulated (Fig. 3.7.B). We found that the  
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Figure 3.5. Generation of a novel YAP gain of function mouse allele.  
(A) Diagram of R26YAP5SA conditional mouse allele. YAP5SA cDNA, 1X-Flag tag, and 
IRES-NucLacZ under control of the CAGGS promoter were knocked into the Rosa26 
locus. Flanking LoxP sites allow transgene expression through traditional Cre-Lox 
technology. (B) HCT116 cells transfected with pCN-YAP5SA plasmid and infected with 
lentiviral pGIPZ-Cre-GFP show exclusive nuclear localization of Flag-YAP5SA.  
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Figure 3.6. YAP gain of function in the developing mesoderm is embryonic lethal. 
(A) Mesodermal expression of R26YAP5SA transgene is embryonic lethal; the majority of 
mutant animals die by E14.5. (B)Nkx3.2CreR26YAP5SA embryos  at E13.5 (C) exhibit a 
severe somite overgrowth phenotype.  
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Figure 3.7. Constitutive R26YAP5SA overexpression drives gastrointestinal 
mesenchymal expansion.  
(A) Gastrointestinal tract from control and mesenchymal YAP gain-of-function 
(Nkx3.2CreR26YAP5SA) mice at E13.5. (B) Real-time PCR analysis of Ctgf and Ankrd1 
mRNA levels in control and Nkx3.2CreR26YAP5SA) mutant stomach at E13.5. (C) Histology 
of stomach and pancreas of control and mesenchymal Nkx3.2CreR26YAP5SA mutant animals 
at E13.5. Inserts show Sox9 immunohistochemical staining in the branching epithelia of 
pancreatic buds. Data are mean ± S.D., n = 3, * = p value ≤0.05, Student’s t-test. 
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Figure 3.8.  Cells in expanded GI compartment are derived from R26YAP5SA + cell 
population.  
(A) Nuclear lacZ staining in the Nkx3.2Cre R26YAP5SA gastrointestinal tract is restricted to 
the mesenchyme. (B) YAP overexpression and nuclear localization in gastrointestinal 
mesenchymal cells in Nkx3.2Cre R26YAP5SA mutants as compared to control.  
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greatly expanded mesenchyme had even begun to engulf the developing pancreatic bud at 
E13.5 (Fig. 3.7.C, insert). Enteric neurons and endothelial cells were present, although 
overall cell organization was disrupted (Fig. 3.9.B-D). Not surprisingly, we find that 
mesenchymal cells with activated YAP were highly proliferative (Fig. 3.9.A).  
We next examined embryos at E11.5, a developmental time point prior to 
induction of differentiated mesenchymal lineages. At E11.5, YAP5SA-induced 
mesenchymal expansion was clearly evident (Fig. 3.10.A) and was likely due to elevated 
proliferation, as measured by Ki67 staining (Fig. 3.10.B, C). Thus, consistent with the 
YAP/TAZ knockout studies, our R26YAP5SA analyses also suggest a critical role of 
YAP/TAZ in the expansion of early gastrointestinal mesenchyme, thereby controlling 
subsequent growth.  
 
YAP/TAZ block smooth muscle differentiation induced by Hedgehog signaling 
The Yap/TAZ loss- and gain-of-function phenotypes in the gastrointestinal 
mesenchyme reminded us of the phenotypes of Hedgehog pathway mutants. It has been 
demonstrated that paracrine Hedgehog signaling from gastrointestinal epithelia plays an 
important role in regulating mesenchymal growth and differentiation (Huang & Cotton et 
al., 2013; Kolterud et al., 2009; Mao et al., 2010; Zacharias et al., 2011). Our prior studies 
showed that loss of Shh and Ihh ligands resulted in significant reduction of mesenchymal 
populations (Mao et al., 2010), while Hedgehog pathway over-activation by R26SmoM2 
(Mao et al., 2006), a Smoothened gain-of-function allele, in the mesenchyme generated 
dramatic overgrowth (Mao et al., 2010). The similarity of these phenotypes  
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Figure 3.9. Highly proliferative GI compartment in Nkx3.2Cre R26YAP5SA mutants is 
mesenchymal in origin.  
Expanded proliferative (A. Ki67) compartment in Nkx3.2Cre R26YAP5SA  mutants  at E13.5 
is mesenchymal in origin (D. PDGFRα staining), with disrupted endothelial cell (C. 
CD31) and enteric neuron (B. β-TubulinIII) organization. 
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Figure 3.10. Expanded GI mesenchymal compartment exhibits elevated 
proliferation even at developmental timepoint E11.5  
(A) Histology and (B)  immunofluorescence Ki67 staining in control and 
Nkx3.2CreR26Yap5SA stomach at E11.5. (C) Quantification of fold change of Ki67+ 
mesenchymal cells at E11.5.  Data are mean ± S.D., n = 3, * = p value ≤0.05; ** = p 
value ≤0.01; *** = p value ≤0.001, Student’s t-test. 
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prompted us to test whether there is a functional interaction between these two important 
signaling pathways during gastrointestinal development. 
We next wanted to investigate whether YAP5SA overexpression impacted 
mesenchymal cell differentiation. Smooth muscle progenitor cells are first marked by the 
expression of α-smooth muscle actin (α-SMA) at E12.0 (McHugh, 1995; Takahashi et al., 
1998). We first investigated expression of differentiation markers α-SMA and Desmin at 
E11.5 and observed no expression in either Nkx3.2Cre R26YAP5SA or control gastrointesintal 
tract, but did observe developmentally appropriate innervation by enteric neurons (Fig. 
3.11.A- D) in both mutant and control tissues.  
One of the key features in SmoM2-induced mesenchymal overgrowth is the 
expansion of the α-SMA-expressing progenitor cells (Fig. 3.12.B), a mesenchymal 
lineage later giving rise to smooth muscle cells (SMC) and myofibroblasts. In wild-type 
gastrointestinal tract, the α-SMA-expressing smooth muscle progenitor population is 
detected as a tight band of cells located in the outer half of the mesenchyme at E13.5 
(Fig. 3.12.A). Surprisingly, we found that α-SMA and neuron-glia2 (NG2) expression 
was dramatically reduced in the R26YAP5SA mutants (Fig. 3.12.C,D). In the YAP5SA 
mutant animals, expression of other mesenchymal markers, such as Vimentin, PDGRA, 
PDGRB, PDGFRα, and PDGFRβ, (Fig. 3.9.D and Fig. 3.12.D), as well as the induction 
of enteric neuron and vasculature system (Fig. 3.9.B,C) were still present; this suggests 
that the effect is specific for the smooth muscle lineage and raises the possibility that 
YAP activation may actually inhibit smooth muscle cell differentiation.  
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Figure 3.11.  At E11.5, there is no difference in mesenchymal differentiation 
between Nkx3.2CreR26YAP5SA and  control tissue.  
(A) Histology and (B)  immunohistochemical staining  for  α-smooth muscle actin  (B), 
desmin (C), and  β-tubulin III (D).  
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Figure 3.12. YAP activation blocks smooth muscle cell differentiation. 
Immunofluorescence a-SMA staining in (A) control, (B) Hedgehog gain-of-function 
(Nkx3.2CreR26SmoM2) and (C) YAP gain-of-function (Nkx3.2CreR26YAP5SA) stomach at 
E13.5. (D) Real-time PCR analysis. Expression of differentiation  markers α-SMA  and 
NG2 is significantly less in Nkx3.2CreR26YAP5SA mutant gut as compared to control, 
whereas there is no significant change in gene expression of  general mesenchymal 
markers Vimentin, PDGRA, PDGRB, PDGFRα, and PDGFRβ. Data are mean ± S.D., n = 
3, * = p value ≤0.05; ** = p value ≤0.01; *** = p value ≤0.001, Student’s t-test. 
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To further elucidate the molecular mechanism underlying YAP activation in the 
gastrointestinal mesenchyme, we performed RNAseq analysis of wild-type and R26YAP5SA 
mutant stomach at E13.5, and intersected the data set with the Affymetrix microarray 
data we generated from E13.5 R26SmoM2 mutant stomach (Huang & Cotton et al., 2013). 
Consistent with our phenotypic analysis, we found that transcription of the genes 
associated with smooth muscle differentiation, including Acta2 (encoding α-SMA), Actg2 
(encoding γ-SMA), and Myocd (encoding myocardin), were up-regulated in R26SmoM2 
mutants, but down-regulated in R26YAP5SA mutants (Fig. 3.13.A and B). It is not surprising 
that Hippo pathway targets, such as Ankrd1, Ctgf, and Cyr61 were up-regulated in the 
R26YAP5SA mutants, while they were largely unaffected in the R26SmoM2 mutants (Fig. 
3.13.A). Interestingly, in the R26YAP5SA mutants Hedgehog targets such as Hhip1, Gli1, 
and Ptch1/2, as well as Hedgehog pathway ligands Shh and Ihh, were downregulated 
(Fig. 3.13. A and B), suggesting that YAP may inhibit SMC differentiation by regulating 
Hedgehog signaling activity, perhaps through ligand secretion.     
To test this possibility, we further examined the Nkx3.2Cre R26SmoM2 mutant 
embryos. Despite the wide-spread expression of SmoM2 in the gastrointestinal 
mesenchyme (Fig. 3.14.C), we noticed a mesenchymal cell population adjacent to the 
intestinal epithelia that remained negative for α-SMA expression and also displayed high 
endogenous nuclear YAP expression (Fig. 3.14.D and E). These data suggest that 
Hedgehog activation by SmoM2 cannot override endogenous YAP activity and that 
Hedgehog signaling does not simply act downstream of YAP/TAZ to induce 
differentiation into SMC lineage.  Consistent with this hypothesis, immunohistochemical  
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Figure 3.13. Gene expression profiling in GI tissues with Hedgehog and YAP 
activation.  
(A) Heat map analysis comparing mRNA expression of YAP/TAZ targets (Ankrd1, Ctgf, 
and Cyr61), Hedgehog pathway targets (Hhip1, Gli1, Ptch1 and Ptch2), and smooth 
muscle differentiation markers (Acta2, Actg2,  and Myocd) in control, Nkx3.2CreR26SmoM2, 
and Nkx3.2CreR26YAP5SA stomach at E13.5, using the data from RNAseq and Affymetrix 
array.  (B) Real-time PCR analysis of Hedgehog Pathway components Gli1, Ptch1, Smo, 
Shh, and Ihh mRNA levels in control and Nkx3.2CreR26Yap5SA stomach at E13.5. Data are 
mean ± S.D., * = p value ≤0.05; ** = p value ≤0.01; *** = p value ≤0.001, Student’s t-
test. 
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Figure 3.14.  YAP and α-SMA expression in wild type and SmoM2-expressing gut 
mesenchyme. 
Immunohistochemical staining of (A) α-SMA and (B) YAP/TAZ in wild-type stomach at 
E13.5. (D) a-SMA and (E) YAP immunoflourescence staining in (C) SmoM2-YFP-
expressing gastrointestinal mesenchyme in Nkx3.2CreR26SmoM2 animals at E13.5.  
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analysis showed that in the wild-type mesenchyme at E13.5, YAP/TAZ expression was 
significantly lower in the ring of the mesenchymal cells where α-SMA was expressed 
(Fig. 3.14.A and B).  
To conclusively test whether endogenous YAP/TAZ was sufficient to inhibit 
Hedgehog-induced differentiation, we generated mesodermal-specific homozygous YAP 
knockout, homozygous TAZ knockout, and double homozygous YAP/TAZ knockouts in 
the SmoM2 gain of function background. We found that homozygous knockout of either 
YAP in Nkx3.2Cre R26SmoM2 Yapflox/flox  animals (Fig. 3.15.A) or TAZ in Nkx3.2Cre R26SmoM2 
Yapflox/f+Tazflox/flox animals (Fig. 3.15.B) is not sufficient to expand the population of 
αSmooth Muscle Actin+ mesenchymal cells in Smoothened gain of function 
mesenchyme. However, homozygous mesodermal knockout of both YAP and TAZ in 
conjunction with R26SmoM2 overexpression in Nkx3.2Cre R26SmoM2 Yapflox/flox Tazflox/flox (Fig 
3.15.C) mutants is sufficient to induce the expression of αSmooth Muscle Actin in 
epithelial-adjacent mesenchymal cells at E13.5. These data provide further evidence that 
Hedgehog signaling is likely acting in parallel to, rather than downstream of, YAP/TAZ, 
to regulate mesenchymal progenitor cell differentiation.  
We decided to further explore the relationship between YAP/TAZ and α-SMA in 
mesenchymal cells in vitro using the C3H10T1/2 cell line. C3H10T1/2 cells are an α-
SMA- mesenchymal progenitor mouse cell line that undergoes differentiation into α-
SMA+ cells following Hedgehog pathway activation (Huang & Cotton et al., 2013; 
Reznikiff et al., 1973; Zacharias et al., 2011) Consistent with previously published 
reports, we also found that treating C3H10T1/2 cells for 24 hours with 0.1µm SAG 
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Figure 3.15.  Loss of endogenous YAP/TAZ extends of αSMA+ cell compartment in 
Smoothened gain of function mutants.  
Homozygous knockout of either YAP in Nkx3.2Cre R26SmoM2 Yapflox/flox  animals (A) or 
TAZ in Nkx3.2Cre R26SmoM2 Yapflox/f+Tazflox/flox animals (B) is not sufficient to expand the 
population of αSmooth Muscle Actin+ mesenchymal cells in Smoothened gain of function 
mesenchyme. Homozygous mesodermal knockout of both YAP and TAZ in conjunction 
with R26SmoM2 overexpression in Nkx3.2Cre R26SmoM2 Yapflox/flox Tazflox/flox (C) mutants is 
sufficient to induce the expression of αSmooth Muscle Actin in epithelial-adjacent 
mesenchymal cells at E13.5.  
 
 
 
 
 
 
 
107 
 
(Smoothened Agonist) was sufficient to induce cell differentiation and α-SMA protein 
expression as compared to DMSO-treated cells (Fig. 3.16.A and B). Importantly, we 
found that YAP overexpression through a lentiviral infection of pGIPZ-3XFlag-YAP5SA 
was sufficient to inhibit differentiation in C3H10T1/2 cells. We observed that following 
SAG treatment, compared to control cells, YAP5SA+ cells showed an inhibition of α-
SMA protein (Fig. 3.16.C and D) and RNA expression, as well as mesenchymal 
differentiation markers Myocd, SMMHC, and SM22α (Fig. 3.16.E). 
Also, we demonstrated that YAP activation was sufficient to inhibit α-SMA 
expression in differentiated Smooth Muscle Myosin Heavy Chain+ (SMMHC+) in vivo. 
We crossed R26YAP5SA to the inducible Myh11CreER-T2 allele, which targets efficient Cre 
recombination in SMMHC+ cells following Tamoxifen injection at E12.5 (Fig. 3.17.A). 
We found that YAP5SA expression in differentiated SMMHC+ mesenchymal cells 
effectively inhibited α-SMA expression (Fig. 3.17.B).  
Finally, we investigated both Hedgehog gain of function and YAP5SA gain of 
function in the same mesenchymal cell population. We were unable to generate 
Nkx3.2CreR26SmoM2/YAP5SA animals because single mutant animals are individually 
embryonic lethal and therefore could not be used as breeders in a genetic cross. We 
instead used the inducible Myh11CreER allele to specifically target the SMMHC+ 
mesenchymal cell population during development. We crossed the R26YAP5SA allele to the 
Myh11CreERR26SmoM2 allele and injected pregnant females intraperitoneally with 
tamoxifen at 12.5 dpc (days post coitus) to induce Cre-recombination, when embryos 
were estimated to be at stage E12.5, and dissected animals three days later at E15.5. We  
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Figure 3.16. YAP5SA overexpression in mesenchymal progenitor cells blocks 
Hedgehog-induced differentiation in vitro.  
C3H10T1/2 cells treated with Smoothened Agonist (SAG) undergo differentiation and 
upregulate expression of αSmooth Muscle Actin (A, immunofluoresence, and B, 
quantification). C3H10T1/2 cells infected with lentiviral pGIPZ-3XFlag-YAP5SA inhibit 
SAG-induced differentiation, as assayed by immunofluorescence (C and D) and mRNA 
expression of Myocd, αSMA, SMMHC, and SM22α (E). Data are mean ± S.D., n = 3, * = 
p value ≤0.05; ** = p value ≤0.01; *** = p value ≤0.001, **** = p value ≤0.0001, 
Student’s t-test. 
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Figure 3.17. YAP5SA overexpression in a SMMHC+ mesenchymal cell population is 
sufficient to inhibit α-SMA expression in vivo.  
(A) GFP images of the Myh11CreERR26mT/mG stomach at E15.5, following intraperitoneal 
tamoxifen injection at E12.5. (B) α-SMA immunofluorescence staining in control and 
Myh11CreERR26YAP5SA stomach at E15.5, following intraperitoneal tamoxifen injection at 
E12.5.  
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Figure 3.18. SmoM2 overexpression is unable to rescue YAP5SA-mediated 
inhibition of smooth muscle differentiation in vivo. 
Smoothened gain of function in SMMHC+ mesenchymal progenitor cells upregulates α-
SMA expression (B) compared to control (A). Smoothened gain of function in 
conjunction with YAP gain of function (D) does not rescue the YAP-mediated inhibition 
(C) of α-SMA protein expression in a differentiated SMMHC+ mesenchymal cell 
population at E15.5, following intraperitoneal tamoxifen injection at E12.5. 
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found that Hedgehog pathway gain of function in conjunction with YAP gain of function 
in Myh11CreERR26SmoM2/YAP5SA mutants yields the same phenotype as 
Myh11CreERR26/YAP5SA; α-SMA protein expression is inhibited (Fig. 3.18. C and D) as 
compared to control and Hedgehog gain of function mutants (Fig. 3.18.A and B). 
Together, these data suggest that persistent YAP activation in either 
undifferentiated mesenchyme or specified smooth muscle progenitor cells is sufficient to 
block smooth muscle differentiation, and that down-regulation of YAP/TAZ expression 
is critical for Hedgehog-induced differentiation of the smooth muscle lineage. 
 
Mesenchymal YAP/TAZ are regulated by canonical Lats1/2-mediated inhibition 
 We next investigated whether canonical Hippo Pathway was responsible for the 
downregulation and nuclear exclusion of YAP/TAZ in the gastrointestinal mesenchyme. 
To investigate this, we crossed mice carrying Lats1flox and Lats2flox alleles to mice 
carrying the Nkx3.2Cre allele to genetically remove LATS1/LATS2 from the developing 
mesoderm. We found that animals tolerated single homozygous knockouts of either Lats1 
or Lats2, survived development through to adulthood, were fertile, and displayed normal 
architecture of the gastrointestinal tract as compared to control (Fig. 3.19. A and B). 
However, we found that double homozygous knockout of both Lats1 and Lats2 in the 
developmental mesoderm faithfully recapitulated the YAP5SA gain of function 
phenotype; Nkx3.2Cre Lats1flox/flox Lats2flox/flox was embryonic lethal by E14.5 and 
exhibited a dramatic gastrointestinal mesenchymal overgrowth phenotype (Fig. 3.19.C).  
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Figure 19. Genetic ablation of both Lats1 and Lats2 generates a gastrointestinal 
mesenchymal overgrowth phenotype.  
(C) Nkx3.2CreLats1flox/floxLats2flox/flox animals at E13.5 as compared to control (A). 
Heterozygous loss of Lats1 or Lats2 is insufficient to drive overgrowth in 
Nkx3.2CreLats1flox/+Lats2flox/flox animals (B) or in Nkx3.2CreLats1flox/floxLats2flox/+animals 
(data not shown).  
 
 
 
 
 
 
 
 
 
113 
 
 
 
Figure 3.20. Lats1/2 deletion inhibits mesenchymal differentiation. 
Mesodermal loss of both Lats1 and Lats2 is sufficient for nuclear localization of 
endogenous YAP protein (C) and inhibition of α-SMA expression (F) in mutant gut 
mesenchyme of Nkx3.2CreLats1flox/floxLats2flox/flox animals at E13.5 as compared to control 
(A, D). Heterozygous loss of Lats1 or Lats2 is insufficient to stabilize nuclear YAP (B) or 
inhibit expression of α-SMA (E) in mesenchyme of Nkx3.2CreLats1flox/+Lats2flox/flox  
animals or in Nkx3.2CreLats1flox/floxLats2flox/+animals (data not shown).  
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 We observed nuclear accumulation of endogenous YAP/TAZ protein in 
LATS1/LATS2 deficient mesenchyme in Nkx3.2Cre Lats1flox/flox Lats2flox/flox mutant 
animals as compared to control, but retaining just a single copy of either Lats1 or Lats2, 
such as in Nkx3.2Cre Lats1flox/+ Lats2flox/flox animals, was sufficient to maintain normal 
mesenchymal YAP/TAZ expression patterning (Fig. 3.20.A-C). Additionally, 
mesodermal loss of both LATS1/LATS2 was sufficient for inhibition of α-SMA protein 
expression in mutant gut mesenchyme. Again, retaining a single copy of either Lats1 or 
Lats2 was sufficient to maintain normal progenitor cell differentiation into α-SMA+ 
mesenchymal cells (Fig. 3.20.D-F). 
 Together these data support our hypothesis that canonical Hippo pathway 
regulation of YAP/TAZ through LATS1/2-mediated inhibitory phosphorylation is 
responsible for exclusion of YAP/TAZ from the nucleus before the Hedgehog-mediated 
mesenchymal differentiation program is able to proceed.  
 
YAP inhibits mesenchymal differentiation through direct regulation of Myocardin 
 Finally, we wanted to elucidate the molecular mechanism through which YAP is 
inhibiting gastrointestinal mesenchymal progenitor cell differentiation. We hypothesized 
that YAP is acting as a direct transcriptional co-repressor of Myocd. To investigate this, 
we performed multiple chromatin immunoprecipitation (ChIP) experiments in 
C3H10T1/2 cells expressing a lentiviral 3x-Flag-YAP5SA construct. We first performed 
chromatin immunoprecipitation with Flag antibody and determined that YAP binds 
directly to the promoter region of Myocd, as well as bona fide YAP target genes Cyr61 
115 
 
and Ctgf (Fig. 3.21.A). Interestingly, we found no enrichment for YAP at the promoter 
region for α-SMA, indicating that the YAP-mediated inhibition of α-SMA is not 
happening through a direct regulation at the transcriptional level. 
We then performed chromatin immunoprecipitation with H3K27ac antibody, a 
generic marker for active gene expression, to determine whether our genes of interest 
were being actively transcribed. We observed that the promoter regions of bona fide YAP 
target genes Cyr61, Ctgf, and Ankrd1 were all strongly enriched for H3K27ac binding, 
indicating these genes were actively expressed. However, when compared to the bona 
fide YAP targets, the Myocd promoter region was not strongly enriched for H3K27ac, 
indicating that it was not actively expressed (Fig. 3.21B), and supporting our data 
showing downregulation of Myocd mRNA following YAP5SA overexpression (Fig. 
3.13.A and Fig. 3.16.E). We also performed a chromatin immunoprecipitation for Chd4, 
the core component of the NURD complex known to be involved in epigenetic 
transcriptional repression (Kim et al., 2015b), and found only the Myocd promoter region 
was statistically enriched by CHD4 pulldown, whereas the bona fide YAP target gene 
promoter regions for Cyr61, Ctgf, and Ankrd1 were not statistically enriched.  
We next wanted to investigate whether this level of transcriptional regulation of 
Myocd was occurring in vivo in our Nkx3.2Cre R26YAP5SA animals. We dissected Nkx3.2Cre 
R26YAP5SA animals at E13.5 and performed chromatin immunoprecipitation using a highly 
concentrated YAP antibody. Similar to our results in C3H10T1/2 cells, we found 
statistically significant enrichment at the promoter regions of bona fide YAP targets Ctgf 
and Cyr61, as well as at the Myocd promoter region (Fig. 3.22).  
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Figure 3.21. YAP directly binds to the promoter region of the Myocd gene in vitro. 
Chromatin immunoprecipitation in C3H10T1/2 cells infected with pGIPZ-3XFlag-
YAP5SA  and incubated with (A) Flag, (B) H3K27ac, and (C) Chd4 antibody. Data are 
mean ± S.D., n = 3, * = p value ≤0.05; ** = p value ≤0.01. Student’s t-test. 
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Figure 3.22.  YAP binds to the promoter region of the Myocd gene in vivo. 
YAP protein binds to the upstream Myocd promoter region, as well as the upstream 
promoter regions of bona fide target genes Ctgf and Cyr61 in the gastrointestinal tracts of 
Nkx3.2CreR26YAP5SA mutants at E13.5. ChIP-qPCR analysis following chromatin 
immunoprecipitation with YAP antibody. Data are mean ± S.D., n = 3, * = p value ≤0.05. 
Student’s t-test. 
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We then analyzed sequence homology of the human Myocd promoter region and 
gene to identify putative TEAD4 binding sites. We found a TEAD4 binding site is 
present in the transcriptional start site (TSS) for Myocd in humans, and is highly 
conserved amongst a number of vertebrates, including mouse, rat, dog, pig, and cow (Fig. 
3.23.A), suggesting a highly conserved evolutionary mechanism. Finally, we investigated 
whether YAP protein binds directly to the TEAD4 binding site in the Myocd TSS. We 
again performed chromatin immunoprecipitation using Flag antibody in C3H10T1/2 cells 
expressing the lentiviral 3x-Flag-YAP5SA construct and determined that YAP binds 
directly to the TEAD4 binding site in the Myocd TSS (Fig. 3.23.B). Together these data 
support our hypothesis that YAP is inhibiting differentiation of gastrointestinal 
mesenchyme by acting as a direct transcriptional co-repressor of Myocd, at the promoter 
region and/or the TSS, and is therefore inhibiting the Myocardin master regulatory 
complex program for mesenchymal differentiation. 
From the data collected in this study, we have arrived at a novel model wherein 
YAP/TAZ act as an evolutionarily conserved molecular switch to control the balance 
between progenitor cell and differentiated cell in the developing gastrointestinal 
mesenchyme. YAP/TAZ associate with TEAD proteins to bind to TEAD binding sites 
within the Myocd promoter region, including a highly evolutionarily conserved site 
within the Myocd TSS, to prevent transcription. Even if Hedgehog Pathway signaling is 
activated (which has been shown to directly upregulate Myocd transcription), YAP/TAZ 
repress Myocd transcription while bound to the TEAD binding site. When differentiation 
is set to begin, LATS1/LATS2 inhibits YAP/TAZ through inhibitory phosphorylation  
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Figure 3.23. YAP binds directly to an evolutionarily conserved TEAD4 binding site 
in the Myocd TSS.  
(A) The TEAD4 binding site (yellow) in the Myocd TSS, as well as the Myocd sequence 
(blue) is highly conserved across multiple vertebrate species, including Human (red), 
Dog, Pig, Mouse, Rat, and Cow.  (B) YAP binds directly to the TEAD4 binding site in 
the Myocd TSS. Data are mean ± S.D., n = 3, * = p value ≤0.05; ** = p value ≤0.01. 
Student’s t-test. 
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and YAP/TAZ are excluded from the nucleus. Once YAP/TAZ leave the nucleus, the 
transcriptional repression on Myocd is relieved, and activated Hedgehog signaling is able 
to drive Myocd transcription. Myocardin then associates with the SRF protein to form the 
Myocardin-SRF master regulatory complex, and drive the smooth muscle differentiation 
target genes such as α-SMA, SMMHC, and SM22α.  
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Materials and Methods 
 
Mouse Genetics 
Myh11CreER (Wirth et al., 2008), R26mT/mG (Muzumdar et al., 2007), Lats1 (Heallen 
et al., 2011b) and Lats2 (Heallen et al., 2013)  mice were obtained from the Jackson 
laboratory. R26SmoM2 (Mao et al., 2006) mice were described previously.  Nkx3.2Cre (Verzi 
et al., 2009), Yapflox (Xin et al., 2011b) and Tazflox (Xin et al., 2013) mice were kindly 
provided by Drs. RA Shivdasani and EN Olson. To generate the R26YAP5SA allele, the 
cDNA fragment encoding YAP5SA (a gift from Kunliang Guan, Addgene plasmid 
#27371) with the N-terminal Flag and NLS sequences was inserted into the pCN vector 
with a C-terminal IRES-nuclear lacZ before being cloned into the pROSA targeting 
vector. The University of Massachusetts Medical School Transgenic Animal Core 
performed ES cell targeting and blastocyst injection to generate chimeric animals. To 
target gastrointestinal mesenchyme and smooth muscle cells, Nkx3.2Cre and Myh11CreER 
mice were bred with Yapflox, Tazflox, R26YAP5SA, R26SmoM2, R26mT/mG mice.  Cre-mediated 
recombination in Myh11CreER R26YAP5SA embryos was induced with intraperitoneal 200 
mg/kg tamoxifen injection in pregnant females at 12.5 dpc and embryos harvested at 15.5 
dpc. All mouse experiments were conducted according to the University of 
Massachusetts Medical School IACUC guidelines. 
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Tissue Collection and Histology 
Following euthanasia, tissue was dissected from adult or embryonic mice and 
fixed in 10% Neutral Buffered Formalin (NBF) at 4°C overnight.  For paraffin sections, 
tissue was dehydrated, embedded in paraffin, and sectioned at 6 µm. Paraffin sections 
were stained using standard hematoxylin & eosin reagents. Mesenchymal width was 
measured in triplicate and normalized to control samples to quantify relative 
mesenchyme width in mutant samples. 
For frozen sections, tissue was dehydrated in 30% sucrose overnight at 4°C, 
embedded in OCT, and sectioned at 12 µm. Frozen sections were stained for lacZ using 
standard X-GAL staining reagents and incubated overnight at 37°C, followed by eosin 
counterstain.  
 
Immunohistochemistry and Immunofluorescence  
For immunohistochemistry (IHC), sections were deparaffinized and rehydrated 
before undergoing heat-induced antigen retrieval in 10mM sodium citrate buffer (pH 6.0) 
for 30 minutes. Slides were blocked for endogenous peroxidase for 20 minutes, then 
blocked for 1 hour in 5% BSA, 1% goat serum, 0.1% Tween-20 buffer in PBS, and 
incubated overnight at 4°C in primary antibody diluted in blocking buffer or 
SignalStain® Antibody Diluent (Cell Signaling). Slides were incubated in biotinylated 
secondary antibodies for 1 hour at room temperature and signal was detected using the 
Vectastain Elite ABC kit (Vector Laboratories).  
123 
 
For immunofluorescence (IF), sections were blocked for 1 hour and incubated 
overnight at 4°C in primary antibody diluted in blocking buffer. Slides were then 
incubated for 1 hour at room temperature in Alexa Fluor-conjugated secondary antibodies 
(Invitrogen) at a 1:500 dilution in blocking buffer and mounted using mounting media 
with DAPI (EMS). Primary antibodies used for IHC/IF are listed in Table 3.1. Image 
quantification of Ki67 immunofluorescence staining in the gastrointestinal mesenchyme 
were performed using Fiji software (Schindelin et al., 2012) and the Renyi Entropy 
algorithm.  
 
C3H10T1/2 cell culture and smooth muscle differentiation 
C3H10T1/2, clone 8 cells were acquired from ATCC (CCL-226™) and 
maintained in Eagle’s Basal medium with 2 mM L-glutatmine, 1.5 g/L sodium 
bicarbonate, Earle’s BSS, Pen/Strep, and 10% FBS at 37°C in 5% CO2. C3H10T1/2 cells 
were maintained at 30-50% confluency to prevent density-induced differentiation. For 
Hedgehog-induced smooth muscle differentiation, cells were transitioned to induction 
media (Eagle’s Basal media with 0.5% FBS) for 12 hrs, following by addition of 0.1 µM 
Smoothened Agonist (SAG) dissolved in DMSO for 24-48 hours.   
 
RNAseq and Affymetrix gene chip analysis 
Embryonic stomachs were dissected from E13.5 control and Nkx3.2CreR26YAP5SA 
embryos, and RNA was extracted for subsequent RNAseq analysis, using independent 
biological quadruplicates. RNAseq reads (paired end 75 bp) were aligned to the mouse 
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genome (mm10) using TopHat, followed by running samtools to filter the reads with 
MAPQ lower than 20. Differential expressed genes were determined by cufflinks.  
Transcriptional profiling of E13.5 Nkx3.2CreR26SmoM2 gastrointestinal using Affymetrix 
Mouse Gene 1.0ST chips was described previously (Huang & Cotton et al., 2013). 
Briefly, gastrointestinal tissue from E13.5 Nkx3.2CreR26SmoM2 and littermate control 
animals was dissected and RNA was isolated, labeled, and hybridized to mouse 
GeneST1.0 chips (Affymetrix) according to manufacturer’s protocols. Three independent 
biological samples were used for chip analysis and statistical analysis was performed 
using R, a system for statistical computation and graphics. Genes with p values <0.05 and 
fold change ≥1.5 were investigated further. The heatmap was generated using heatmap (v 
1.0.7) package. 
 
Western Blotting 
Tissue from perinatal and adult intestine was dissected. Protein lysates were 
probed with primary antibodies. Primary antibodies are listed in Table 3.2. HRP-
conjugated Secondary antibodies were obtained from Jackson Laboratories. 
 
Chromatin immunoprecipitation-qPCR analysis 
Chromatin immunoprecipitation (ChIP) assays were performed according to 
manufacturer’s instructions (Active Motif, High Sensitivity Kit). Briefly, 6×106 cells per 
sample were fixed using 1% formaldehyde, washed with PBS, and lysed in lysis buffer. 
Fixed cells were sonicated and sheared DNA was incubated with 4 µg of primary 
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antibody on a rotator at 4℃ overnight. Primary antibodies used were Flag, H3K27ac, and 
CHD4. Antibody concentrations and company are listed in Table 3.3. After washing with 
buffer, Protein G agarose beads were added to ChIP reactions and incubated on a rotator 
for 3 hours at 4℃ before elution. Cross-links were reversed and DNA was purified for 
qPCR analysis. Primers used for ChIP-qPCR of YAP, H3K27ac, and CHD4 cis-
regulatory elements are listed in Table 3.4.   
 
Quantitative Real-Time PCR 
RNA of animal tissues or cultured cells was isolated using Trizol reagent 
(Invitrogen), followed by reverse-transcription using SuperscriptII Reverse Transcriptase 
(Invitrogen). Quantitative real-time PCR was performed using Sybr Mastermix (Kapa 
Bioscience). The primers used for real-time PCR were described in Table 3.5. All qPCR 
experiments were conducted in biological triplicates, error bars represent mean ± 
standard deviation, and Student’s t-test was used to generate p-values (* = p value ≤0.05; 
** = p value ≤0.01; *** = p value ≤0.001; **** = p value ≤0.0001). 
 
Myocd Promoter Sequence Analysis 
 The upstream promoter region and transcriptional start site (TSS) for the Myocd 
gene were analyzed for putative TEAD4 binding sites. Sequences from a number of 
vertebrates (human, dog, rat, cow, mouse, and pig) were analyzed and overlaid to reveal 
homology.  
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Table 3.1: IHC/IF Antibodies 
 
Antibody Dilution Company 
YAP 1:200 Cell Signaling 
YAP/TAZ 1:200 Cell Signaling 
Ki67 1:10000 Abcam 
H/K-ATPase 1:500 MBL 
β-catenin  1:500 BD Biosciences 
CD44 1:400 eBioscience 
Desmin 1:400 ThermoFisher 
α-SMA 1:5000 Abcam 
β-tubulin III  1:800 Covance 
CD31 1:200 BD Pharmingen 
cleaved caspase 3 1:400 Cell Signaling 
β-galactosidase  1:2000 Abcam 
PDGFRα 1:400 BD Biosciences 
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Table 3.2: Western Blot Antibodies 
 
Antibody Dilution Company 
YAP 1:1000 Cell Signaling 
TAZ 1:1000 BD Pharmingen 
β-actin 1:1000 Genescript 
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Table 3.3: Antibodies for ChIP 
 
Antibody Concentration Company 
Flag 4 ug Sigma 
H3K27Ac 4ug Active Motif 
CHD4 4ug Abcam 
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Table 3.4: ChIP-qPCR Primers 
 
ChIP-qPCR Primers Sequence 
mouse Cyr61 forward CTCTGATGGATCTGAGAAGAGG 
mouse Cyr61 reverse GCCCTTTATAATGCCTGCCTA 
mouse Ctgf forward CAATCCGGTGTGAGTTGATG 
mouse Ctgf reverse GGCGCTGGCTTTTATACG 
mouse Ankrd1 forward CCAAGAGGGAGATGACAAGC 
mouse Ankrd1 reverse GTGGTCACTGCCAAAGGAAT 
mouse Myocd forward ATTCTCTGGGTTGCACCAAT 
mouse Myocd reverse AGTTGAGTAGCAGGGCTCCA 
mouse Myocd TSS forward ACTGTGCGTCCTCCTACCC 
mouse Myocd TSS reverse CCCAGAGGACAGCAGCTAAC 
mouse α-SMA forward AGCAGAACAGAGGAATGCAGTGGAAGAGAC 
mouse α-SMA reverse CCTCCCACTCGCCTCCCAAACAAGGAGC 
mouse GADPH forward GCCTCTGCGCCCTTGAGCTA 
mouse GADPH reverse GATGCGGCCGTCTCTGGAAC 
mouse intergenic region forward GCTCCGGGTCCTATTCTTGT 
mouse intergenic region reverse TCTTGGTTTCCAGGAGATGC 
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Table 3.5: qPCR Primers 
 
qPCR Primers Sequence 
mouse CTGF forward TGTGCACTGCCAAAGATGGTGCAC 
mouse CTGF reverse TGGGCAGGCGCACGTCCATG 
mouse ANKRD1 forward GGAACAACGGAAAAGCGAGAA 
mouse ANKRD1 reverse GAAACCTCGGCACATCCACA 
mouse α-SMA forward ATTGTGCTGGACTCTGGAGATGGT 
mouse α-SMA reverse TGATGTCACGGACAATCTCACGCT 
mouse NG2 forward ACCATGCTACTCCGCAACAG 
mouse NG2 reverse CCGGTGAACATCTATGTGTACG 
mouse Vimentin forward CGGCTGCGAGAGAAATTGC 
mouse Vimentin reverse CCACTTTCCGTTCAAGGTCAAG 
mouse PDGRA forward CCTGTGCCCATCCGCAGGAAGAGA 
mouse PDGRA reverse TTGGCCACCTTGACGCTGCGGTG 
mouse PDGRB forward ATCGCCGAGTGCAAGACGCG 
mouse PDGRB reverse AAGCACCATTGGCCGTCCGA 
mouse PDGFRα forward CGACTCCAGATGGGAGTTCCC 
mouse PDGFRα reverse TGCCATCCACTTCACAGGCA 
mouse PDGFRβ forward AGCTACATGGCCCCTTATGA 
mouse PDGFRβ reverse GGATCCCAAAAGACCAGACA 
mouse Gli1 forward CGCCAAGCACCAGAATCGG 
mouse Gli1 reverse CCGAGACACAAGGTCCTTCATCC 
mouse Ptch1 forward AACAAAAATTCAACCAAACCTC 
mouse Ptch1 reverse TGTCTTCATTCCAGTTGATGTG 
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mouse Smo forward CGCCAAGGCCTTCTCTAAGCG 
mouse Smo reverse CCTCTGCCTGGGCTCAGCAT 
mouse Shh forward CAAAGCTCACATCCACTGTTCTG 
mouse Shh reverse GAAA CAGC CGCC GGATTT 
mouse Ihh forward CACGTGCATTGCTCTGTCAA 
mouse Ihh reverse AGGAAAGCAGCCACCTGTCTT 
mouse Myocd forward AAGGTCCATTCCAACTGCTC 
mouse Myocd reverse CCATCTCTACTGCTGTCATCC 
mouse SMMHC forward GAGAAAGGAAACACCAAGGTCAAGC 
mouse SMMHC reverse AACAAATGAAGCCTCCTGGTGGCTC 
mouse SM22α forward CTCTAATGGCTTTGGGCAGTTTGG 
mouse SM22α reverse GCTCCTGGGCTTTCTTCATAAACC 
mouse GAPDH forward GTGAAGGTCGGTGTGAACG 
mouse GAPDH reverse ATTTGATGTTAGTGGGGTCTCG 
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CHAPTER IV 
Discussion 
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Functional requirement of YAP/TAZ in the mammalian GI  
 
 The fundamental question I sought to answer in this dissertation was: What is the 
function of YAP/TAZ in the mammalian gastrointestinal tract? In order to adequately 
discuss how my data address this question, it is first necessary to briefly review what was 
known in the Hippo Pathway/Gastrointestinal field and remember the main open-ended 
questions when this work was initiated five years ago. Following this concise review, I 
will discuss how my current findings in the gastrointestinal epithelia fit into the 
somewhat contentious field of YAP/TAZ in the gastrointestinal tract, and what additional 
open-ended questions remain. Finally, I will discuss the newly identified requirement for 
YAP/TAZ in the gastrointestinal mesenchyme, including the implications for 
mesenchymal progenitor cell maintenance and important future directions for this work.  
 When I began this work in 2011, the Mammalian Hippo Pathway field was 
arguably still in its infancy. Just four years earlier, in 2007, it was discovered that the 
Hippo organ size control pathway identified in Drosophila melanogaster was also 
conserved in mammals (Dong et al., 2007). Another group had just announced that YAP 
subcellular nuclear localization could be regulated by cell density and that mutation of 5 
canonical LATS1/LATS2 phosphorylation sites in YAP5SA mutants allowed cells to 
overcome contact inhibition (Zhao et al., 2007). Finally, Camargo et al., were the first 
group to link the Hippo Pathway to the mammalian gastrointestinal tract; they showed 
that endogenous YAP is restricted to the intestinal epithelial stem cell compartment and 
that YAP overexpression rapidly expanded an intestinal progenitor cell population 
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(Camargo et al., 2007). Three years later in 2010, another group added to the intestinal 
epithelia commentary when they showed that genetic ablation of YAP has no effect on 
normal intestinal homeostasis but causes severe regeneration defects following DSS 
treatment (Cai et al., 2010). The authors also showed that genetic knockout of Salvador 
(SAV1), a scaffold protein that interacts with MST1/MST2, generates a serrated polyp 
phenotype, presumably due to accumulation of nuclear YAP protein (Cai et al., 2010). 
Together, these findings indicated that YAP is an oncogene in colorectal cancer and that 
further work was needed to fully elucidate how YAP contributed to tumorigenesis. 
 Given the understanding of the YAP/intestinal epithelia field at the time when I 
began my work in 2011, I decided to focus on the main unanswered questions relevant to 
the Mao Lab’s previous expertise: (1) Does TAZ functionally compensate for YAP in the 
epithelia during development and homeostasis? (2) What is the relationship between 
YAP/TAZ and Wnt Pathway Signaling in the intestinal epithelia? 
 
Does TAZ functionally compensate for YAP in the epithelia during development and 
homeostasis? 
 
 YAP knockout in the intestinal epithelia during development has no effect on 
homeostasis or tumorigenesis, leading to the conclusion that YAP is dispensable in these 
cells (Barry et al., 2013; Cai et al., 2010). This finding is somewhat surprising because 
YAP/TAZ are essential in many tissues during development and YAP/TAZ activity in GI 
tumors confers a poor prognosis for colorectal cancer patients (Morin-Kensicki et al., 
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2006; Steinhardt et al., 2008). However, YAP and TAZ are functionally redundant in vivo 
under some conditions (Nishioka et al., 2009).  
 Knowing that YAP/TAZ can sometimes compensate for the other’s loss in vivo, I 
hypothesized that endogenous TAZ protein was functionally compensating for YAP 
genetic knockout in the intestinal epithelia. I decided to investigate this by genetically 
knocking out both YAP and TAZ using floxed alleles and two different Cre alleles; 
ShhCre and VillinCre. I decided to use two Cre alleles because they are constitutively 
expressed at different developmental time points and in different tissue compartments. By 
using two different Cre driver alleles, I was able to investigate both the spatial and 
temporal requirement for YAP/TAZ during development. ShhCre is expressed starting in 
E8.5 in the developing endoderm, which eventually gives rise to the epithelial layer of 
both the lung and gastrointestinal tract. VillinCre is expressed later in development, at 
E12.5, and expression is restricted to the intestinal epithelia.  
 I found that there is a compartmental requirement for YAP/TAZ in the developing 
endoderm. In ShhCreYapflox/floxTazflox/flox embryos, YAP/TAZ is required in the developing 
lung epithelia but is dispensable in the intestinal epithelia. Knockout of YAP/TAZ in the 
developing endoderm caused a severe lung development defect but had no phenotype in 
the intestine (Fig. 2.1). While our work was ongoing, a paper was published showing that 
YAP is required for epithelial tube formation and branching in the developing lung 
(Mahoney et al., 2014). The authors showed that in ShhCreYapflox/flox animals, boundaries 
in the lung are demarcated by the subcellular localization of YAP protein. When YAP is 
knocked out, branching is inhibited because epithelial progenitor cells are unable to 
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properly distribute Sox2 protein (Mahoney et al., 2014). However, in their mutant 
animals, endogenous TAZ protein was still present. In our own ShhCreYapflox/floxTazflox/flox 
mutant embryos, we knocked out both YAP and TAZ to investigate whether TAZ was 
compensating for YAP loss in vivo. However, I observed an identical phenotype in the 
ShhCreYapflox/floxTazflox/flox as compared to the ShhCreYapflox/flox; both exhibited a defect in 
epithelial cell branching in the developing lung (Fig. 2.1). Therefore, my work 
corroborates the epithelia branching defect findings published by Mahoney et al, and 
expands to confirm that TAZ does not functionally compensate for YAP in the 
developing lung endoderm.   
 When the YAP/TAZ knockout is limited to the intestinal epithelia, I found that 
VillinCreYapflox/floxTazflox/flox animals appeared phenotypically normal and did not exhibit 
hyperplasia or polyposis even after aging to 12 months. Additionally, I observed genetic 
knockout of YAP/TAZ does not impact epithelial cell differentiation or proliferation 
(Fig. 2.3, Fig. 2.4). Again, while this work was ongoing a number of papers were 
published with conclusions identical to my own (Azzolin et al., 2014; Cai et al., 2015; 
Gregorieff et al., 2015; Zanconato et al., 2015). In contrast to my findings, another group 
concluded that TAZ actually can compensate for YAP in the intestinal epithelia (Imajo et 
al., 2015). The authors in this study observed that YAP/TAZ knockdown inhibited 
progenitor cell growth and differentiation into goblet cells. However, it should be noted 
that in this particular study, the authors used a shRNA approach to knockdown 
YAP/TAZ, instead of the genetic knockout approach used by our lab and others, which 
may explain the differing results they observed. Overall, my data showing that TAZ does 
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not functionally compensate for YAP in the intestinal epithelia in vivo corroborates the 
current view in the Hippo field that neither YAP nor TAZ is required in the intestinal 
epithelia during both development and homeostasis.  
  Taken together, my data introduce a number of additional questions regarding the 
compartmental requirement for endodermal YAP/TAZ. Firstly, why is YAP/TAZ 
required for lung epithelial development but not gastrointestinal epithelial development? I 
showed evidence via immunohistochemistry that YAP/TAZ localization is predominantly 
nuclear in lung epithelial cells, whereas YAP/TAZ are cytoplasmic in gastrointestinal 
epithelial cells during normal development (Fig. 3.1). Given this observation, a logical 
hypothesis would be that the difference in subcellular localization explains the tissue 
compartment requirement for activity. Another directly related question is: Does the 
YAP/TAZ spatial requirement continue through postnatal and adult stages? One 
experiment to investigate this would be to use inducible Cre alleles, such as the Sox2CreER 
allele, to delete YAP/TAZ postnatally in the lung epithelia (Arnold et al., 2011).  
 Finally, what other organs have a similar tissue compartment-specific requirement 
for YAP/TAZ? In solid tumors, YAP and TAZ represent attractive targets for novel 
therapies because they have been shown to drive growth and proliferation. As such, 
treating patients with small molecule YAP/TAZ inhibitors may be a way to reduce tumor 
growth. However, one caveat to drug treatments is that in order to inhibit YAP/TAZ in a 
tumor, the drug will also be disseminated systemically and will inhibit YAP/TAZ in a 
wide range of cells in the body. Therefore, if there are tissues where YAP/TAZ activity is 
absolutely required for normal homeostasis, this would negatively impact the feasibility 
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of using a YAP/TAZ inhibitor as a cancer therapy. Ultimately, a greater understanding of 
the spatial and temporal requirement for YAP/TAZ is needed.   
 
What is the relationship between YAP/TAZ and Wnt Pathway signaling in the intestinal 
epithelia? 
 
 When I first began this work, part of the experimental rationale was to dissect the 
exact relationship between YAP/TAZ and Wnt pathway signaling in the intestine. Wnt/β-
catenin signaling is required to maintain the intestinal epithelial stem cell population; 
inhibiting Wnt signaling or knocking out β-catenin in the intestinal epithelia causes rapid 
loss of intestinal crypts and differentiation of stem cells into terminally differentiated 
lineages (Fevr et al., 2007). In Drosophila melanogaster, Yorkie activation causes the 
upregulation of Wingless target gene expression, suggesting that YAP activates Wnt 
signaling (Cho et al., 2006). Conversely, other reports showed that elevated YAP nuclear 
protein is detected in Apc-mutant tumor cells, suggesting that in certain contexts Wnt 
signaling could activate YAP (Camargo et al., 2007). Finally, one publication showed 
that endogenous YAP knockout had no effect on the intestinal stem cell compartment 
until challenged with DSS, when it exhibited a severe regeneration defect (Cai et al., 
2010).  
 Based on these findings, I hypothesized that the VillinCreYapflox/flox mutants had no 
apparent phenotype due to functional compensation by endogenous TAZ. I additionally 
hypothesized that if both YAP and TAZ were genetically ablated from the intestinal crypt 
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stem cell, I would observe an effect on Wnt pathway signaling during normal 
homeostatic conditions. However, I was surprised to find that in both 
ShhCreYapflox/floxTazflox/flox and VillinCreYapflox/floxTazflox/flox intestine, β-catenin localization 
remains indistinguishable from controls (Fig. 2.2 and Fig. 2.4). These observations 
indicated that YAP/TAZ are likely not involved in the regulation of β-catenin localization 
during either embryogenesis or postnatal stages. Additionally, I also observed no change 
in either the expression of stem cell marker Lgr5 or of bona fide Wnt target genes CD44 
and Sox9. Taken together, these data told us that YAP/TAZ are dispensable for Wnt 
pathway signaling in the intestinal crypt stem cell in vivo during both development and 
homeostasis.  
 Given the lack of consensus regarding YAP/TAZ and Wnt at the time this work 
began, I was particularly interested in investigating the relationship between YAP/TAZ 
and Wnt during tumorigenesis. I found that both YAP and TAZ are required when Wnt 
pathway signaling is hyperactivated both in vitro and in vivo (Fig. 2.6 and Fig. 2.7). 
When Wnt pathway signaling was inhibited by expressing a dominant-negative TCF4 
construct in either HCT116 (β-catenin mutation) or DLD1 (APC mutation) human 
colorectal cancer cell lines, I observed that expression of YAP and TAZ mRNA is 
decreased. Importantly, I also observed that YAP/TAZ is required for tumorigenesis 
when Wnt pathway signaling is hyperactivated, such as in in vitro organoid cultures as 
well as in a APC-mutant mouse polyps. Finally, I found that Wnt pathway signaling 
activates YAP/TAZ directly at the transcriptional level (Fig. 2.5).  
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 While this work was being finished, a number of groups published observations 
relating to YAP/TAZ/Wnt in the intestinal epithelia. My data showing that YAP/TAZ are 
dispensable for Wnt pathway signaling in the intestinal crypt stem cell in vivo under 
normal conditions were corroborated when a number of groups published nearly identical 
findings (Azzolin et al., 2014; Cai et al., 2015; Gregorieff et al., 2015; Zanconato et al., 
2015). However, my results represent the first record of YAP/TAZ double knockout in 
the early endodermal lineage, as the ShhCreYapflox/floxTazflox/flox mutant data has not yet 
been published. Overall, my observations that YAP/TAZ are not involved with Wnt 
pathway signaling in the intestinal stem cell under normal conditions corroborates the 
recently published findings. My data showing that YAP/TAZ activation is required in 
Wnt-driven tumorigenesis also serves to corroborate the recent findings published by 
other labs. In the recent months, a number of groups, in addition to our own lab, have 
reported that genetic ablation of YAP/TAZ in an APC-mutant background is sufficient to 
inhibit tumorigenesis in vivo and proposed that YAP/TAZ are attractive therapeutic 
targets in tumors with Wnt hyperactivation (Azzolin et al., 2014; Cai et al., 2015; 
Gregorieff et al., 2015).  
 In the Hippo Pathway/Gut field, the controversy relating to YAP/TAZ/Wnt 
signaling in the intestinal epithelial stem cell can be distilled down to the following 
question: Is YAP/TAZ a member of the APC-Axin-GSK3β destruction complex? In 
response to this question, two core fields of thought have emerged. One hypothesis 
suggests that YAP/TAZ are not members of the APC-Axin-GSK3β destruction complex, 
but rather inhibit Wnt pathway signaling through inhibition of the Wnt effector 
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Dishevelled (Barry et al., 2013; Varelas et al., 2010). The second hypothesis suggests that 
YAP/TAZ are critical components of the APC-Axin-GSK3β destruction complex 
(Azzolin et al., 2014; Azzolin et al., 2012). In this alternative hypothesis, it has been 
suggested that YAP/TAZ are inhibited during normal Wnt pathway conditions, and can 
inhibit β-catenin through association with Axin. However, when Wnt pathway signaling 
is hyperactivated, such as in tumorigenesis, the APC-Axin-GSK3β destruction complex 
dissociates, and nuclear YAP/TAZ accumulate. 
 In this study, my data does not directly address the relationship between the 
destruction complex and YAP/TAZ, but rather introduces an additional layer of 
YAP/TAZ transcriptional regulation mediated by TCF4 during Wnt pathway 
hyperactivation. I show that during tumorigenesis, Wnt pathway directly activates Yap 
and Taz transcription through TCF4 binding in HCT116 cells (Fig. 2.5).  A previously 
published study linked Wnt pathway and YAP activity via transcriptional regulation in 
HCT116 colorectal cancer cells (Konsavage et al., 2012). However, my work differs 
somewhat from this report. Konsavage et al. observed β-catenin/TCF4 bind a DNA 
enhancer within the first intron of the Yap gene in HCT116 cells, whereas I observed 
TCF4 occupancy in the Yap promoter region. My research also uncovers an unknown 
connection between Wnt pathway regulation of TAZ via TCF4 binding to an enhancer 
region upstream of Taz. Together, these findings help to highlight the complex 
relationship between Wnt and YAP/TAZ in the intestinal epithelia. 
 However, there are experimental limitations to the conclusions presented here 
regarding the Wnt/YAP/TAZ relationship. One caveat to my conclusions about the direct 
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TCF4 transcriptional regulation of YAP/TAZ is that these experiments were performed in 
colorectal cancer cells. Taken together, my in vitro and in vivo data suggests that 
YAP/TAZ are Wnt targets in tumorigenesis because of direct transcriptional regulation 
by TCF4. To robustly show that the TCF4 transcriptional regulation occurs in vivo, a 
future experiment would be to perform chromatin immunoprecipitation in both APC-
mutant polyps as well as control epithelium tissue. However, the data from the in vitro 
ChIP experiments I performed represent evidence that this transcriptional regulation is 
important for tumorigenesis in colorectal cancer.  
 This work also raises new and unanswered questions. Primarily, why is 
YAP/TAZ a downstream Wnt pathway target only during pathway hyperactivation? Wnt 
activity is required for maintenance of the ISC population, but data from our lab and 
others conclusively shows that YAP/TAZ are not required for ISCs under normal 
homeostasis. To begin to answer this question, further work is needed to understand the 
fundamental differences that exist between ISCs in homeostasis versus ISCs in 
regeneration or tumorigenesis. One hypothesis is that YAP/TAZ regulate a set of genes 
that are required in Wnt-driven tumorigenesis but are dispensable in development. 
Therefore, a future experiment to investigate this would be to induce transformation in 
ISCs and identify a transcriptional signature specific to tumorigenesis.  
 Another question raised by these data is whether YAP/TAZ are transcriptional 
targets of Wnt pathway signaling in a range of different cancer types. Our lab has 
previously shown that Wnt signaling regulates YAP activity at the transcriptional level in 
hepatocellular carcinoma cells (Wang et al., 2013). This suggests that transcriptional 
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regulation of YAP/TAZ by Wnt/TCF4 may be a conserved mechanism, but further work 
is needed to confirm this. One future experiment to investigate this would be to perform 
chromatin immunoprecipitation for TCF4 in cancer cell lines as well as non-transformed 
cell lines. Data from this experiment would reveal if the molecular mechanism we 
uncovered in APC-mutant colorectal cancer is important in other cancer types. 
 Answering these questions will help to understand how YAP/TAZ transcriptional 
regulation by the Wnt pathway contributes to tumorigenesis. Overall, my work uncovers 
an additional level of YAP/TAZ regulation mediated by Wnt/TCF4 in addition to protein-
protein interactions in the cytoplasm, and highlights the complexity that exists with 
Wnt/YAP/TAZ signaling in the intestinal epithelia (Fig. 4.1). 
 
Are endodermal YAP/TAZ required for mesodermal differentiation? 
 
 In addition to the complex relationship that exists between YAP/TAZ and Wnt 
signaling within the epithelia, I also investigated how YAP/TAZ contributes to signaling 
between the epithelia and mesenchyme. We and others have shown that signaling 
between the GI endoderm and mesoderm in development is important for patterning and 
differentiation (Huang & Cotton et al., 2013; Walton et al., 2012; Zacharias et al., 2011). 
In our own lab, we previously showed that endodermal knockout of Hedgehog ligands 
Shh and Ihh inhibits smooth muscle differentiation and mesenchymal growth in 
ShhCre/floxIhhflox/flox embryos (Mao et al., 2010). These data led us to conclude that 
Hedgehog ligands are required to transmit signals from endoderm to mesoderm signaling  
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Figure 4.1. Proposed model for YAP/TAZ as Wnt targets during in intestinal 
epithelial transformation.  
(A) Under conditions of normal Wnt signaling, such as intestinal development and stem 
cell maintenance, YAP/TAZ is dispensable. (B) When Wnt signaling is hyperactivated, 
such as during regeneration and tumorigenesis, β-catenin/TCF bind to cis-regulatory 
elements of both Yap and Taz to activate transcription. YAP/TAZ protein is required 
during conditions of Wnt hyperactivation.  
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during differentiation. If endodermal YAP/TAZ were similarly involved with this 
crosstalk between tissue compartments, I would have observed a similar defect in 
gastrointestinal mesenchymal differentiation and growth in ShhCreYapflox/floxTazflox/flox  
embryos. However I did not observe this. GI mesoderm in ShhCreYapflox/floxTazflox/flox 
embryos successfully differentiated into mesenchyme and muscle cells, as assayed by 
expression of markers for differentiated tissue (Fig. 2.2). Taken together, these 
observations led us to conclude that endodermal YAP/TAZ is not required for 
mesenchymal differentiation induced by paracrine Hedgehog Pathway signaling.  
 However, there are caveats to this conclusion, due in part to experimental 
limitations. I reached this conclusion on expression pattern of differentiation markers α-
smooth muscle actin and desmin, as assayed by IHC. By relying on the expression of 
these two differentiation markers as my experimental strategy, it is possible that I missed 
detecting minor defects in differentiation. Comparing the gene expression signature in 
ShhCreYapflox/floxTazflox/flox mesenchyme to control tissue would provide a deeper 
experimental analysis.  
 Additionally, IHC analysis does not provide information regarding functionality 
of the differentiated mesenchyme and muscle tissue. It is possible that the 
ShhCreYapflox/floxTazflox/flox mesenchyme has functional defects that are not readily observed 
due to perinatal lethality. I showed that VillinCreYapflox/floxTazflox/flox animals are viable and 
do not exhibit any functional defects in the GI mesenchyme. These data support my 
conclusion that endodermal YAP/TAZ are dispensable for mesenchymal differentiation 
and functionality. However, a caveat of this conclusion exists due to experimental 
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limitations. ShhCre is expressed beginning from E8.5, whereas VillinCre expression does 
not begin until E12.5. Paracine Hedgehog signaling initiates mesenchymal 
differentiation, which begins at approximately E12.0. Therefore, YAP/TAZ knockout in 
VillinCreYapflox/floxTazflox/flox animals occurs just after this mesenchymal differentiation 
begins. One way to investigate the developmental window between E8.5 and E12.5 
would be to use the tamoxifen inducible ShhCreER allele (Harfe et al., 2004). The inducible 
ShhCreER allele allows for greater temporal control over YAP/TAZ knockout. Overall, this 
experiment would yield insight into whether YAP/TAZ are involved in mesenchymal 
differentiation between E8.5 and E12.5.  
 
Functional requirement of YAP/TAZ in the GI mesenchyme 
 
We and others have shown that YAP/TAZ are required in the developing lung 
endoderm but are dispensable in the intestinal endoderm during development and 
homeostasis (Barry et al., 2013; Cai et al., 2015; Mahoney et al., 2014; Zanconato et al., 
2015). Our data also shows that YAP/TAZ act as downstream Wnt pathway effectors 
only when Wnt pathway is hyperactivated, such as in tumorigenesis. 
However, to date there has been nothing reported regarding the role of YAP/TAZ 
in non-epithelial cells in the gastrointestinal tract. We have previously shown that the 
relationship between the intestinal epithelia and underlying mesenchyme is both complex 
and required for normal development and patterning (Huang & Cotton et al., 2013; Mao 
et al., 2010). Given our lab’s extensive experience with gastrointestinal mesenchymal 
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development, I believed that the next logical scientific leap was to investigate whether the 
Hippo Pathway played a role in this process.  
 
Tissue compartment-specific YAP/TAZ localization and expression 
 
I first set out to determine the normal expression pattern for YAP/TAZ protein in 
the developing gastrointestinal tract at midgestation, as this has not been investigated 
previously. I showed via immunohistochemistry that YAP/TAZ subcellular localization 
in the developing gastrointestinal tract is predominantly nuclear in the mesenchyme but is 
predominantly cytoplasmic in the developing epithelia (Fig. 3.1). This is in contrast to the 
subcellular YAP/TAZ protein localization in the developing lung, where YAP/TAZ is 
localized in the nucleus in both the epithelia and mesenchyme. These data led me to ask 
why YAP/TAZ protein localization was predominantly nuclear in the mesenchyme but 
was cytoplasmic in the epithelia. I speculated whether the differential YAP/TAZ 
subcellular localization was related to functionality, because I showed previously that the 
endoderm requires YAP/TAZ in the developing lung, but not in the developing 
gastrointestinal tract.  
Similar to the developing gastrointestinal tract, the developing lung also requires 
tightly regulated reciprocal signaling between the lung epithelia and lung mesenchyme. 
The lung mesenchyme secretes factors such as Wnt and FGF to adjacent epithelial cells 
to regulate critical developmental and differentiation processes, such as branching 
morphogenesis, epithelial differentiation, and lineage distinctions (Chow et al., 2013; 
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McCulley et al., 2015). Recently, it was shown that nuclear YAP in the lung epithelia 
regulates branching and establishes the proximal-distal axis in the developing lung bud 
(Lange et al., 2015; Mahoney et al., 2014); however, to date no studies have investigated 
the role of YAP/TAZ in the developing lung mesenchyme.  
An unanswered question that remains is whether YAP/TAZ are required in the 
lung mesenchyme during development. Given the importance of the lung mesenchyme in 
lung development and the robust nuclear YAP/TAZ subcellular localization observed in 
normal lung tissue, it is logical to hypothesize that, like the gastrointestinal mesenchyme, 
the lung mesenchyme also requires YAP/TAZ protein for appropriate epithelial 
patterning. If this is true, mutant animals would likely exhibit a profound lung branching 
defect if YAP/TAZ were genetically ablated in the developing lung mesenchyme. To test 
this hypothesis in a future experiment, I would use the recently generated Tbx4-
rtTA/TetO-Cre  to investigate YAP/TAZ in the lung mesenchyme during embryogenesis 
(Zhang et al., 2013). These experiments would help to reveal the contribution of 
mesenchymal YAP/TAZ activity in lung development and branching. 
If YAP/TAZ are shown in the future to be required for lung mesenchymal 
development, this then opens up the possibility that YAP/TAZ could be required in the 
mesenchyme of other organs, such as the pancreas or breast. If so, what does this indicate 
about YAP/TAZ in the maintenance of mesenchymal cells more broadly, and is there a 
conserved YAP/TAZ mechanism in mesenchymal tissue development? The overall 
importance of the mesenchyme during normal development, as well as during 
maintenance of the tumor microenvironment, is starting to attract significant attention by 
149 
 
the scientific community. If an immunohistochemical staining for YAP/TAZ protein can 
reveal other tissue compartments with robust YAP/TAZ nuclear localization during 
development, we may uncover additional mesenchymal compartments that are critical for 
organogenesis. Ultimately, furthering the understanding of Hippo/YAP signaling, and its 
contribution to normal development, will reveal how YAP/TAZ maintain a pro-survival 
tumor microenvironment in a multitude of solid tumors.   
 
YAP/TAZ in normal GI mesenchymal development 
 
Once I established that there was a dichotomy between subcellular YAP/TAZ 
localization in the mesenchyme and subcellular localization in the epithelia, the next 
logical question I sought to answer was whether YAP/TAZ are required for normal 
gastrointestinal development. To answer this question, I used the mesodermal Cre allele 
Nkx3.2Cre to knock out both copies of Yap and Taz in the developing gastrointestinal 
mesenchyme (Fig. 3.2). I also investigated mesenchymal YAP gain of function using 
both a novel transgenic gain of function allele, R26YAP5SA, as well as genetic ablation of 
the upstream Hippo Pathway kinases Lats1 and Lats2 (Fig. 3.7 and Fig. 3.19).  
I found that mesodermal deletion of both Yap and Taz is perinatal lethal and 
results in a reduced mesenchymal compartment when both are knocked out during 
development. This is the first study to implicate YAP/TAZ as having a required role in 
gastrointestinal development; previous studies, including those in our own laboratory 
described in Chapter II, focused on the intestinal epithelia and showed that YAP/TAZ 
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are dispensable during both intestinal epithelial development and homeostasis (Barry et 
al., 2013; Cai et al., 2015; Zanconato et al., 2015).  
Here, I showed that deletion of YAP/TAZ in the developing gastrointestinal 
mesenchyme caused a significantly smaller mesenchymal compartment (Fig. 3.2 and Fig. 
3.4). This was due to a reduction in mesenchymal proliferation, as opposed to an increase 
in apoptosis. This was not overly surprising; I had hypothesized that a decrease in 
proliferation was the explanation for this phenotype because many other labs have 
reported a significant decrease in proliferation when YAP/TAZ proteins are either 
knocked down via RNAi or knocked out using Cre-recombination both in vitro and in 
vivo (Meng et al., 2016; Zanconato et al., 2016; Zhou et al., 2015a). Non-mesodermal cell 
lineages, such as enteric neurons and endothelial cells, are present in the YAP/TAZ 
deficient mesenchyme. This data suggests that mesenchymal YAP/TAZ are dispensable 
for either enteric neuron intravasation or angiogenesis in the developing gastrointestinal 
tract.  
Additionally, I observed that mesenchymal cells in Nkx3.2CreYapflox/floxTazflox/flox 
animals still were able to undergo differentiation, as assayed by detection of α-smooth 
muscle actin and desmin expression via IHC/IF (Fig. 3.3 and Fig. 3.4). These data 
suggest that YAP/TAZ are not required for differentiation of mesenchymal progenitor 
cells into differentiated mesenchyme and smooth muscle cells. This is in agreement with 
an observation from another group, which observed that in myoblasts, YAP is required 
for myoblast proliferation, but that YAP knockdown does not impact differentiation 
(Fischer et al., 2016; Judson et al., 2012). However, future experiments are needed to 
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determine if YAP/TAZ are truly dispensable in differentiated mesenchymal cells. One 
way to investigate this would be to investigate postnatal knockout of YAP/TAZ in the GI 
mesenchyme using either the Gli1CreER allele or the Myh11CreER allele.  
While my data supports my hypothesis that YAP/TAZ are dispensable for 
gastrointestinal mesenchymal progenitor cell differentiation, it would be interesting to 
further investigate if the ratio of the resulting YAP/TAZ deficient differentiated 
mesenchymal cells is skewed from the wildtype expected ratios. Specifically, does loss of 
YAP/TAZ cause differentiation of more smooth muscle cells versus fibroblasts versus 
myofibroblast cells? The best way to investigate this would be with a cell lineage 
experiment, where it would be possible to track the percentages of differentiated 
subpopulations of mesenchymal cells within both control and mutant gut. I can also use 
fluorescence activated cell-sorting (FACS) to identify individual mesenchymal cell 
populations based on expression of distinct surface markers. Overall, uncovering the 
relationship between YAP/TAZ and mesenchymal differentiation could also provide 
insight into how aberrant YAP/TAZ activity in stromal cells may be contributing to the 
tumor microenvironment. 
After observing the growth defect in the GI mesenchyme of 
Nkx3.2CreYapflox/floxTazflox/flox mutant animals, I hypothesized that a mesenchymal YAP 
gain of function would result in the opposite phenotype. The mesenchyme in 
Nkx3.2CreR26YAP5SA/+ mutant animals did in fact exhibit mesenchymal overgrowth due to 
elevated mesenchymal cell proliferation (Fig. 3.7). This observation is in agreement with 
the majority of the previously published work investigating transgenic YAP gain of 
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function in vivo— other labs previously showed that YAP gain of function in the mouse 
liver generates a profound overgrowth phenotype due to increased proliferation (Camargo 
et al., 2007; Dong et al., 2007).  
However, it is always possible that the overgrowth phenotype was due to an 
artifact of the transgenic allele design. The R26YAP5SA transgene is the human cDNA copy 
of YAP5SA, rather than the mouse cDNA, and is knocked into the Rosa26 locus instead 
of the endogenous YAP locus. Therefore, to confirm that I was not observing an artifact 
of the transgene, I repeated the experiment using Lats1 and Lats2 floxed alleles, to more 
faithfully interrogate YAP activation in vivo. I observed that 
Nkx3.2CreLats1flox/floxLats2flox/flox animals exhibited identical phenotypes to the 
Nkx3.2CreR26YAP5SA/+ animals, including the mid-gestational embryonic lethality, 
accumulation of nuclear YAP, and downregulation of α-smooth muscle actin expression 
in the mesenchymal compartment (Fig. 3.20). Based on these data, I concluded that the 
Nkx3.2CreR26YAP5SA/+ phenotype is physiologically relevant and mesenchymal R26YAP5SA 
transgene expression faithfully recapitulates upstream Hippo Pathway kinase inactivation 
and subsequent YAP activation. Additionally, these data also confirm that in the 
developing gastrointestinal mesenchyme, YAP/TAZ protein localization are regulated by 
canonical Hippo Pathway kinases LATS1/LATS2, instead of through a non-canonical 
mechanism.  
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Why are the YAP/TAZ mutant phenotypes most severe in the developing stomach? 
 
Interestingly, I observed that the mutant phenotypes in both the YAP/TAZ 
knockouts mutants (Nkx3.2CreYapflox/floxTaz flox/flox ) and the YAP gain of function mutants 
(Nkx3.2CreR26YAP5SA/+ and Nkx3.2CreLats1flox/floxLats2flox/flox) was organized along a caudal-
rostral gradient, with the most severe phenotype observed in the stomach and least severe 
in the intestine and colon. This phenotype is likely explained by the endogenous 
expression pattern of Nkx3.2 (also known as Bapx1). Nkx3.2 protein expression is first 
detected in the hindstomach at E9.5, and then expression continues on a caudal-rostral 
gradient during development (Faure et al., 2013; Hecksher-Sorensen et al., 2004; Tribioli 
and Lufkin, 1999; Verzi et al., 2009). When we used the Nkx3.2Cre allele to specifically 
restrict genetic ablation of Yap and Taz to the developing mesoderm, we were directing 
the YAP/TAZ knockout to follow the same caudal-rostral expression pattern as Nkx3.2.  
Therefore, I hypothesize that the stomach tissue exhibits the strongest phenotype 
because these cells underwent Cre-mediated recombination earliest in development. To 
test this, an inducible gastrointestinal mesenchymal Cre allele, such as the Gli1CreER or the 
Myh11CreER allele, could be used to delay Yap/Taz knockout until tamoxifen 
administration. This would direct the genetic ablation to occur simultaneously along the 
length of the gastrointestinal tract. I hypothesize that if I induce Cre-recombination in the 
developing mesenchyme simultaneously instead of along an expression gradient, the 
phenotype severity would be the same across the caudal-rostral axis in the GI tract. 
However, it is still possible that the requirement for YAP/TAZ in the developing 
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mesoderm is organized along this caudal-rostral gradient and is higher in the stomach 
mesenchyme than in the colon. If the results from an inducible Cre still yield a phenotype 
that presents in a gradient, this would indicate that the requirement for YAP/TAZ must be 
different along the length of the gastrointestinal tract.  
 
A Goldilocks Effect for YAP/TAZ activity in the developing GI mesoderm 
 
Paradoxically, I observed that in the developing mesoderm, both YAP/TAZ 
knockout (Nkx3.2CreYapflox/floxTazflox/flox) as well as constitutive YAP activation 
(Nkx3.2CreR26Yap5SA/+ and Nkx3.2CreLats1flox/floxLats2flox/flox) is embryonic lethal. These 
data suggest that the Hippo Pathway maintains tight regulation of YAP/TAZ activity to 
support progenitor cell proliferation while also inhibiting uncontrolled growth and tissue 
expansion. Another tissue where YAP/TAZ levels must be tightly regulated to allow for 
proper growth and differentiation is in the developing heart; both YAP knockout as well 
as YAP constitutive activation are embryonic lethal in this compartment (von Gisea et al., 
2012; Xin et al., 2013; Xin et al., 2011c; Zhou et al., 2015a). Therefore, I propose that, as 
in the developing heart, a Goldilocks Principle exists within the gastrointestinal 
mesenchymal. YAP/TAZ activity is confined to a narrow window for homeostasis, and 
either too little or too much YAP/TAZ activity is detrimental.  
What remains unanswered, however, is why the deviation from the optimal 
window of YAP/TAZ activity is so detrimental during mesodermal development. Rather, 
why are both YAP/TAZ loss of function, as well as YAP/TAZ gain of function, 
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embryonic lethal? Does YAP/TAZ loss cause lethality in the same manner that 
YAP/TAZ gain of function does? Or are two critical developmental events being 
perturbed, one that requires YAP/TAZ activation and another that requires YAP/TAZ 
inactivation?  
To begin to address these questions, I considered the previously published work 
surrounding YAP/TAZ and mammalian development. To explore this further, one must 
consider that the mesodermal Cre allele I used, Nkx3.2Cre, is constitutively expressed 
during development and expression is not restricted to the gastrointestinal mesenchyme. 
In addition to the developing gastrointestinal mesenchyme, Nkx3.2 is also expressed 
predominantly in the developing skeletal system (Akazawa et al., 2000; Sivakamasundari 
et al., 2012; Tribioli et al., 1997; Tribioli and Lufkin, 1999). In fact, one group showed 
that a whole body knockout of Nkx3.2 protein in Nkx3.2-/- mutants resulted in a severe 
skeletal dysplasia phenotype and perinatal lethality (Akazawa et al., 2000).  
In my study, Nkx3.2CreYapflox/floxTazflox/flox mutant animals also exhibited a severe 
perinatal lethal phenotype, with 100% of mutant animals dying within hours of birth. 
Therefore I hypothesize that this observed lethality could be due to YAP/TAZ knockout 
in the developing skeletal system, especially considering a number of groups have 
identified links between YAP/TAZ and maintenance of the skeletal stem cells (SSCs) 
population. One group determined that the transcription factors Slug and Snail associate 
with YAP/TAZ to regulate skeletal stem/stromal cell (SSC) proliferation and 
differentiation (Tang et al., 2016). Another group showed that RASSF2, which is known 
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to regulate YAP/TAZ through direct binding to upstream Hippo Pathway kinases 
MST1/MST2, regulates osteoblast and osteoclast differentiation (Song et al., 2012).  
This could be experimentally investigated by staining with Alizarin Red/Alcian 
Blue to determine if Nkx3.2CreYapflox/floxTazflox/flox mutants exhibit skeletal defects as 
compared to control animals. Additionally, another experiment to test this hypothesis 
would be to use a bone cell specific Cre allele, such as the OCCre transgene (expressed in 
osteoblasts), to restrict Yap and Taz knockout to the developing bone and see if a similar 
phenotype occurred (Zhang et al., 2002). 
The embryonic lethality I observed in the genotypes with mesodermal YAP gain 
of function, Nkx3.2CreR26Yap5SA/+ and Nkx3.2CreLats1flox/floxLats2flox/flox, occurred during 
mid-gestation around approximately E14.5. Interestingly, another group observed 
embryonic lethality at a similar developmental timepoint when YAP was overexpressed 
in the developing mouse heart (von Gisea et al., 2012). In this study, the authors used a 
Tet-On system to express a doxycycline-induced Yap-S127A overexpression construct 
starting from E8.5, and observed lethality by E15.5 (von Gisea et al., 2012). To suggest 
that this may be a reason for my observed phenotype, the GenePaint Atlas shows that 
Nkx3.2 expression has been detected in the developing heart via RNA in situ 
hybridization (Visel et al., 2004).  
It is possible that the mid gestatation lethality in YAP gain of function mutants 
could be due to cardiac developmental defects. A closer examination of the developing 
heart could confirm this; for example, lacZ staining would reveal whether the R26YAP5SA 
transgene had been expressed in the heart of Nkx3.2CreR26Yap5SA/+ animals. To better 
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investigate this, inducible Cre-alleles, such as the ubiquitiously expressed, tamoxifen-
inducible Cre allele UbcCreER can be used to bypass critical developmental points and 
induce genetic knockout of YAP/TAZ at a later developmental time point.  
 
Epithelial Wnt signaling and mesenchymal YAP/TAZ 
 
It is well acknowledged that paracrine signaling from the mesenchyme to the 
epithelia is important for both development and stem cell maintenance in the 
gastrointestinal tract (Kabiri et al., 2014; Li et al., 2007; Mao et al., 2010). Interesting, in 
my study, I observed that epithelial cells adjacent to YAP/TAZ deficient mesenchyme in 
Nkx3.2CreYapflox/floxTazflox/flox animals displayed seemingly normal Wnt pathway signaling 
and parietal cell differentiation (Fig. 3.3). Given the great interest (and controversy) that 
exists regarding the YAP/TAZ/Wnt relationship in the gastrointestinal tract (Hong et al., 
2016; Imajo et al., 2015; Yu et al., 2015; Zanconato et al., 2016), we were particular 
surprised to observe apparently normal canonical Wnt pathway signaling in the epithelia 
adjacent to YAP/TAZ deficient mesenchymal tissue.  
The relationship between YAP/TAZ deficient mesenchyme and overlying 
epithelia needs additional attention to fully characterize how loss of YAP/TAZ impacts 
the reciprocal signaling relationship between the two tissue compartments. To investigate 
this, an experiment to characterize the expression signature of the both the mesenchyme 
and epithelia compartments, such as RNAseq or proteomics, will be helpful in identifying 
differentially expressed transcripts in YAP/TAZ deficient tissue as compared to control.  
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Additionally, the overall architecture of the overlying epithelia appears disrupted 
in Nkx3.2CreYapflox/floxTazflox/flox mutant animals as compared to controls (Fig. 3.3). 
Therefore, it is necessary to further investigate this epithelial cell compartment to 
elucidate whether this is due to defects in proliferation or differentiation, and how 
mesenchymal YAP/TAZ contributes to this phenotype.  
Finally, my data brings us to an unanswered question regarding whether 
YAP/TAZ mesenchymal knockout affects Wnt signaling in the epithelia during 
regeneration or tumorigenesis. This question is somewhat tricky to answer because the 
Nkx3.2CreYapflox/floxTazflox/flox animals die at birth. In order to thoroughly probe this 
question in vivo, an inducible mesenchymal Cre allele such as Gli1CreER should be used to 
genetically ablate YAP/TAZ protein from the gastrointestinal mesenchyme after the 
critical developmental timepoint before injury is induced via DSS treatment. 
Understanding the mesenchymal function of YAP/TAZ during regeneration could reveal 
important information about how mesenchymal YAP/TAZ contributes to the tumor 
microenvironment. Ultimately, this type of experiment would provide important insight 
as to whether targeting stromal YAP/TAZ may be a viable treatment strategy in cancer 
patients. 
 
Is Hedgehog signaling impacted by YAP/TAZ mesenchymal knockout? 
 
Hedgehog pathway signaling is critical for normal GI development.  Our lab 
previously published a Hedgehog mutant phenotype with a mesenchymal growth defect 
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that was reminiscent of the phenotype I observed in Nkx3.2CreYapflox/floxTazflox/flox animals 
(Mao et al., 2010). In that study, our group showed that gastrointestinal epithelial 
knockout of Hedgehog ligands Shh and Ihh in ShhCre/floxIhh-/flox animals yielded a severe 
gastrointestinal mesenchymal defect and embryonic lethality by E18.5 (Mao et al., 2010).  
In a critical follow-up study published a few years later, we further found that 
mesenchymal knockout of the Hedgehog pathway component Smoothened in 
Nkx3.2CreSmoflox/flox animals yielded a mesenchymal growth defect (Huang & Cotton et 
al., 2013) quite similar to the YAP/TAZ mesenchymal knockout.  
It is important to note that in the Nkx3.2CreSmoflox/flox mutants, we observed a 
severe intestinal villi developmental defect in addition to Wnt pathway signaling being 
virtually abolished in the adjacent epithelia (Huang & Cotton et al., 2013). However, in 
the intestinal epithelia of Nkx3.2CreYapflox/floxTazflox/flox mutants, I observed normal crypt-
villi architecture and normal Wnt pathway signaling (Fig. 3.2). I also detected a reduction 
in expression of Hedgehog pathway ligands Ihh and Shh in mutant gastrointestinal tract 
with mesenchymal YAP gain of function when analyzed by RNAseq. Together, these 
observations led me to the hypothesis that mesenchymal YAP/TAZ signaling is not 
required for establishing intestinal villi structures but could be involved with reciprocal 
signaling to the gastrointestinal epithelia to regulate the Hedgehog pathway. A critical 
follow-up study would be to perform transcriptional analysis of 
Nkx3.2CreYapflox/floxTazflox/flox gastrointestinal tissue. I expect to see an increase in both Ihh 
and Shh expression following mesenchymal YAP/TAZ loss of function if my hypothesis 
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is true. This experiment would help expand our understanding of YAP/TAZ in the 
mesenchyme. 
Nevertheless, it is clear that loss of either YAP/TAZ or Smoothened in the 
developing gastrointestinal mesenchyme generates a severe growth defect. Therefore 
both YAP/TAZ and Hedgehog pathway signaling are required during gastrointestinal 
mesenchymal development. However, further studies are needed to fully elucidate how 
mesenchymal YAP/TAZ could be regulating epithelial Hedgehog signaling. 
The YAP/TAZ mesenchymal knockout (Nkx3.2CreYapflox/floxTazflox/flox) described in 
this study displayed a similar mesenchymal growth defect as compared to the 
Smoothened mesenchymal knockout (Nkx3.2CreSmoflox/flox) we published previously 
(Huang & Cotton et al., 2013). Additionally, the YAP gain of function mutant 
(Nkx3.2CreR26YAP5SA/+) exhibited a mesenchymal overgrowth and tissue compartment 
expansion phenotype akin to the Smoothened gain of function mutant 
(Nkx3.2CreR26SmoM2/+). We and others have shown that activated Hedgehog signaling is 
sufficient to induce differentiation of mesenchymal progenitor cells into smooth muscle 
progenitor cells both in vitro and in vivo (Huang & Cotton et al., 2013; Mao et al., 2010; 
Zacharias et al., 2011). Transgenic overexpression of a mutant Smoothened allele, 
R26SmoM2/+, in the developing mesoderm drives the expansion of a differentiated 
gastrointestinal mesenchymal cell population in Nkx3.2CreR26SmoM2/+ animals (Mao et al., 
2010; Zacharias et al., 2011). Based on these previously published findings, I initially 
hypothesized that in the Nkx3.2CreR26YAP5SA/+ animals, YAP5SA was activating 
Hedgehog-mediated differentiation to drive mesenchymal cell overproliferation. 
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However, my data convincingly showed that YAP inhibits the Hedgehog-
mediated differentiation program both in vitro and in vivo (Fig. 3.16 and Fig. 3.17). In 
C3H10T1/2 cells, expression of the mutant YAP5SA is sufficient to inhibit Hedgehog-
induced differentiation following SAG treatment. In vivo nuclear YAP localization is 
sufficient to halt and perhaps even reverse the smooth muscle differentiation program. In 
a differentiated SMMHC+ population of cells, YAP5SA expression is sufficient to inhibit 
α-SMA expression. Finally, it is important to note that constitutive Hedgehog activity is 
not sufficient to override YAP constitutive activity in vivo. My data showed that 
endogenous nuclear YAP/TAZ inhibits the smooth muscle differentiation program, even 
when SmoM2 is overexpressed. Additionally, mesenchymal differentiation is still 
inhibited in SMMHC+ cells when both YAP5SA and SmoM2 overexpression transgenic 
alleles are co-expressed in the Myh11CreERR26SmoM2/YAP5SA animals. Based on my data 
showing that the SmoM2 mutant phenotype is not sufficient to override the YAP5SA 
mutant phenotype, I hypothesized that in the gastrointestinal tract, YAP and Hedgehog 
are not acting in a direct linear pathway to regulate differentiation, but rather the 
interaction between the two must be more complex.  
One question that remains is whether YAP/TAZ directly inhibit Hedgehog-
mediated mesenchymal differentiation. Results from the RNA transcriptional analysis 
showed Hedgehog Pathway targets such as Gli1, Ptch1, Ihh, and Shh were downregulated 
in the gastrointestinal tract of Nkx3.2CreR26YAP5SA/+ embryos. However, in C3H10T1/2 
cells that are overexpressing YAP5SA, I did not observe a significant difference in 
expression of Gli1 or Ptch1. This discrepancy is likely due to experimental conditions. 
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For the RNA-seq experiment, I isolated RNA from the entire Nkx3.2CreR26YAP5SA/+ 
gastrointestinal tract— a heterogenous cell population that included epithelial and non-
mesenchymal cells. However, the C3H10T1/2 cells were a homogenous culture of mouse 
mesenchymal progenitor cells. The downregulated Hedgehog Pathway target expression 
in the microarray could therefore be due to the epithelial cell contribution. 
Another possibility to explain why I observed downregulation of Hedgehog target 
gene expression in the Nkx3.2CreR26YAP5SA/+ it that mesenchymal YAP/TAZ may not 
inhibit mesenchymal Hedgehog signaling (i.e. Gli-mediated transcription) directly. 
Rather, mesenchymal YAP/TAZ could inhibit Hedgehog pathway signaling indirectly, 
through paracrine inhibition of epithelial secretion of the Hedgehog Pathway ligands. To 
examine this further, a similar experiment could be performed where the GI epithelium 
and mesenchyme are physically separated via EDTA treatment. Then, RNA would be 
isolated from separated populations of epithelial tissue and mesenchymal tissue. In this 
way, the gene expression profiles specific to the epithelium and mesenchyme can be 
individually analyzed using RNA isolated from homogenous cell populations. 
Overall, future experiments will help to elucidate whether YAP/TAZ directly 
regulate Hedgehog pathway activity intrinsically, or whether mesenchymal YAP/TAZ are 
involved with paracine regulation of Hedgehog pathway in the epithelia.  
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The molecular mechanism underlying YAP/TAZ inhibition of mesenchymal differentiation 
 
The link between Hedgehog pathway and the differentiation program in the 
gastrointestinal mesenchymal tract has been studied by a number of labs (Huang & 
Cotton et al., 2013; Kolterud et al., 2009; Madison et al., 2005; Mao et al., 2010; van den 
Brink, 2007; Walton et al., 2012; Zacharias et al., 2011). It is suggested that Hedgehog 
pathway directly induces smooth muscle differentiation through direct Gli-binding to the 
Myocd gene to drive transcription and formation of the Myocardin-SRF master regulatory 
complex (Zacharias et al., 2011). What is less understood, however, is how the progenitor 
cell population is maintained in the gastrointestinal mesenchyme. Additionally, to date 
there have been no studies investigating YAP/TAZ in the developing gastrointestinal 
mesenchyme.  
I have shown that YAP/TAZ activity must be tightly regulated during 
gastrointestinal development: both the loss of YAP/TAZ in Nkx3.2CreYapflox/floxTazflox/flox 
mutants as well as YAP gain of function in Nkx3.2CreR26YAP5SA/+ mutants yields severe 
gastrointestinal mesenchymal growth defects. When I further explored the relationship 
between YAP/TAZ protein subcellular localization and differentiation in the 
gastrointestinal mesenchyme, I observed that there was a robust relationship between α-
SMA+ and subcellular YAP/TAZ localization; α-SMA- cells showed robust nuclear 
YAP/TAZ localization whereas in α-SMA+ cells, YAP/TAZ was excluded from the 
nucleus (Fig. 3.14).  
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Based on this information, I hypothesized that in the gastrointestinal 
mesenchyme, YAP/TAZ protein must be excluded from the nucleus and either 
sequestered in the cytoplasm or degraded, before the Hedgehog-mediated smooth muscle 
differentiation program can begin. While there has been no link between YAP/TAZ and 
gastrointestinal mesenchymal progenitor cells, YAP has been linked to smooth muscle 
differentiation in vascular smooth muscle cells (Xie et al., 2012a). Similar to my findings, 
another group found that YAP is upregulated in vascular smooth muscle progenitor cells 
following vascular injury to expand the progenitor cell population, and that YAP 
knockdown induces differentiation into vascular smooth muscle contractile cells (Xie et 
al., 2012a).  
I showed that in both C3H10T1/2 mouse mesenchymal progenitor cells in vitro 
and in the mouse gastrointestinal tract in vivo, YAP inhibits Hedgehog-mediated smooth 
muscle differentiation by acting as a transcriptional co-repressor by directly binding to 
the Myocd promoter region at an evolutionarily conserved TEAD binding site to inhibit 
Myocd transcription, while also simultaneously acting as a transcriptional co-activator for 
its canonical targets Cyr61 and Ctgf (Fig. 3.21 and Fig. 3.23). It is important to note that 
in mesenchymal progenitor cells, my data showed that YAP/TAZ do not bind directly to 
the α-SMA promoter to directly inhibit α-SMA transcription. This provides further 
evidence that downregulation of α-SMA is a read-out of Myocardin-SRF differentiation, 
rather than YAP/TAZ directly inhibiting α-SMA expression. My work agrees with a 
recent study by Dae-Sik Lim’s group, which was one of the first studies to identify an 
oncogenic role for YAP/TAZ by acting as transcriptional co-repressors in MCF10A cells 
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in vitro by repressing transcription of tumor suppressors Ddit4 and Trail (Kim et al., 
2015b). My data support the observations made by Kim et al., and expand them by 
providing the first in vivo example of YAP/TAZ acting as transcriptional co-repressors.  
Based on my data, I proposed a model wherein YAP/TAZ function as molecular 
gatekeepers in the gastrointestinal mesenchyme to regulate progenitor cell differentiation 
(Fig. 4.2). In mesenchymal progenitor cells, YAP/TAZ migrate to the nucleus where they 
associate with TEAD proteins to bind to the Myocd TSS at an evolutionarily conserved 
TEAD binding site. YAP/TAZ function as transcriptional co-repressors, along with 
TEAD, to inhibit Myocd transcription and prevent the formation of the Myocardin-SRF 
master regulatory complex. When differentiation begins, canonical Hippo Pathway 
inhibits YAP/TAZ through LATS1/LATS2-mediated inhibitory phosphorylation. Once 
this occurs, activated Hedgehog signaling is able to initiate Myocd transcription, allowing 
for the Myocardin-SRF master regulatory complex to form. Myocardin-SRF in turn 
drives the smooth muscle differentiation program by upregulating target genes such as α-
SMA, SMMHC, and SM22α.  
One potential caveat to this model is that it is possible that YAP/TAZ potentiate 
part of their inhibitory role through protein-protein interactions, rather than just through 
transcriptional co-repression via TEAD binding. Other groups have shown that YAP 
inhibits differentiation in vascular smooth muscle cells through inhibiting the formation 
of the Myocardin-SRF master regulatory complex. One group found that YAP binds 
directly to and sequesters the Myocardin protein away from associating with SRF, 
thereby inhibiting the formation of the Myocardin-SRF master regulatory complex and  
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Figure 4.2. Model for YAP/TAZ in gastrointestinal mesenchymal differentiation.  
(A) In primitive mesenchymal progenitor cells, YAP/TAZ/TEAD bind to the Myocd 
promoter to repress transcription. (B) During differentiation, YAP/TAZ are inhibited by 
LATS1/2, and excluded from the nucleus. Activated Hedgehog  activates Myocd 
transcription through direct Gli binding. MYOCD associates with SRF to form the 
Master Regulatory Complex and upregulate expression of differentiation target genes 
such as SM22α, α-SMA, and SMMHC.  
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preventing differentiation (Xie et al., 2012a). Additionally, TEAD proteins have also 
been linked to vascular smooth muscle differentiation; another group has observed that 
TEAD binds directly to SRF proteins to inhibit the formation of the Myocardin-SRF 
complex and inhibit differentiation in vascular smooth muscle progenitor cells (Gupta et 
al., 2001; Liu et al., 2014). Therefore, it is possible that a secondary level of regulatory 
inhibition exists in mesenchymal progenitor cells, similar to vascular smooth muscle 
cells, via protein-protein regulation and sequestration. Future work is needed to 
investigate if YAP/TAZ protein binds to members of the Myocardin-SRF master 
regulatory complex as a secondary level of differentiation in mesenchymal progenitor 
cells. If so, this would add an additional level of complexity to the YAP/TAZ regulatory 
mechanism for differentiation in the gastrointestinal mesenchyme.  
 
Future Directions 
 
 The data in this study represents the first evidence implicating YAP/TAZ as 
having a critical role in the developing gastrointestinal mesenchyme and in progenitor 
cell differentiation. It has also generated a number of additional questions that will be 
important to consider for future studies. The following speculations represent what I 
believe to be the most logical next questions to ask and the exciting future directions for 
mesenchymal YAP/TAZ in tumorigenesis. 
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Does YAP/TAZ act as transcriptional co-repressors in other tissues? 
 
I identified a TEAD binding site motif that is present in the Myocd transcriptional 
start site (TSS) that is evolutionarily conserved amongst human, mouse, rat, dog, cow, 
and pig (Fig. 3.23). Given that the TEAD binding site is highly conserved in the Myocd 
TSS, it is possible that I have uncovered an evolutionarily critical mechanism through 
which YAP/TAZ control gastrointestinal mesenchymal progenitor cell differentiation in 
vertebrates. If so, this raises a number of questions about YAP/TAZ functioning as 
transcriptional co-repressors: Do YAP/TAZ function as transcriptional co-repressors in 
other progenitor cell populations during postnatal homeostasis or is this function specific 
to development? Given that Xie et al. previously reported that YAP knockdown induces 
differentiation in vascular smooth muscle progenitor cells (Xie et al., 2012a), it is logical 
to investigate whether the YAP/TAZ transcriptional co-repression mechanism I 
uncovered in the gastrointestinal mesenchyme is also conserved in vascular smooth 
muscle progenitor cells. 
Another question brought to light by my data is whether the YAP/TAZ 
mechanism is specific to the gastrointestinal mesenchyme or if YAP/TAZ function as 
transcriptional co-repressors in other organs? For example, similar to the gastrointestinal 
mesenchyme, mammalian heart development requires tight regulation of YAP/TAZ 
activity in cardiomyocytes; both embryonic YAP/TAZ knockout as well as YAP 
activation in cardiomyocytes results in lethality (von Gisea et al., 2012). Therefore, it is 
possible that YAP/TAZ also function as transcriptional co-repressors in cardiomyocyte 
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progenitor cells to control appropriate differentiation. Cardiac stem cells are quiescent at 
adult stages; it is impossible to regenerate cardiac tissue following myocardial infarction 
(Madonna et al., 2014). However, if YAP/TAZ function as transcriptional co-repressors 
in cardiac progenitor cells at adult stages, then inhibiting YAP/TAZ in this population 
might allow for cardiac regeneration. Conversely, another group has shown that 
constitutive YAP activation following myocardial infarction actually drives cardiac 
regeneration (Xin et al., 2013). Clearly, more work is needed to understand how 
YAP/TAZ regulate progenitor cell populations in the heart and whether YAP/TAZ 
function as transcriptional co-repressors in the cardiomyocyte progenitor cell population. 
Beginning to address these questions in future work will allow for a greater 
understanding of normal mammalian development and how YAP/TAZ, as critical 
members of the Hippo organ size control pathway, regulate growth and proliferation. 
 
How is the YAP/TAZ differentiation program regulated? 
 
I have shown that the canonical Hippo Pathway is responsible for inhibiting 
YAP/TAZ prior to Hedgehog-mediated differentiation in the gastrointestinal 
mesenchyme, but what signals upstream of LATS1/LATS2 to initiate this regulation? 
There are several possibilities for this mechanism, including a morphogen gradient or 
mechanical regulation.  
Morphogen gradients, established when signaling molecules are secreted and 
form a concentration gradient, have been shown to be integral to many developmental 
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processes such as establishing polarity and determining cell fate identity (Ashe and 
Briscoe, 2006). For example, secreted Shh ligand organizes into a concentration gradient 
to pattern the ventral neural tube in mammalian development (Ericson et al., 1997; 
Pierani et al., 1999). Additionally, the Hippo Pathway has previously shown to be 
responsive to a morphogen gradient; one group showed that in the developing Drosophila 
melanogaster wing, the morphogen Decapentaplegic (Dpp) regulates the Hippo pathway 
through the membrane receptor Fat (Rogulja et al., 2008). Therefore, it is possible that a 
similar morphogen gradient activates canonical Hippo Pathway signaling to inhibit 
nuclear YAP/TAZ through LATS1/LATS2-mediated phosphorylation and allow for 
upregulation of mesenchymal progenitor cell differentiation.  
Another possible mechanism for the upstream differentiation mechanism could be 
mechanical forces. In recent years, the importance of physical and mechanical forces 
present in the tissue microenvironment has been appreciated. A number of groups have 
demonstrated that specific lineage of mesenchymal stem cell differentiation can be 
controlled by changing the rigidity of the extracellular matrix (ECM) because of the 
different forces acting on the progenitor cells (Engler et al., 2006; McBeath et al., 2004).  
For example, mesenchymal stem cells plated on a soft ECM will differentiate into neural 
cells but will differentiate into either muscle cells or bone cells when plated on firmer 
ECM (Engler et al., 2006). Additionally, it has been shown by a number of groups that 
YAP/TAZ nuclear localization can be regulated by mechanical forces, such as stretching 
(Driscoll et al., 2015; Dupont et al., 2011; Yu et al., 2012; Zhao et al., 2012). As the 
gastrointestinal tract grows and expands in size, the stretching forces and resulting 
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tension on each individual cell is presumably also changing. It is possible that these 
stretching forces in the developing GI tract might contribute to Hippo Pathway activation. 
To investigate this further, C3H10T1/2 cells can be cultured on different ECM substrates 
to begin to investigate whether mechanical forces can induce smooth muscle 
differentiation. Overall, future experiments to identify how Hippo Pathway maintains this 
mesenchymal progenitor cell population may also provide greater insight into how the 
Hippo Pathway contributes to tumorigenesis. 
 
What does this developmental study reveal about mesenchymal YAP/TAZ in 
tumorigenesis? 
 
 My work has revealed that accumulation of nuclear YAP/TAZ in mesenchymal 
cells is sufficient to drive the hyperproliferation and expansion of a progenitor cell 
population during gastrointestinal development. However, several unknown questions 
remain regarding the requirement for YAP/TAZ in the mesenchyme during normal 
postnatal homeostasis as well as tumorigenesis. Is mesenchymal YAP/TAZ required for 
normal homeostasis in the adult gastrointestinal tract? Is postnatal mesenchymal 
YAP/TAZ activation sufficient to initiate an overgrowth phenotype in the gastrointestinal 
tract? Does mesenchymal YAP/TAZ contribute to the tumor cell niche in colorectal 
cancer and/or in other solid tumors?  
 One future experiment to investigate the role for YAP/TAZ in postnatal 
mesenchymal cell populations would be to use a conditional Cre allele, such as the 
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Gli1CreER or the Myh11CreER allele, to target the GI mesenchyme during postnatal stages. I 
would use these Cre drivers to investigate both YAP/TAZ loss of function as well as 
YAP5SA activation in adult mice. This type of experiment would reveal whether 
mesenchymal YAP/TAZ activity is required in normal homeostasis. This experiment 
would also reveal whether YAP activation in a GI mesenchymal cell population 
contributes to tumorigenesis.  
Preliminary work in our lab has revealed that YAP/TAZ appear to be dispensable 
in a gastrointestinal myofibroblast population during postnatal stages, but that YAP 
activation is sufficient to drive expansion of a mesenchymal cell population. 
Additionally, another project revealed that YAP/TAZ are required for polyp initiation in 
an LKB1-deficient background, indicating that the gastrointestinal hamartomatous 
polyposis disorder, Peutz Jegher’s Syndrome, has a molecular requirement for Hippo 
Pathway signaling (See Appendix B). From these data combined, we are confident that 
investigating the function of YAP/TAZ in the gastrointestinal mesenchyme is certain to 
enhance our understanding of the Hippo Pathway in the tumor microenvironment.   
My work presented here also revealed a critical mechanism whereby YAP/TAZ 
function as transcriptional co-repressors to maintain a mesenchymal progenitor cell 
population. Based on these data, the next logical question is whether YAP/TAZ function 
similarly in cancer associated fibroblasts (CAFs). CAFs are mesenchymal cells that exist 
in the tumor microenvironment and play a tumor-promoting role through secretion of 
growth factors in a number of solid tumors, such as breast, prostate, and pancreas (Luo et 
al., 2015; Olumi et al., 1999; Pan et al., 2015; Spaeth et al., 2009). As a result of their 
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tumor promoting role through paracrine signaling to tumor cells, CAFs represent 
attractive drug targets for targeted therapies in patients with solid tumors (Calon et al., 
2015; Conti and Thomas, 2011; Isella et al., 2015). However, further work is needed to 
understand exactly how CAFs maintain the pro-growth niche environment, and whether 
this mechanism involves YAP/TAZ. One such experiment could involve genetic 
mesenchymal Yap/Taz knockout in the ApcMin model for colorectal cancer. If 
mesenchymal YAP/TAZ activity contributes to the tumor microenvironment in APC-
mutant polyps, I would expect to observe a reduction in tumor burden when YAP/TAZ 
are genetically removed from the mesenchyme.  
Furthering our understanding of YAP/TAZ during normal gastrointestinal 
development will ultimately help us explain the role YAP/TAZ is playing during 
tumorigenesis. However, my work has also revealed a multitude of new and exciting 
questions. Answering these questions will allow us to better understand how YAP/TAZ 
contribute to tumorigenesis and if YAP/TAZ are attractive drug targets for targeted 
therapies in the clinic. 
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Final Thoughts 
 
 Cumulatively, the data presented here highlight the critical importance of tissue 
compartment specificity during both development and tumorigenesis. YAP/TAZ clearly 
are dispensable in the epithelia under normal conditions and are only required during Wnt 
hyperactivation. In the developing gastrointestinal mesenchyme however, YAP/TAZ are 
required. Uncovering the temporal and spatial requirements for developmental signaling 
pathways, such as the Hippo Pathway, helps to understand whether it is efficacious to 
develop YAP/TAZ inhibitors for clinical use.  
 This study is also the first to link Hippo Pathway signaling to the maintenance of 
gastrointestinal mesenchymal progenitor cells and to discover a relationship between 
Hippo Pathway and Hedgehog-Pathway mediated differentiation in the mesenchyme. 
Given the tumor-promoting role that the stroma has been shown to play through paracrine 
signaling to associated tumor cells in the tumor microenvironment, the identification of 
the Hippo Pathway as a critical mediator of the mesenchymal progenitor cell population 
expands understanding of both Hippo Pathway signaling, as well as the importance of the 
mesenchyme in gastrointestinal development and tumorigenesis. 
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Preface 
 
Of the most commonly used model organisms— bacteria, yeast, worms, flies, and 
mice— the laboratory mouse is the most similar to humans in both genomic homology as 
well as in anatomical similarity (Eppig et al., 2012). Using mice to develop genetically 
engineered mouse models (GEMMs) allows for precise spatial and temporal control of 
gene expression in an in vivo system. Despite advances in genetic engineering, these 
mouse models are not always a perfect recapitulation of human disease; mouse models of 
colorectal cancer in particular highlight the dichotomy that exists between polyp 
initiation in mice as compared to humans. Similar to humans with an APC mutation, mice 
also develop polyps driven by elevated Wnt pathway signaling in the GI epithelia (Su et 
al., 1992). However, humans generally develop APC-mutant polyps in their large bowel, 
whereas mice predominantly develop APC-mutant polyps in the small intestine (Jackstadt 
and Sansom, 2016). Additionally, humans born with Peutz Jeghers’ Syndrome caused by 
an inherited autosomal dominant mutation in LKB1 develop multiple hamartomatous 
polyps throughout the GI tract, whereas mice carrying a heterozygous knockout of Lkb1 
develop hamartomatous polyps only at the pylorus (Bardeesy et al., 2002; Jishage et al., 
2002; Miyoshi et al., 2002). The small intestine and large bowel are both functionally and 
structurally different; the small intestine is involved with nutrient absorption and is 
organized in crypt-villi architecture, whereas the large bowel is primarily involved with 
water absorption and villi are absent (Ménard, 2004). Therefore, comparing a small 
intestine polyp in mouse to a large bowel polyp in a human can be challenging due to the 
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vast differences that exist along the GI tract. Finally, the majority of mouse models of 
CRC do not undergo metastasis and are primarily experimental examples of adenomas 
and carcinoma in situ; these models do not recapitulate the metastatic CRC which 
ultimately leads to death in human patients (Deming et al., 2013). Overall, there still 
remain many experimental questions which the mouse models currently available are 
incapable of addressing.   
While GEMMs are not perfect facsimiles of human disease, mouse models are 
still considered to be a powerful experimental tool for cancer research. The time to 
adulthood for a laboratory mouse is approximately 4-6 weeks, whereas this process takes 
18 years in humans (Vandamme, 2014). While the chimpanzee is the most similar animal 
to humans according to genome sequence homology, the costs and space required for 
primate research are prohibitive for many studies, whereas mice take significantly less 
space and cost per animal (Conlee and Rowan, 2012). Finally, the ideal experiment to 
study polyp progression and tumorigenesis would be conducted within humans; however, 
strict ethical regulations and morality prevent scientists from conducting these type of 
experiments with human subjects (Festing and Wilkinson, 2007). Therefore, mouse 
models represent an ideal in vivo model organism to conduct tumor studies due to the 
abbreviated mouse lifespan, biological similarities to humans, and the strict ethical 
regulations involved with human research. The CRC mouse models available represent 
the best technology to investigate polyp initiation and progression in vivo, however, 
development of new mouse models that more closely recapitulate human disorders will 
continue to bridge the gaps that exist between mouse and human. Ultimately, developing 
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and studying these new mouse models should lead to new drugs and treatments for 
human patients. 
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APPENDIX A 
SMAD7 promotes serrated polyposis in the GI epithelia 
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Preface 
 
 Appendix A represents work I performed in Dr. Junhao Mao’s lab at the 
University of Massachusetts. The data presented herein is my own, with the following 
exceptions listed below: 
 
Fig. A.7.A: Dr. He Huang isolated RNA from VillinCreR26Smad7/+ polyps. Dr. Jianhong 
Ou performed data set comparison and analysis. 
 
 These data are unpublished. Further experiments are needed to complete this 
manuscript. Therefore the story presented in Appendix A represents our current 
understanding of the science based upon our interpretation of the data. Additional data 
and conclusions may be added in the published version.  
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Abstract 
 
 Mutations in SMAD7 have been shown to be a prognostic marker in colorectal 
cancer (CRC) patients, but the exact relationship between SMAD7 and tumorigenesis 
remains elusive. To determine the effect of SMAD7 on transformation, I stably expressed 
a SMAD7 expression construct in FET cells, a noninvasive colorectal cancer cell line, as 
well as IEC6 cells, an immortalized, non-transformed intestinal epithelial cell line. I 
observed that SMAD7 expression allows cells to overcome contact-mediated inhibition. 
To investigate this finding further, we generated a novel mouse allele for SMAD7 
expression, the R26Smad7 allele. SMAD7 expression in the intestinal epithelia is sufficient 
to initiate serrated polyposis, independently of WNT-pathway mutations. Furthermore, 
SMAD7-mutant polyps express the serrated polyp markers Vsig1 and Anxa10. Together, 
SMAD7 may initiate serrated polyposis through the upregulation of canonical serrated 
polyp markers. Thus, this study describes a novel mouse model that expresses the 
serrated polyp molecular signature and links SMAD7 to the serrated polyp initiation 
cascade. 
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Introduction 
 
Colorectal cancer (CRC) is the third leading lethal cancer subtype in the United 
States and is responsible for almost 50,000 deaths per year in the United States (Siegel et 
al., 2016). CRC has long believed to arise according to the Vogelstein model for 
tumorigenesis with an initiating mutation in the APC/Wnt signaling pathway initiating 
hyperplasia, followed by a stepwise accumulation of genetic events as polyps progress 
from adenomas to carcinoma in situ and eventually malignant carcinoma (Fearon and 
Vogelstein, 1990).  
The serrated polyp subtype, including both traditional serrated polyps and sessile 
serrated polyps, are histologically distinct from conventional adenomatous polyps 
(Torlakovic et al., 2008). Adenomatous polyps, such as pedunculated adenomas, are 
characterized by a smooth or tube-like crypt structure (Bariol et al., 2003; Fodde, 2002; 
Shibata et al., 1997). Serrated polyps are characterized by a “saw-tooth” pattern in the 
crypts, and can also be organized into a “tennis-racket” type structure in early lesions 
(Bariol et al., 2003; Bordacahar et al., 2015; Salaria et al., 2012; Torlakovic et al., 2008).  
For many years it was believed that the serrated polyp group were benign and did 
not progress to carcinoma (Longacre and Fenoglio-Preiser, 1990). However, it has 
recently been appreciated that histologically serrated polyps represent as many as 30% of 
all malignant colorectal cancer cases (Makkar et al., 2012; Salaria et al., 2012). 
Additionally, it has been shown that serrated polyps arise through a genetically distinct 
molecular pathway, known as the Serrated Polyp Pathway (Laiho et al., 2007). The 
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Serrated Polyp Pathway is independent of the canonical APC/Wnt signaling pathway, 
which is responsible for conventional adenoma initiation and progression (Laiho et al., 
2007). Activating mutations in KRAS and BRAF have been proposed to be involved in 
the Serrated Polyp Pathway, however many questions remain about whether other genes 
are instrumental in serrated polyp pathogenesis (Davies et al., 2014; Feng et al., 2011; 
Laiho et al., 2007; Patai et al., 2013) 
SMAD7 is the inhibitory R-SMAD for both the TGFβ and BMP pathways and 
mechanistically prevents the phosphorylation of either SMAD2/3 or SMAD1/5/8 (Zhu et 
al., 2011). Recently, SMAD7 has been identified as a prognostic marker for colorectal 
cancer (Slattery et al., 2010; Stolfi et al., 2013; Tenesa et al., 2008; Thompson et al., 
2009). Additionally, recent Genome-wide Association Studies (GWAS) identified single-
nucleotide polymorphisms (SNPs) within the Smad7 gene that confers an elevated risk 
for developing colorectal cancer (Broderick et al., 2007; Jiang et al., 2013; Pittman et al., 
2009; Slattery et al., 2010; Tenesa et al., 2008).  
There are conflicting reports regarding whether SMAD7 gain of function or 
SMAD7 loss of function is tumorigenic. The Smad7 gene is located within the 
chromosomal region 18q21, which has been frequently observed to be deleted in 
colorectal cancer (CRC) (Boulay et al., 2003). One report suggests that SMAD7 inhibits 
tumorigenicity through inhibiting TGFβ growth factor secretion (Javelaud et al., 2005). 
However, there is also evidence that SMAD7 gain of function can also be tumorigenic by 
blocking TGFβ-mediated apoptosis (Halder et al., 2005; Halder et al., 2008).  
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 We report here that SMAD7 gain of function is tumorigenic in the intestinal 
epithelia, and is sufficient to initiate polyposis independently of WNT pathway 
activation. Furthermore, we show that SMAD7 overexpression drives growth of serrated 
polyps, through a Hippo Pathway-independent mechanism. Additionally, we report that 
SMAD7 expression is sufficient to drive the expression of the molecular signature for 
serrated polyposis. Overall we have uncovered a link between SMAD7 and serrated 
polyposis in vivo, and have developed a novel mouse model that recapitulates the 
histological and molecular signature of human serrated polyposis.  
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Results and Discussion 
 
SMAD7 increases anchorage-independent cell growth and induces foci formation 
 Recent GWAS studies have identified SNPs in SMAD7 that correlate with a 
greater risk for colorectal cancer as well as a poorer prognosis. To investigate this further, 
I first investigated SMAD7 expression in FET cells, a non-invasive colorectal cancer cell 
line (Brattain et al., 1980). I first cloned the mouse Smad7 cDNA containing a flag-tag 
into the pGIPZ2a plasmid. I then transfected FET cells with either the pGIPZ2a or 
pGIPZ2a-Smad7 plasmid and assayed for anchorage-independent cell growth using a soft 
agar assay. I confirmed that overexpression of the SMAD7 protein is sufficient to 
increase anchorage-independent growth of FET colorectal carcinoma cells in vitro (Fig. 
A.1.A), corroborating previously published findings (Halder et al., 2005; Halder et al., 
2008). 
  I next wanted to investigate the role of SMAD7 in the process of transformation. 
I used lentiviral infection to express the pGIPZ2a or pGIPZ2a-Smad7 plasmid in IEC6 
cells, an immortalized non-transformed cell line (Quaroni et al., 1979). I then assayed 
whether overexpression of SMAD7 was sufficient to allow IEC6 cells to overcome 
contact-mediated growth inhibition in a foci formation assay. I found that after three 
weeks of growth in culture, IEC6-pGIPZ2a-Smad7 cells formed significantly more foci 
colonies than control cells (Fig. A.1.B,C). Together, my analysis suggested a role for 
SMAD7 in anchorage-independent cell growth and in foci formation.   
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Figure A.1. SMAD7 drives colony and foci formation.  
(A) In vitro SMAD7 expression increases anchorage-independent cell growth and soft 
agar colony formation in FET cells and (B,C) induces foci formation in the non-
transformed rat intestinal epithelia cell line IEC6.  
 
 
187 
 
SMAD7 does not affect WNT pathway signaling in vitro 
 I next investigated whether SMAD7 overexpression was activating Wnt pathway 
signaling in vitro. Activation of Wnt pathway signaling in IEC6 cells is sufficient to 
induce foci formation in vitro (Ouko et al., 2004). Given that SMAD7 has been shown to 
interact with and stabilize β-catenin, I hypothesized that SMAD7 was initiating 
tumorigenesis by stabilizing β-catenin, thereby activating Wnt pathway target gene 
expression (Edlund et al., 2005; Tang et al., 2008). 
 Interestingly, I observed that SMAD7 expression in IEC6 cells does not result in 
elevated -catenin protein levels (Fig. A.2.A). Additionally, protein expression of 
canonical Wnt pathway targets axin2 and c-myc were not increased following expression 
of the pGIPZ2a-Smad7 construct (Fig. A.2.B,C). Finally, I found that SMAD7 expression 
does not affect TCF/LEF luciferase reporter activity in IEC6 cells (Fig. A.2.D). From 
these data, I concluded that SMAD7 does not affect Wnt pathway signaling in vitro. 
 
SMAD7 overexpression induces polyposis in the intestinal epithelia 
 I next wanted to investigate whether SMAD7 expression in the intestinal epithelia 
in vivo was sufficient to initiate polyposis. To do this, our lab generated a conditional 
allele targeted into the Rosa26 locus, R26Smad7, which expresses Smad7 and a C-terminal 
IRES-nuclear LacZ under control of a hybrid CMV enhancer/β-actin CAGGS promoter 
following traditional Cre-Lox mediated recombination (Fig. A.3.A). To restrict the 
expression of the R26Smad7 allele specifically to the intestinal epithelia, I crossed the 
R26Smad7 mice to Villin
Cre mice to generate mice with the VillinCreR26Smad7/+ genotype. I  
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Figure A.2. SMAD7 does not affect Wnt pathway signaling in vitro.  
(A) β-catenin protein levels are unchanged in IEC6 cells following SMAD7 expression. 
(B,C) Canonical Wnt pathway targets axin2 and c-myc affect TCF/LEF reporter activity 
in vitro.  
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Figure A.3. VillinCreR26Smad7/+ animals develop intestinal and colon polyps.  
(A) Smad7 gain of function transgenic allele. (B) VillinCreR26Smad7/+ animals develop 
polyps in both the intestine and colon. Scale bar = 100 µM. (C) Mosaic expression of the 
R26Smad7 transgene  in the intestinal epithelia demonstrates the oncogenic capability of 
SMAD7; polyps are comprised of βgal+ cells whereas adjacent wildtype appearing tissue 
is negative for SMAD7 transgene expression. Scale bar = 5 µM.  
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allowed VillinCreR26Smad7/+ animals to age and observed that animals developed polyps in 
both intestine and colon (Fig. A.3.B), and animals survived to approximately 14 months 
of age (Fig. A.8.A). Expression of the VillinCreR26Smad7/+ transgene appeared to be 
mosaic, yet I observed that both hyperplastic villi and polyps were comprised exclusively 
of -galactosidase+ cells (Fig. A.3.C), indicating that expression of the R26Smad7 allele in 
intestinal epithelia cells is sufficient to initiate hyperplasia and polyposis. 
 
Villin
Cre
R26
Smad7/+ polyps exhibit serrated morphology  
 I next decided to compare the morphology of the VillinCreR26Smad7/+ polyps to the 
classic adenomatous polyp morphology. According to the widely accepted Vogelstein 
model of tumorigenesis, colorectal cancer progresses through a sequential series of 
accumulating genetic aberrations (Fearon and Vogelstein, 1990). One of the earliest 
genetic mutations is the loss of APC, which results in the stabilization of nuclear -
catenin and upregulation of Wnt signaling. Elevated Wnt pathway activity has been 
correlated with tumorigenesis in colorectal cancer in patients.  
To test this, I first generated VillinCreApcflox/+ animals; genetic ablation of Apc 
specifically in the intestinal epithelia is sufficient to drive polyposis through activation of 
the Wnt pathway and stabilization of -catenin (Fearon and Vogelstein, 1990; Powell et 
al., 1992; Siu et al., 1997; Su et al., 1992; Yuan et al., 2001). Polyps in VillinCreApcflox/+ 
animals exhibited classic adenomatous histology with rounded polyp morphology.  
I consulted with the UMass Pathology Department to review the pathology of the 
APC-mutant polyps to SMAD7-mutant polyps. Dr. Zhong Jiang confirmed that the 
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VillinCreR26Smad7/+ polyps exhibited the characteristics of serrated polyps, included the 
“saw-tooth” like crypt structures, rather than classic adenomatous polyps (Fig. A.4.A,B) 
(Bariol et al., 2003). Additionally, early VillinCreR26Smad7/+ polyp lesions displayed the 
“tennis racket” morphology characteristic of serrated polyps, rather than the rounded 
adenomatous morphology characteristic of APC-mutant polyps (Patai et al., 2013; 
Torlakovic et al., 2008). A previous publication showed that whole-body Smad4 
heterozygous knockout mice can generate serrated adenomas in vivo (Hohenstein et al., 
2003). My findings corroborate this finding that aberrant TGFβ/BMP signaling in the 
intestinal epithelia is sufficient to initiate serrated polyposis, and also links SMAD7 to 
this process for the first time. 
 Finally, immunohistochemical analysis revealed that in contrast to robust nuclear 
accumulation of -catenin in APC-mutant polyps, -catenin localization in SMAD7-
mutant polyps is primarily membranous (Fig. A.5.A). Additionally, canonical Wnt 
pathway targets CD44 and Sox9 are highly elevated in APC-mutant polyps, but not in 
SMAD7-mutant polyps (Fig. A.5.B,C). The molecular mechanisms and mutations 
involved with serrated polyp tumorigenesis are believed to be independent of the 
Vogelstein/WNT pathway model for adenoma tumorigenesis (Carragher et al., 2010; 
Davies et al., 2014; Hawkins et al., 2002; Makinen, 2007; Patai et al., 2013). Therefore, I 
conclude that SMAD7 is driving polyposis independently of Wnt pathway signaling, and 
is initiating a serrated polyp pathway to drive tumorigenesis. 
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Figure A.4. VillinCreR26Smad7/+ polyps exhibit serrated morphology.  
(A-B) VillinCreApcflox/+ polyp histology is representative of classical adenomatous polyps, 
whereas VillinCre R26Smad7/+ polyp  histology is representative of serrated polyposis. 
VillinCreR26Smad7/+ polyps display “tennis-racket” morphology rather than the rounded 
adenomatous morphology in VillinCreApcflox/+. Scale bar = 50 µM. 
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Figure A.5. Wnt pathway signaling is not affected in VillinCreR26Smad7/+ polyps in 
vivo.  
(A) Subcellular localization of β-catenin is nuclear in VillinCreApcflox/+ polyps but is 
membranous in VillinCreR26Smad7/+ polyps. (B, C) Canonical Wnt pathway targets CD44 
(B) and Sox9 (C) are not elevated in VillinCreR26Smad7/+ polyps. Scale bar = 5 µM.  
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Villin
Cre
R26
Smad7/+ polyps express markers specific to serrated polyps 
 It has recently been reported that human serrated polyps express a core set of 
signature markers, Vsig1 and ANXA10, specific to serrated polyps (Bae et al., 2015; Kim 
et al., 2015a). I obtained patient samples from the UMass Pathology Department for both 
traditional adenomas as well as serrated adenomas. I observed that the VillinCreR26Smad7/+ 
polyps exhibit the characteristic “sawtooth” epithelial morphology, consistent with the 
human serrated polyps (Fleming et al., 2012; Makinen, 2007).  
 As expected, I found that the human serrated adenomas samples exhibited high 
expression for serrated polyp markers Vsig1 and ANXA10, whereas the traditional 
adenomas were negative for these markers (Fig. A.6.B,C). Next, I wanted to investigate 
whether the VillinCreR26Smad7/+ polyps exhibit the serrated polyp expression signature. I 
found that the APC-mutant adenomatous polyps in the VillinCreApcflox/+ animals were 
negative for Vsig1 and ANXA10 expression, but that the VillinCreR26Smad7/+ polyps 
expressed Vsig1 and ANXA10 in the intestinal epithelia.  
 I then decided to investigate the transcriptional profile in the VillinCreR26Smad7/+ 
polyps via microarray. I found 1683 differentially expressed transcripts in the 
VillinCreR26Smad7/+ polyps as compared to control tissue (Fig. A.7.A). Interestingly, I 
found that Vsig1 was the highest expressed transcript, and Anxa10 was one of the highest 
expressed transcripts (Fig. A.7.B). Finally, I compared the VillinCreR26Smad7/+ microarray 
data to two publically available datasets: GSE46513, a human serrated polyp RNAseq 
data set, and GSE43841, a human serrated polyp microarray data set (Fig. A.7.A). I found 
a shared set of 46 genes that were common amongst the three data sets, including both  
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Figure A.6. SMAD7-driven polyps in mouse phenocopy human serrated polyps.  
(A) VillinCreR26Smad7/+ polyps exhibit histological characteristics of serrated polyps, not 
adenomatous polyps. (B-C) VillinCreR26Smad7/+ polyps exhibit upregulation of bona fide 
serrated polyposis markers Vsig1 and ANXA10. Scale bar = 10 µM. 
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Figure A.7. Gene expression of VillinCreR26Smad7/+ polyps overlaps with canonical 
serrated polyp signature markers.  
(A) Comparison of gene expression. Affymetrix microarray data from the 
VillinCreR26Smad7/+ polyps compared to GSE46513, a human serrated polyp RNAseq data 
set, and GSE43841, a human serrated polyp microarray data set. (B) Canonical serrated 
polyp markers Vsig1 and AnxA10 are amongst the highest expressed genes in 
VillinCreR26Smad7/+ polyps. 
 
 
 
 
197 
 
Vsig1 and AnxA10. Therefore I concluded that the VillinCreR26Smad7/+ polyps are both 
histologically consistent with human serrated adenomas and are robustly recapitulating 
the molecular serrated polyp expression in vivo.  
 
Villin
Cre
R26
Smad7/+ polyps are not regulating Hippo Pathway components YAP/TAZ 
 It has been reported that intestinal epithelia knockout of the Hippo Pathway 
component Sav1 is sufficient to drive a serrated polyp histological phenotype in an in 
vivo mouse model (Cai et al., 2010). Additionally, we and others have shown that 
YAP/TAZ are critical during conditions of WNT pathway overactivation and that genetic 
knockout of both YAP/TAZ in an APC-mutant background is sufficient to prevent polyp 
formation (Azzolin et al., 2014; Cai et al., 2015; Gregorieff et al., 2015; Zanconato et al., 
2015). Finally, SMAD7 has been shown to interact with YAP through direct binding 
(Ferrigno et al., 2002). Therefore, I decided to investigate whether YAP/TAZ are also 
required for SMAD7-driven serrated polyp formation. 
I first investigated overall YAP protein expression in the VillinCreR26Smad7/+ 
polyps. I observed that the VillinCreApcflox/+ polyps exhibited elevated nuclear YAP levels, 
whereas VillinCreR26Smad7/+ polyps did not exhibit elevated nuclear YAP localization. I 
next decided to use mouse genetics to investigate the requirement for YAP/TAZ in 
VillinCreR26Smad7/+ mutant polyps. I generated VillinCreR26Smad7/+Yapflox/floxTazflox/flox 
animals and aged them to 14 months. In an Apc-mutant background, I observed that 
genetic ablation of both Yap and Taz was sufficient to inhibit polyposis. However, I 
found no change in overall lifespan of animals (Fig. A.8.A) as compared to  
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Figure A.8.  YAP/TAZ are not required for SMAD7-driven serrated polyposis.  
(A) Survival curve of VillinCreR26Smad7/+ and VillinCreR26Smad7/+Yapflox/flox Tazflox/flox 
animals as compared to controls. (B) YAP protein is predominantly nuclear in 
VillinCreApcflox/+ polyps, whereas YAP is predominantly cytoplasmic in VillinCre 
R26Smad7/+ polyps in vivo. (C) Genetic knockout of both Yap and Taz is insufficient to 
inhibit SMAD7-driven serrated polyposis.  Scale bar = 5.0 µM. 
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VillinCreR26Smad7/+ animals, despite robust knockout of YAP/TAZ (Fig. A.8.C). This leads 
me to conclude that YAP/TAZ are dispensable for SMAD7-driven serrated polyposis in 
the intestinal epithelia. 
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Conclusions 
 
This is the first study to link SMAD7 to serrated polyposis. Furthermore, this 
work also represents the first mouse model that robustly recapitulates human serrated 
polyposis both histologically and molecularly through expression of a bona fide serrated 
polyposis molecular signature. This work also provides evidence that SMAD7 expression 
drives the growth of serrated polyps independently of either Wnt pathway activation or 
YAP/TAZ signaling, uncovering a novel genetic mechanism for serrated polyposis 
through SMAD7 activation. The mouse model presented in this work will be hugely 
beneficial for future studies investigating the molecular basis for serrated polyposis, and 
will hopefully provide clinical benefit from the knowledge gained.  
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Materials and Methods 
 
Mouse Genetics 
The VillinCre, AhCre, and Apcflox alleles were obtained from the Jackson 
Laboratory. The Yapflox and Tazflox alleles were a gift from Drs. WE Zimmer, OJ Sansom, 
DJ Winton, and EN Olson. To generate the R26Smad7 allele, the Smad7 cDNA was cloned 
into the pROSA targeting vector. The construct was electroporated into mouse ES cells 
for blastocyst injection and chimeric animals were generated. To target the intestinal 
epithelia, VillinCre or AhCre was crossed to R26Smad7, Apcflox, Yapflox, and Tazflox alleles. 
AhCre expression was induced at postnatal day 30 through intraperitoneal injection of 80 
mg/kg β-napthoflavone.  
 
Tissue Collection and Histology 
 Mice were dissected and tissue was fixed in 10% neutral buffered formalin 
overnight at 4°C.  Tissues were dehydrated in ethanol, embedded in paraffin, and 
sectioned at 6 µm for paraffin sections. Standard hematoxylin & eosin reagents were used 
to stain paraffin sections. For frozen sections, tissues were dehydrated in sucrose, 
embedded in OCT media, and sectioned at 12 µm.  
 
Human clinical samples 
 Clinical samples representing normal colon tissue, adenomatous polyps, and 
serrated polyps were provided by the UMass Medical School Department of Pathology. 
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Histological analyses of mouse tissues were conducted by Dr. Zhong Jiang, Department 
of Pathology, UMass Medical School. 
 
Immunohistochemistry 
 For immunohistochemistry (IHC), paraffin sections were deparaffinized and 
antigen retrieval was performed using heat-induced epitope retrieval in 10mM sodium 
citrate buffer, pH 6.0. Slides were blocked for endogenous peroxidase in a 3% H2O2-
MeOH solution before being blocked for 1 hour in a 5% BSA, 1% goat serum, 0.5% 
Tween-20 solution. Slides were incubated in primary antibody diluted in either blocking 
buffer or SignalStain® Antibody Diluent (Cell Signaling) overnight at 4°C. Slides were 
incubated in biotinylated secondary antibody for 1 hour and then signal was amplified 
and detected using the Vectastain Elite ABC kit and the DAB Peroxidase Substrate kit 
(Vector Laboratories). Primary antibodies used for IHC were: β-galactosidase (1:2,000, 
Abcam), β-catenin (1:500, BD Biosciences), CD44 (1:400, eBioscience), Sox9 (1:200, 
Abcam), Vsig1 (1:100, Novus Biologicals), ANXA10 (1:100, Novus Biologicals), and 
YAP (1:200, Cell Signaling).  
 
Cell Culture 
FET and IEC6 cells were obtained from ATCC. FET cells were cultured in 
Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum and IEC6 cells were 
cultured in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum and 0.1 
Unit/mL insulin.  
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To generate the pGIPZ2a-Smad7 plasmid, Smad7 cDNA was cloned and ligated 
into the pGIPZ2a plasmid. For anchorage-independent growth assay, HCT116 cells were 
grown in soft agar and colonies were counted. For foci formation assay, IEC6 cells were 
seeded and grown for 3 weeks, after which point foci colonies were counted. For 
luciferase assay, either pGIPZ2a empty vector, pGIPZ2a-Smad7, or pGIPZ2a-dnTcf4 
were transfected along with TCF/LEF reporter constructs, and luciferase activity 
monitored per Dual-Luciferase Reporter Assay System manufacturer’s protocol 
(Promega).  
 
Western Blotting 
Cells were lysed and probed for the following primary antibodies: β-catenin 
(1:1,000, BD Biosciences), β-actin (1:1000, Genescript), axin2 (1:1000, Abcam), c-myc 
(1:1000, Abcam), GAPDH (1:1000, CST). Secondary antibodies (1:5000) were 
purchased from Jackson Laboratories. 
 
Quantitative Real-Time PCR 
RNA was isolated from cell lines using Trizol and was reverse-transcribed into 
DNA using the SuperscriptII kit (Invitrogen). Quantitative real-time PCR was performed 
using SYBR MasterMix (Kapa Biosystems). Primers for real-time PCR were: 
Axin2 (rat):  Forward: 5′-TGGTGCATACCTCTTCCGGACTTT-3′ 
  Reverse- 5′-TTTCCTCCATCACCGCCTGAATCT-3′ 
GAPDH (rat): Forward:  5’-GGCAAGTTCAATGGCACAGT-3’ 
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  Reverse:  5'-TGGTGAAGACGCCAGTAGACTC-3'.  
 
Affymetrix Gene Chip Transcriptional Profiling 
Intestinal polyps from VillinCreR26Smad7/+ animals were carefully dissected and 
RNA was isolated using Trizol reagent. For Affymetrix Gene Chip analysis, RNA was 
labeled and hybridized to Mouse Gene 1.0ST chips according to Affymetrix 
manufacturer protocols. Independent biological triplicates were used for chip analysis 
and data was analyzed using the statistical language R. Genes with a p value <0.05 and a 
fold change > 1.0 were identified for further analysis. The VillinCreR26Smad7/+ 
transcriptional profile was then compared against publically available data sets for human 
serrated polyposis (Accession numbers GSE46513 and GSE43841) to identify a common 
shared gene expression signature. 
 
 
 
 
 
 
 
 
 
 
205 
 
APPENDIX B 
 
Genetically distinct GI hamartomatous polyps arise from a common mesenchymal 
progenitor cell 
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Preface 
 
 The work presented in this Appendix, including all mouse models, is exclusively 
my own work at the University of Massachusetts in the lab of Dr. Junhao Mao.  
 These data are unpublished. Further experiments are needed to complete this 
manuscript. Therefore the results presented in Appendix B represent my current 
interpretation of the data based on the experiments I have performed. Additional data and 
conclusions will be performed and will be added in the published version.  
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Abstract 
 
 Gastrointestinal hamartomatous polyposis syndromes have been shown to confer 
an elevated risk for colorectal cancer in patients, but the exact mechanism of polyp 
initiation remains unclear. I report here the first evidence linking three genetically distinct 
gastrointestinal hamartomatous polyposis syndromes together through a shared 
mesenchymal cell of origin. I show that despite different initiating mutations and 
downstream signaling, Peutz Jeghers Syndrome, Juvenile Polyposis, and PTEN 
Hamartoma Syndrome/Cowden’s Syndrome polyps all arise from a gastrointestinal 
myofibroblast cell. Furthermore, I report the Gli1CreERPtenflox/flox mouse as the first mouse 
model for PTEN Hamartoma Syndrome with gastrointestinal polyposis and the 
Gli1CreERR26Smad7/+ mouse as the first mouse model using SMAD7 expression to model 
Juvenile Polyposis Syndrome. I also use mouse genetics to show that in Peutz Jeghers 
Syndrome polyps, mTOR pathway signaling is not required, but that YAP/TAZ are 
required. Overall this study describes a number of novel mouse models that recapitulate 
human gastrointestinal polyposis syndromes, identifies the gastrointestinal myofibroblast 
as a critical cell type in polyposis, and begins to elucidate the critical downstream 
signaling required for polyp growth. 
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Introduction 
 
 Gastrointestinal hamartomatous polyposis syndromes are rare, inherited genetic 
disorders that cause multiple hamartomatous polyps to grow in the gastrointestinal tract. 
Gastrointestinal hamartomatous polyps are generally comprised of fully differentiated 
cells native to the gastrointestinal tract, with a prominent mesenchymal contribution and 
a highly disorganized architecture. Patients with GI hamartomatous polyposis syndromes 
have an elevated risk of developing both colorectal cancer as well as other epithelial 
cancers.  
 Juvenile Polyposis Syndrome (JPS) is a gastrointestinal hamartomatous polyposis 
syndrome affecting approximately 1 in 160,000 people and linked to mutations in 
TGFβ/BMP pathway signaling (Chow and Macrae, 2005). JPS patients can have upwards 
of 50-200 polyps in their gastrointestinal tract, which are histologically characterized as 
being comprised of mucus-filled cystic lesions and a prominent stromal contribution. JPS 
patients have an approximately 50% chance of developing gastrointestinal cancer (Howe 
et al., 1998). Mechanistically, 40% of JPS patients carry an inherited mutation in either 
SMAD4 or BMPR1A (Merg and Howe, 2004). However, 60% of JPS patients have no 
identified genetic mutation, indicating that additional research is needed to uncover 
initiating mutations for this inherited syndrome. 
 PTEN Hamartoma Syndromes is a family of rare inherited genetic disorders 
caused by mutations in the tumor suppressor Pten. The most common of the PTEN 
Hamartoma Syndromes is Cowden’s Syndrome, and affects approximately 1 in 250,000 
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people. Cowden’s Syndrome patients have up to a 24% risk of developing colorectal 
cancer in their lifetime (Riegert-Johnson et al., 2010). Histologically, Cowden’s 
Syndrome polyps usually arise in the colon, rarely have mucus-filled cystic lesions, and 
commonly have lymphoid follicles present (Shaco-Levy et al., 2016).  
Peutz-Jeghers Syndrome (PJS) is a rare inherited autosomal dominant disorder 
affecting approximately 1 in 120,000 people and is characterized by the growth of 
multiple benign hamartomatous gastrointestinal polyps throughout the gastrointestinal 
tract, primarily in the small intestine (Jenne et al., 1998; McGarrity et al., 2000; Riegert-
Johnson et al., 2009). Almost all Peutz Jeghers patients carry a mutation in the 
Lkb1/Stk11 gene, a serine/threonine kinase known to phosphorylate and activate AMP-
activated protein kinase (AMPK) (Hawley et al., 2003; Hemminki et al., 1998; Jenne et 
al., 1998; Shaw et al., 2004). Peutz Jeghers patients have a 93% chance of malignant 
transformation by the age of 65 and a 48% chance of dying from cancer by age 57 
(Giardiello et al., 1987; Hearle et al., 2006; Spigelman et al., 1989).  
PJS intestinal polyps are characterized by the hyperproliferation of disorganized 
yet fully differentiated cells, a prominent stromal contribution and a smooth muscle core 
(Jishage et al., 2002). Heterozygous Lkb1 knockout in mice phenocopies human Peutz 
Jeghers Syndrome polyps (Bardeesy et al., 2002; Jishage et al., 2002; Miyoshi et al., 
2002). Recently it was shown that homozygous loss of Lkb1 in the intestinal epithelia 
does not initiate polyposis (Shorning et al., 2009), while heterozygous loss of Lkb1 
specifically in the smooth muscle compartment is sufficient to initiate PJS polyps 
(Katajisto et al., 2008) with a prominent contribution from the myofibroblast population. 
210 
 
These data suggest the myofibroblast population in the mesenchyme is of key importance 
in the initiation of PJS polyposis.  
 Even with the identification of Lkb1 as the commonly mutated gene in Peutz 
Jeghers Syndrome, the exact downstream mechanism through which Lkb1 loss leads to 
polyposis and tumorigenesis has been poorly characterized. It has been hypothesized that 
the LKB1-mediated mechanism disrupted in PJS patients is facilitated by the aberrant 
activation of mTORC1, which is downstream of AMPK (Shackelford et al., 2009). There 
are conflicting reports as to whether mTORC1 activity, as assayed through levels of pS6, 
is impacted in Lkb1+/- polyps and whether rapamycin, a partial mTORC1 inhibitor, can 
reduce the polyp burden in Lkb1+/- mice (Katajisto et al., 2008; Robinson et al., 2009; 
Wei et al., 2008). Additionally, there have been recent reports showing that LKB1 can 
interact with the Hippo Pathway transcriptional co-activator YAP in vitro and that 
YAP/TAZ are elevated in human Peutz Jeghers polyp samples (Mohseni et al., 2014). 
However, there is no genetic evidence to conclusively implicate either mTOR or 
YAP/TAZ as the downstream targets through which loss of Lkb1 leads to polyp initiation 
in Peutz Jeghers Syndrome.  
The role of the tumor stroma and disruption of homeostatic mesenchymal-
epithelial signaling in tumorigenesis has only recently begun to be appreciated as a 
contributing factor to the initiation and progression of cancer (Ishiguro et al., 2006; 
Nakamura et al., 1997). The tumor stroma, which is composed of fibroblasts, 
myofibroblasts, inflammatory cells, along with extracellular matrix (ECM) proteins, is 
known to secrete various growth factors that stimulate cancer cell proliferation 
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(Shackelford et al., 2009; Ylikorkala et al., 2001). Given the prominent stromal 
contribution in GI hamartomatous polyps and patient predisposition to carcinomas, it can 
be hypothesized that the disruption of mesenchymal-epithelial signaling is a critical 
aspect of tumorigenesis in GI hamartomatous polyps. However, both the exact cell of 
origin as well as critical downstream signaling required for GI hamartomatous polyp 
initiation and growth remained poorly characterized. 
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Results and Discussion 
 
Gli1+ mesenchymal cells are gastrointestinal myofibroblasts. 
 I first wanted to restrict Cre-Lox recombination specifically to the gastrointestinal 
mesenchymal compartment. To do this, I decided to use the Gli1CreER allele. Gli1 is 
expressed in a subpopulation of gastrointestinal mesenchymal cells during development 
and postnatal stages following induction via tamoxifen injection (Mao et al., 2010; Park 
et al., 2000). To induce expression, I first crossed Gli1CreER to R26LacZ, a nuclear-LacZ 
reporter construct. I then injected Gli1CreERR26LacZ/+ mice at postnatal day 30 (P30) with 
120 mg/kg tamoxifen. Consistent with the previously published reports, I observed 
prominent nuclear LacZ staining in a subpopulation of mesenchymal cells in the 
gastrointestinal mesenchyme in both the intestine and colon when animals were dissected 
two weeks later (Fig. B.1.A) (Kolterud et al., 2009).  
 I then needed to determine the identity of the Gli1+ mesenchymal cell. I decided 
to use immunofluorescence and double-staining to determine markers expressed by the 
Gli1+ cells. I found that in both the intestine and colon, the β-gal+ cells (marking the 
Gli1+ population) were also positive for α-Smooth Muscle Actin (αSMA) but negative for 
Desmin (Fig. B.1.B,C). In the gastrointestinal mesenchyme, the myofibroblast population 
is characterized as being αSMA+/Desmin- (Mifflin et al., 2011; Pinchuk et al., 2010). 
 These data corroborate findings published by others. Members of the Gumucio 
lab showed that Gli1+ cells are amongst the α-smooth muscle actin+/desmin- 
myofibroblast population in the intestine (Kolterud et al., 2009). More recently,  
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Figure B.1. Gli1+ mesenchymal cells are gastrointestinal myofibroblasts.  
(A) LacZ staining in the intestine and colon of Gli1CreERR26lacZ/+ animals following P30 
tamoxifen injection. (B, C) Intestine and colon tissue from Gli1CreERR26lacZ/+ animals 
probed for β-galactosidase, α-Smooth Muscle Actin (α-SMA), and Desmin. Scale bar = 
50 µM.  
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Humphreys and colleagues showed that in a number of organs, Gli1 is a marker for a 
mesenchymal stem cell population that differentiates into myofibroblast cells following 
injury (Kramann et al., 2015). Therefore, I concluded that in my own system, the 
Gli1CreER allele is restricting recombination to a gastrointestinal myofibroblast population.  
 
SMAD7 expression in Gli1+ myofibroblasts promotes hamartomatous polyps that 
phenotype Juvenile Polyposis Syndrome.  
 I then decided to investigate if perturbing TGFβ/BMP pathway signaling in the 
gastrointestinal mesenchyme was sufficient to initiate polyp growth. To do this, I used 
the R26Smad7/+ allele that our lab recently generated (see Appendix A for additional 
details) and again used the Gli1CreER driver allele. I induced Cre-mediated recombination 
at postnatal day 10 (P10) by tamoxifen injection. I found that Gli1CreERR26Smad7/+ animals 
became moribund and died by 5 months of age, possibly due to obstruction caused by a 
large polyp at the pylorus (Fig. B.2.A,B). Gli1CreERR26Smad7/+ mice also developed colon 
polyps with cystic lesions and a prominent stromal contribution, reminiscent of the colon 
polyps that develop in patients with Juvenile Polyposis Syndrome (JPS) (Fig. B.2.C).  
 This observation provides further evidence that aberrant TGFβ/BMP pathway 
signaling is linked to Juvenile Polyposis. Previous labs have shown that whole body 
heterozygous Smad4 knockout generates gastrointestinal polyps that phenocopy Juvenile 
Polyposis Syndrome, but this study definitively links JPS to a myofibroblast cell 
population (Sirard et al., 1998; Takaku et al., 1999; Xu et al., 2000). Additionally, it has 
been shown that 40% of all identified mutations in JPS are linked to mutations in  
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Figure B.2. SMAD7 expression in Gli1+ myofibroblasts promotes hamartomatous 
polyps that phenotype Juvenile Polyposis Syndrome.  
(A) Survival of Gli1CreERR26Smad7/+ animals injected with tamoxifen at postnatal day 10 
(P10) as compared to littermate controls. (B, C) Gli1CreERR26Smad7/+ animals injected with 
tamoxifen at P10 develop polyps at the pylorus between the stomach and duodenum, as 
well as in the colon. Gli1CreERR26Smad7/+ colon polyps display cystic lesions and 
prominent mesenchymal contribution, characteristic of the gastrointestinal 
hamartomatous polyps in Juvenile Polyposis Syndrome (JPS). Scale Bar = 50 µM.  
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SMAD4 or BMPR1A; this data suggests that mutations in SMAD7 might also be 
involved in JPS as well. 
 
PTEN knockout in Gli1+ myofibroblasts promotes hamartomatous polyps that 
phenotype PTEN Hamartoma Syndrome/Cowden’s Syndrome. 
 I also wanted to investigate whether homozygous PTEN knockout in the 
gastrointestinal myofibroblast population is sufficient to initiate polyposis reminiscent to 
PTEN Hamartoma Syndrome/Cowden’s Syndrome. I again used the Gli1CreER allele and 
crossed it to Ptenflox mice to generate Gli1CreERPtenflox/flox animals. I induced Cre 
recombination via tamoxifen injection at postnatal day 30 (P30). I observed that 
Gli1CreERPtenflox/flox animals became moribund and died by 4 months of age (Fig. B.3.A). 
Upon dissection, I observed numerous polyps in the colons of Gli1CreERPtenflox/flox 
animals, with the greatest numbers present at the distal colon, although small polyps were 
present in the intestine as well (Fig. B.3.B,C).  
 I observed lymphoid follicles were present in the majority of the 
Gli1CreERPtenflox/flox colon polyps, but never observed them in the Gli1CreERLkb1flox/+ or the 
Gli1CreERR26Smad7/+ polyps (Fig. B.3.C,D). Lymphoid follicles are significantly more 
common in Cowden’s Syndrome polyps than in other gastrointestinal hamartomatous 
polyps (Shaco-Levy et al., 2016). Even more confounding is that the lymphoid follicles 
appear to be αSMA-/Desmin+, providing evidence that the follicles are not densely 
populated regions of Gli1+ myofibroblasts. However, fibroblastic reticular cell networks 
in lymphoid follicles, which are comprised of both stromal and hematopoietic cells, have  
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Figure B.3. PTEN knockout in Gli1+ myofibroblasts promotes hamartomatous 
polyps that phenotype PTEN Hamartoma Syndrome/Cowden’s Syndrome.  
(A) Survival of Gli1CreERPtenflox/flox animals injected with tamoxifen at postnatal day 30 
(P30) as compared to controls. (B) Numerous polyps are observed in the colon of 
Gli1CreERPtenflox/flox animals. (C,D) Gli1CreERPtenflox/flox mice develop polyps in both the 
intestine and colon, with lympoid follicles characteristic of Cowden’s Syndrome polyps. 
Scale Bar = 50 µM.  
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been shown to be αSMA-/Desmin+ (Malhotra et al., 2013). From these data, I conclude 
that the Gli1CreERPtenflox/flox mouse robustly recapitulates Cowden’s Syndrome polyps, 
and represents the first mouse model for this gastrointestinal hamartomatous polyposis 
syndrome. 
 
Heterozygous loss of Lkb1 in Gli1+ myofibroblasts promotes hamartomatous polyps 
that phenotype Peutz Jeghers Syndrome. 
 I next used the Gli1CreER to knock out a single copy of Lkb1 in the gastrointestinal 
myofibroblast cell population. I induced Cre recombination through injection of 120 
mg/kg tamoxifen at P30, and found that all Gli1CreERLkb1flox/+ mice developed polyps by 
12 months (Fig. B.4.A). Additionally, I observed that all LKB1-mutant polyps arose at 
the pylorus between the stomach and duodenum, and they were histologically consistent 
with human Peutz Jeghers Syndrome polyps (Fig. B.4.B). 
 This work is consistent with previously published mouse models of Peutz 
Jeghers’ Syndrome. Like the mouse models with whole body heterozygous knockout of 
Lkb1, the Gli1CreERLkb1flox/+ mice developed polyps at the pylorus and had an overall 
survival of approximately 12 months (Bardeesy et al., 2002; Jishage et al., 2002; Miyoshi 
et al., 2002). Additionally, this work corroborates a previous study that showed that 
genetic ablation of Lkb1 in a smooth muscle cell compartment, marked by expression of 
SM22α, was sufficient to initiate polyposis (Katajisto et al., 2008). Our work adds to this 
group’s findings by showing that the myofibroblast population is sufficient to give rise to 
Peutz Jeghers polyps.  
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Figure B.4. Heterozygous loss of Lkb1 in Gli1+ myofibroblasts promotes 
hamartomatous polyps that phenotype Peutz Jeghers’ Syndrome.  
(A) Polyp free survival in Gli1CreERLkb1flox/+ animals as compared to controls following 
P30 tamoxifen injection. (B) Gli1CreERLkb1flox/+ animals develop polyps at the pylorus 
between the stomach and duodenum. (C) Polyps in Gli1CreERLkb1flox/+ animals exhibit a 
mesenchymal compartment and smooth muscle core, reminiscent of human Peutz 
Jeghers’ Syndrome (PJS) polyps. Scale Bar = 50 µM.  
 
 
220 
 
PTEN mutant polyps but not LKB1-mutant or SMAD7-mutant polyps exhibit 
elevated mTOR pathway signaling. 
 I next decided to investigate mTOR pathway signaling in the three gastrointestinal 
hamartomatous polyposis mouse models. Via immunohistochemistry, I observed that the 
mesenchymal compartment as well as the epithelia of the Gli1CreERPtenflox/flox polyps 
exhibited pS6 and pAktS473 staining. However, both the Gli1CreERLkb1flox/+ and the 
Gli1CreERR26Smad7/+ polyps only displayed pS6 and pAktS473 staining in the epithelia, not 
the mesenchyme (Fig. B.5.A,B). Further data supporting this initial observation came 
from the genetic ablation of mTOR in the PTEN-deficient background; 
Gli1CreERPtenflox/floxmtorflox/flox animals had a higher survival rate than Gli1CreERPtenflox/flox 
animals (Fig. B.5.C). This data indicated that in the gastrointestinal myofibroblast 
population, only PTEN knockout is sufficient to activate mTOR pathway signaling in 
hamartomatous polyps.  
 
LKB1-mutant polyps do not require mTOR pathway signaling for polyp initiation 
and growth. 
 I shifted my focus back to the LKB1-mutant polyps to try to better understand the 
molecular mechanism through which Lkb1 heterozygous knockout drives polyposis. At 
the time when this work began, the hypothesis in the field was that Peutz Jeghers 
Syndrome polyps arise through activation of mTOR due to loss of upstream 
LKB1/AMPK activity. Therefore, I hypothesized that if the polyposis mechanism in 
Gli1CreERLkb1flox/+ polyps is through signaling from LKB1 to AMPK1/AMPK2 to inhibit  
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Figure B.5. PTEN mutant polyps but not LKB1-mutant or SMAD7-mutant polyps 
exhibit elevated mTOR pathway signaling.  
(A,B) Immunohistochemical analysis of pS6 and pAkt-S473 expression in 
Gli1CreERLkb1flox/+, Gli1CreERR26Smad7/+, and Gli1CreERPtenflox/flox polyps. (C) Overall 
survival of Gli1CreERPtenflox/floxmtorflox/flox animals as compared to Gli1CreERPtenflox/flox 
animals. Scale Bar = 10 µM.  
 
 
222 
 
mTOR, then the Gli1CreERAmpk1flox/floxAmpk2flox/flox phenotype should recapitulate the 
Gli1CreERLkb1flox/+ polyposis phenotype. 
 I started by knocking out both Ampk1 and Ampk2 in the Gli1+ myofibroblast 
population. I found that after tamoxifen injection, Gli1CreERAmpk1flox/floxAmpk2flox/flox had 
no difference in overall survival as compared to control mice (Fig. B.6.A). Furthermore, 
Gli1CreERAmpk1flox/floxAmpk2flox/flox mice never developed polyps in the gastrointestinal 
tract (Fig. B.6.B). 
 To further investigate the relationship between LKB1 and mTOR in the 
gastrointestinal mesenchyme, I next crossed the Gli1CreERLkb1flox/+ to mtorflox alleles to 
generate Gli1CreERLkb1flox+mtorflox/flox animals. I hypothesized that if mTOR pathway is 
activated in LKB1-mutant tissue in Peutz Jeghers Syndrome, then genetic knockout of 
mtor in conjunction with Lkb1 knockout should inhibit polyposis. However, I observed 
no difference in polyp-free survival in Gli1CreERLkb1flox+mtorflox/flox animals as compared 
to Gli1CreERLkb1flox+ animals (Fig. B.6.C,D). I additionally observed expansion of a 
proliferative mesenchymal compartment comprised of predominantly αSMA+/Desmin- 
myofibroblast cells in both Gli1CreERLkb1flox+mtorflox/flox polyps and in Gli1CreERLkb1flox+ 
polyps (Fig. B.6.E and Fig. B.7.A-C).   
 Overall, these data showed that in LKB1-deficient polyps, activation of the 
mTOR pathway is not the molecular mechanism for polyposis. This finding is 
contradictory to findings published reporting that administration of rapamycin was 
sufficient to suppress polyp formation in Lkb1+/- mice (Robinson et al., 2009; Wei et al., 
2008). Therefore, it would be interesting to investigate whether rapamycin is somehow  
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Figure B.6. LKB1-mutant polyps do not require mTOR pathway signaling for polyp 
initiation and growth.  
(A,B) Genetic knockout of AMPK1 and AMPK2 does not affect overall survival and is 
not sufficient to drive polyp growth in Gli1CreERAmpk1flox/floxAmpk2flox/flox animals. (C,D) 
Genetic knockout of mTOR in conjunction with Lkb1 heterozygous knockout does not 
inhibit polyp initiation and growth in Gli1CreERLkb1flox/+mtorflox/flox animals. (E) 
Gli1CreERLkb1flox/+mtorflox/flox polyps are histologically identical to Gli1CreERLkb1flox/+ 
polyps, as assayed through immunohistochemical Ki67 and α-SMA staining. Scale Bar = 
50 µM.  
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Figure B.7. Gli1CreERLkb1flox/+mtorflox/flox polyps are comprised of an expanded 
myofibroblast population phenotypically consistent with Gli1CreERLkb1flox/+polyps.  
(A-C) The expanded mesenchymal compartment in Gli1CreERLkb1flox/+polyps and 
Gli1CreERLkb1flox/+mtorflox/flox polyps is comprised of an α-SMA+/Desmin- myofibroblast 
population, as assayed through immunohistochemical staining. Scale Bar = 50 µM.  
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suppressing polyp growth independently of mTOR regulation. However, these data 
represents the first conclusive in vivo evidence excluding mTOR pathway activation in 
Peutz Jeghers polyps, and suggests that another molecular mechanism must be 
responsible for LKB1-deficient polyposis.  
 
LKB1-mutant polyps require YAP/TAZ for polyp initiation and growth. 
 Recent reports have linked LKB1 to YAP/TAZ regulation and showed that human 
PJS polyp samples exhibited elevated YAP/TAZ nuclear protein levels (Mohseni et al., 
2014; Nguyen et al., 2013). Therefore, I next decided to investigate YAP/TAZ, the 
transcriptional co-activators of the Hippo Pathway, in the LKB1-deficient polyps. I 
observed higher YAP/TAZ protein in both Gli1CreERLkb1flox+ polyps as well as non-polyp 
adjacent intestine, as compared to control tissue (Fig. B.8.A). I then investigated the 
tissue compartment expression of YAP, and found YAP protein expressed in the 
mesenchymal compartment of the Gli1CreERLkb1flox+ polyps. From these data, I concluded 
that YAP/TAZ protein is elevated in myofibroblasts when LKB1 is knocked out.  
 To conclusively link YAP/TAZ to the molecular mechanism for polyposis in 
Gli1CreERLkb1flox+ polyps, I again used mouse genetics. I crossed Gli1CreERLkb1flox+ 
animals to animals carrying Yapflox/floxTazflox/flox alleles to generate 
Gli1CreERLkb1flox/+Yapflox/floxTazflox/flox animals. I again induced Cre recombination at P30 
and allowed animals to age to 12 months of age. I was excited to observe that genetic 
ablation of both YAP and TAZ in the gastrointestinal myofibroblast population not only  
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Figure B.8. LKB1-mutant polyps require YAP/TAZ for polyp initiation and growth. 
(A) Western blot showing protein expression of YAP and TAZ in two polyps isolated 
from Gli1CreERLkb1flox/+animals, as well as non-polyp adjacent LKB1-deficient tissue, as 
compared to control tissue. (B) Mesenchymal tissue in Gli1CreERLkb1flox/+polyps displays 
YAP protein expression, as assayed by immunofluorescence. (C-E) Homozygous genetic 
ablation of both Yap and Taz, in an Lkb1-deficient background, in the gastrointestinal 
myofibroblast cell population is sufficient to extend lifespan and prevent polyp formation 
in Gli1CreERLkb1flox/floxYapflox/floxTazflox/flox animals as compared to Gli1CreERLkb1flox/+ 
animals. Scale Bar = 50 µM.  
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extended overall survival but also was sufficient to inhibit LKB1-deficient polyposis in 
Gli1CreERLkb1flox+Yapflox/floxTazflox/flox animals (Fig. B.8.C-E).  
 Therefore, these data corroborate the previously published findings linking LKB1 
and YAP/TAZ, and expand them to conclusively show that in Peutz Jeghers Syndrome, 
YAP/TAZ activity is critical for polyp initiation and growth (Mohseni et al., 2014; 
Nguyen et al., 2013). This study represents the first time that this finding has been shown 
conclusively in vivo, and suggests that inhibiting YAP/TAZ in patients with Peutz 
Jeghers Syndrome may be a viable treatment strategy.  
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Conclusions 
 
 This study represents the first in vivo evidence suggesting that genetically distinct 
inherited gastrointestinal hamartomatous polyposis syndromes arise from a shared cell of 
origin, and identifies that cell as a gastrointestinal myofibroblast. This work also 
represents the first reported mouse model for PTEN Hamartoma Syndrome/Cowden’s 
Syndrome: the Gli1CreERPtenflox/flox mouse model. Finally, this work also uses mouse 
genetics to conclusively show that in Peutz Jeghers Syndrome polyps, mutations in Lkb1 
initiate polyposis through aberrant regulation of YAP/TAZ activity, not through mTOR 
activity, as has been previously believed. Overall this work represents newly generated 
genetic models and critical findings for the field of gastrointestinal hamartomatous 
polyposis syndromes, and will hopefully yield clinically relevant information to help 
patients born with these syndromes. 
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Materials and Methods 
 
Mouse Genetics 
 The Gli1CreER, R26LacZ , Lkb1flox, Ptenflox, Ampk1flox, Ampk2flox, and mtorflox mouse 
alleles were obtained from Jackson Laboratory. Yapflox (Xin et al., 2011b) and Tazflox (Xin 
et al., 2013) mice were a kind gift from Dr. EN Olson. The R26Smad7 mouse allele 
generation was described in APPENDIX A. To target the gastrointestinal myofibroblast 
population, Gli1CreER mice were crossed to R26LacZ , Lkb1flox, Ptenflox, Ampk1flox, 
Ampk2flox, mtorflox, Yapflox  and Tazflox alleles. Cre recombination was induced by 
intraperitoneal injection of 120 mg/kg tamoxifen dissolved in corn oil. Overall survival 
was determined as the age of animal when it became moribund. 
 
Tissue Collection and Histology 
 Animals were humanely euthanized with CO2 and cervical dislocation. Tissue 
was dissected and fixed in 10% NBF at 4°C. For paraffin sectioning, tissue was 
dehydrated in 70% EtOH and embedded in paraffin wax. Frozen sections were 
dehydrated in 30% sucrose and embedded in OCT media. Paraffin sections were cut at 6 
µm on a microtome and frozen sections were cut at 12 µm on a cryotome. Hematoxylin 
& eosin reagents were used for routine staining of paraffin sections, and X-GAL staining 
reagents were used for routine lacZ staining of frozen sections. Histological analyses of 
mouse tissues were conducted by Dr. Zhong Jiang, Department of Pathology, UMass 
Medical School. 
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Western Blotting 
 Mouse tissue was dissected and minced in lysis buffer using tissue pestles. Protein 
lysates were probed with the following primary antibodies: YAP/TAZ (Cell Signaling) 
and β-actin (Genescript). HRP-conjugated Secondary antibodies were from Jackson 
Laboratories. 
 
Immunohistochemistry / Immunofluorescence 
 For IHC, paraffin slides were first dewaxed in xylene and then rehydrated in serial 
dilutions of ethanaol. Slides were incubated in 10mM sodium citrate buffer pH 6.0 for 30 
minutes in a rice cooker to expose antigens via heat-induced epitope retrieval. 
Endogenous peroxidase was blocked for 20 minutes in 3% H2O2-MeOH and then blocked 
for 1 hour at room temperature in 5% BSA, 1% goat serum, 0.5% Tween-20. Slides were 
incubated in primary antibody overnight at 4°C, and then secondary antibody for 1 hour 
at room temperature. Antibodies were diluted in either blocking buffer or SignalStain® 
Antibody Diluent (Cell Signaling). Signal was detected using the Vectastain Elite ABC 
kit and the DAB Peroxidase Substrate kit (Vector Laboratories) according to 
manufacturer protocols. Primary antibodies for IHC were: pS6 (Cell Signaling), 
pAktS473 (Cell Signaling), Ki67 (Abcam), and α-smooth muscle actin (αSMA) (Abcam). 
 For IF, slides were blocked in 5% BSA, 1% goat serum, 0.5% Tween-20 for 1 
hour at room temperature, and then incubated in primary antibody overnight at 4°C. The 
next day, slides were incubated in secondary antibody for 1 hour at room temperature, 
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and then mounted with DAPI. Secondary antibodies were AlexaFluor-488, AlexaFluor-
568, and AlexaFluor-647 conjugated antibodies (ThermoFisher) diluted in blocking 
buffer. Antibodies for IF were: β-galactosidase (Abcam), α-smooth muscle actin (αSMA) 
(Abcam), Desmin (ThermoFisher), and YAP (Cell Signaling). 
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